close

August 2022

Medical supplies

HonorHealth employee from Ukraine leads medical supply effort

PHOENIX — “My stepfather is on the front line,” Svitlana Sbonsler told her colleagues on Wednesday. “We don’t know when it will end, hopefully by next summer it will end.”

Every second of every day, Svitlana’s thoughts and heart are with her family who are fighting in Ukraine.

“I look at all the photos, I was very shocked by what was done, it’s hard to see, it’s heartbreaking,” said Svitlana, supply chain manager for HonorHealth.

Her stepfather serves in the Ukrainian forces. His mother, a psychologist, rehoused families struggling with the trauma of war.

“I immediately told my mother, leave the country, you have to go, and she said no, we will stay, we have to stay in Ukraine and stand up for freedom,” Svitlana said.

A mindset that has inspired her and her colleagues at HonorHealth to do all they can too.

“Chest tubes and drainage systems, scalpels, needles and syringes, whatever you would use in a quick trauma, tourniquets, they’re in those boxes and that’s what we want to be able to send out there. “said the nurse and volunteer. Camie Rideout.

The war in Ukraine has caused a health care crisis.

The country now desperately needs medical equipment and supplies.

Since April 2022, HonorHealth has donated tens of thousands of essential items.

Many supplies already packed in the boxes are expiring, but will soon have a new purpose.

“Just because it’s expired, on our end, under our regulations here in the United States, doesn’t mean they can’t necessarily use it in other parts of the world,” Rideout said.

Today, if it can be used, it will not be wasted.

Items like masks, gloves, bandages, medical tape, trauma dressings, antibiotic ointments and sutures.

The impact of their efforts on each expedition is even more evident when they hear Svitlana’s stories.

“I just think how much we help them, that’s what the nurses do,” nurse Beth Sposito said. “Hearing what his family is going through is really impactful.”

For Svitlana, the kindness she sees in her co-workers helps her find hope for a future where the fighting stops, where families come together and heal together…a day when she can go home. and kiss his mother and father.

“I pray every day for this war to end,” Svitlana said. “Until then, I will do everything I can to support my brave family and friends who are fighting for their land, their country.”

read more
Prescription drugs

Prescription drugs and children: what you need to know

Prescription drugs and children: what you need to know



MARIA: AS PARENTS CONTINUE TO FACE THE MENTAL HEALTH CRISIS AFFECTING OUR CHILDREN, THERE ARE SO MANY ISSUES THEY ARE FACING, INCLUDING OUTSIDE HELP AND THEY WENT – HOW TO HELP AND WHEN MEDICINE ON ORDER MAY BE PART OF THE SOLUTION. SHAYNA: HERE TO OFFER SOME IMPORTANT INSIGHTS IS DR. KHADIJAH BOOTH WATKINS, ASSOCIATE DIRECTOR OF THE CLAY CENTER FOR HEALTHY YOUNG MINDS AT THE MGH. THANK YOU SO MUCH FOR BEING HERE. A RECENT REPORT FROM EXPRESS SCRIPTS, A MAIL-ORDER PHARMACY, FOUND ANTIDEPRESSANT PRESCRIPTIONS FOR TEENAGERS HAVE INCREASED BY 38% BETWEEN 2015 AND 2019. DOES THIS NUMBER SURPRISE YOU? >> THANK YOU FOR WELCOMING ME. UNFORTUNATELY, THE NUMBER DOES NOT SURPRISE ME. WE HAVE SEEN AND INCREASED DEPRESSION, ANXIETY, SUICIDAL THOUGHTS AND LONENESS. THESE NUMBERS STARTED TO RISE BEFORE THE GLOBAL PANDEMIC. ALTHOUGH THE MEDICATIONS ARE NOT WITHOUT SIDE EFFECTS, THEY HAVE MADE A HUGE DIFFERENCE IN THE LIVES OF MANY CHILDREN. MARIA: THIS STUDY WAS BEFORE THE PANDEMIC, AND LOOK WHAT THE PANDEMIC HAS DONE. YOU CAN IMAGINE THAT THESE NUMBERS ARE RISING OR HAVE RISEN, UNFORTUNATELY. BUT WE KNOW THERE IS NO EASY ANSWER, BUT AS PARENTS TRY TO DETERMINE THE BEST WAY TO HELP DEAR TEENS, WHAT SHOULD THEY CONSIDER WHEN USING PRESCRIPTIONS? >>I’M HAPPY YOU ASKED THIS QUESTION, BECAUSE THERE IS A LOT OF STIGMA AROUND MENTAL HEALTH TREATMENT AND MENTAL HEALTH IN GENERAL, AND EDUCATION IS THE ONLY WAY TO FIGHT THIS. THERE ARE MANY ANGLES TO CONSIDER, BUT NOBODY IS PRESCRIBING MEDICINES FOR LIGHTWEIGHT CHILDREN, PARENTS OR DOCTORS. IT REQUIRES A GOOD RELATIONSHIP WITH YOUR DOCTOR AND THINKING ABOUT THE SYMPTOMS YOUR CHILD IS EXPERIENCING. ARE THERE ANY SECURITY ISSUES? HOW THINGS HAVE–HOW HAVE THINGS GOED? IS THERE A DISABILITY? CAN THEY NO LONGER WORK, GO TO SCHOOL OR BE WITH FRIENDS? AND I THINK OF SUFFERING — SO MANY CHILDREN SUFFER IN SILENCE THEN THEY CAN SUFFER INSIDE EVEN THOUGH FROM THE OUTSIDE THEY SEEM TO HOLD TOGETHER. THIS IS SOMETHING TO CONSIDER WITH THE DOCTOR IN TERMS OF THE ROLE THE MEDICATIONS COULD PLAY. SHAYNA: AND ONE OF THE CONCERNS RAISED BY SOME EXPERTS AS THIS MENTAL HEALTH CRISIS CONTINUES IS THAT SOME OF THESE DRUGS ARE NOT INTENDED FOR YOUTH, THEY ARE INTENDED FOR ADULTS. WHAT KIND OF QUESTIONS SHOULD PARENTS ASK WHEN WORKING WITH THEIR DOCTORS TO PROVIDE THE BEST APPROACH TO THEIR CHILDREN? >> UNINTENDED IS NOT THE WAY HI WOULD THINK, BUT THERE ARE NO DRUGS – THERE ARE DRUGS THAT ARE NOT FDA APPROVED FOR CHILDREN AND TEENS. WE USE THEM SUCCESSFULLY IN AN OFF-LABEL WAY, BUT THERE ARE SO MANY MEDICINES AVAILABLE IN VARIOUS CATEGORIES FOR CHILDREN THAT CAN REALLY HELP YOUR CHILD THAT HAVE BEEN APPROVED, IF APPROPRIATE. THINGS YOU WANT TO THINK ABOUT, TREATMENT OF THIS MEDICINE’S SYMPTOMS, POTENTIAL BENEFITS AND POTENTIAL SIDE EFFECTS, AND WHAT ARE THE ALTERNATIVES TO MEDICATION, BECAUSE THERE ARE ALTERNATIVES. WE KNOW THAT OUR CHILDREN HAVE DIFFICULTIES AND SOME OF THESE THINGS HAVE DIFFICULTIES WITH OUR DEATH. WE WANT TO THINK OF THE BIG PICTURE, TALK TO YOUR DOCTOR AND TRUST YOUR DOCTOR AND COLLABORATE TOGETHER. THIS IS THE BEST WAY TO GO FOR YOUR CHILDREN. MARIA: TALK TO YOUR DOCTOR — DR. BOOTH WATKINS, THANK YOU FOR YOUR TIME. SHAYNA

Prescription drugs and children: what you need to know

Dr. Khadijah Booth Watkins, associate director of the Clay Center for Young Healthy Minds at the MGH, talks about prescription drugs and children.

Dr. Khadijah Booth Watkins, associate director of the Clay Center for Young Healthy Minds at the MGH, talks about prescription drugs and children.

read more
Medical supplies

British students refurbish medical supplies for eastern Kentucky flood victims

HAZARD, Ky. (FOX 56) – University of Kentucky students are doing their part in a unique way to help those affected by flooding in Eastern Kentucky.

Most donations so far have been for non-perishable food, cleaning supplies, water and clothing. Now responders realize that there is a great need to replace the medical equipment that was damaged during the event.

This is where members of the UK Coordinate and assist in the reuse of assistive technologies (CARAT) come into play.

The CARAT project, funded by the University of Kentucky Center of Excellence in Rural Health (CERH), repairs, disinfects and repatriates used medical equipment.

The CARAT Hazard project refurbished nearly $23,000 worth of equipment from January 2022 to April 2022, and $9,000 in March alone.

Now, students in the program are working hard to refurbish medical equipment to bring to those in need in eastern Kentucky, but they still need donations.

Accepted donations include:

  • Manual wheelchairs
  • Shower chairs
  • Shower/bathtub seats
  • Bedside chests
  • Grab bars
  • Walkers
  • walking sticks
  • Crutches
  • Rollators
  • portable ramps
  • Transfer units

For more information on article donations, contact Keisha Hudson at [email protected] or 606-439-3557.

read more
Medical supplies

Relief flight from UAE arrives with food and medical supplies for flood victims – Pakistan




Pakistan


Relief flight from United Arab Emirates arrives with food and medical supplies for flood victims





RAWALPINDI (Dunya News) – The eighth relief flight from the United Arab Emirates (UAE) in the past three days, carrying food, medical supplies and tents, arrived at Nur Khan Air Base on Tuesday.

The flight followed the humanitarian air bridge established between Pakistan and the United Arab Emirates.

The next relief flight is expected to arrive at Nur Khan Airbase later this evening.

In a statement, the Foreign Ministry praised the assistance provided by the United Arab Emirates in times of crisis.

‘; var i = Math.floor(r_text.length * Math.random()); document.write(r_text[i]);

read more
Medical supplies

Thirty million dollars in drugs and medical supplies to distribute

August 30, 2022

Thirty million dollars in drugs and medical supplies to distribute

Kevin Bernard

The Department of Health and Wellness recently signed tender contracts worth thirty million dollars for the supply of drugs and medical supplies. Health Minister Kevin Bernard explained that there is a brief delay in the delivery of these items, as the contracts give suppliers thirty to sixty days to deliver. Minister Bernard says supplies, including Tylenol, are already in the country and being processed for distribution. Here is what he told us.

Kevin Bernard, Minister of Health and Wellness

“The problem with medical supplies is that we had delays. We now receive these items in stock from suppliers. We decided that by the end of September we shouldn’t have these problems where people say they don’t have the basic drugs and so on. We receive our items as they arrive. I know one of the big stories is that we don’t have Tylenol and so on. We have Tylenol, you know, but we have it in pill form. But, the liquid form has just entered the country from the supplier and is now being inspected by the Ministry of Health. Every time a supplier brings in a product, it has to be inspected and we can disperse it to the different facilities. »

Paul Lopez

“If our suppliers are not delivering fast enough, shouldn’t we change our suppliers to more reliable suppliers? »

Kevin Bernard, Minister of Health and Wellness

“It’s not that suppliers don’t deliver on time. Please keep in mind that we have just signed bidding contracts of about a month, so the delivery time was between thirty and sixty days. So that created a sort of delay. But, remember what led to many other problems was the previous RFP where we had to reject almost two million dollars from a specific supplier of products because the department could not accept the quality of the product delivered. So that even made the problem worse. This is something that was happening long before even before the previous administration. We put an end to that. This is why, when we made this call for tenders, we talked about quality. We talked about value for money. We also talked about fast delivery. This is what we are going to improve. When we start receiving products, you should not hear in the next three months that you have this problem. »

Paul Lopez

“How much did we spend on this recent purchase? »

Kevin Bernard, Minister of Health and Wellness

“The tender, you are talking about a tender of nearly thirty million dollars. These are medicines and medical supplies.

read more
Medical products

Second Sight Medical Products announces the successful completion of its merger with Nano Precision Medical and its name change to Vivani Medical, Inc.

LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable vision prostheses intended to create an artificial form of useful vision for people who are blind, announced today the completion of its merger with Nano Precision Medical, Inc. (“NPM”). NPM is a biopharmaceutical company that develops miniaturized subcutaneous drug implants using its proprietary NanoPortal™ technology to enable long-term, near-constant rate delivery of a wide range of drugs to treat chronic diseases.

As part of the merger, Second Sight changed its name to Vivani Medical, Inc. (“Vivani”). The Company’s common stock will trade on the Nasdaq Capital Market under the symbol “VANI”. ThinkEquity acted as financial advisor to Second Sight in connection with the merger.

Upon completion of the merger, the Company has approximately $55 million in cash to advance the development of Vivani’s portfolio, which includes lead asset NPM-119 (exenatide implant), toward development in clinical stage for the treatment of patients with type 2 diabetes and to identify and execute strategic options to advance its Orion visual prosthesis to the clinical stage to treat people with blindness due to a wide range of underlying causes.

The company will operate under the direction of NPM CEO, Dr. Adam Mendelsohn, and his management team of seasoned industry veterans.

“The completion of the merger marks an important milestone for Vivani as we continue to grow the business with a strong team, sufficient funding and an attractive group of investors who support our goal of developing and commercializing a new portfolio of products. miniaturized drug implants that can effectively address medication nonadherence, a major challenge in the treatment of chronic diseases, including type II diabetes. We are also committed to identifying a sustainable path forward to bring Second Sight’s Orion Cortical Visual Prosthesis System to people who are blind due to a wide range of causes,” said Adam Mendelsohn, Ph.D., President and CEO. general of the company. “Our proprietary NanoPortal technology has broad potential across a wide range of therapeutic molecules. We anticipate that the first application of our technology will be ready to begin human evaluation later this year with NPM-119. Medication non-adherence in type II diabetic patients taking oral or injectable therapies is approximately 50%. We believe that a six-month implant may be an important alternative for non-adherent patients and the physicians who treat them.

About Vivani Medical, Inc.

Vivani Medical, Inc., soon to be trading under the Nasdaq symbol VANI, is the combination of Nano Precision Medical, Inc. and Second Sight Medical Products, Inc. The company leverages proprietary technologies to develop and commercialize drug implants and of devices that treat patients with chronic conditions with a high unmet medical need.

Prior to the merger, Nano Precision Medical, Inc. was a privately held biopharmaceutical company developing drug implants using its proprietary NanoPortal drug implant technology. These drug implants, designed to provide low-fluctuation drug profiles, will address medication nonadherence, which is a primary reason for the suboptimal clinical benefit associated with oral and injectable products that treat chronic disease. The company’s lead product, NPM-119, is a GLP-1 receptor agonist in development to treat patients with type 2 diabetes. More information is available at www.nanoprecisionmedical.com.

Vivani also develops implantable visual prostheses intended to provide useful artificial vision to blind people. Visual prosthetic developments are a continuation of the work carried out by Second Sight Medical Products, Inc. prior to the merger and renaming to Vivani Medical, Inc. The recognized world leader in neuromodulation devices for blindness, Vivani is s is committed to identifying and implementing the best strategic options that will enable its innovative technologies to treat the broadest population of visually impaired people. More information is available at secondight.com.

Vivani’s corporate headquarters are located in Emeryville, California. More information for investors is available at www.vivani.com.

Notice of Intention to Delist Warrants (Nasdaq: EYESW)

As part of Nasdaq’s approval of the merger transaction, the merged company is required to comply with Nasdaq’s listing rule 5110(a). This rule requires the post-merger company to meet all Nasdaq listing criteria. The Company has satisfied the listing requirements for the common shares of the combined company after the merger. Because the warrants (Nasdaq:EYESW) will not meet Nasdaq’s original listing standards upon closing of the merger, the company would not be in compliance with listing rule 5110(a) with respect to warrants only. Accordingly, the Company has voluntarily elected to delist the Warrants, which will enable the Company to otherwise comply with Nasdaq listing rules. The Company intends to file a Delisting Notification on Form 25 with the SEC on or about September 8, 2022, to withdraw the Warrants from trading on the Nasdaq Capital Markets. The delisting of the warrant class from the Nasdaq listing is effective 10 days after the Form 25 is filed.

Safe Harbor

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as: “target”, ” believe”, “expect”, “will”, “could”, “anticipate”, “estimate”, “would”, “position”, “future” and other similar expressions which, in this press release, refer to the Company’s post-merger strategy . Forward-looking statements are neither historical facts nor guarantees of future performance. Instead, they are based solely on the Company’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are beyond our control. Actual outcomes and results may differ materially from those indicated in the forward-looking statements. Accordingly, you should not rely on any such forward-looking statements. Important factors that could cause actual results and results to differ materially from those set forth in the forward-looking statements include, among others, the following: (1) our ability to recognize the anticipated benefits of the merger; (2) risks associated with the development and commercialization of NPM-119 (exenatide implant); (3) claims or legal proceedings relating to the termination of the MoU with Pixium Vision and related costs; (4) changes in applicable laws or regulations; (5) the Company’s ability to achieve or maintain profitability in the future; (3) the possibility that the Company will be adversely affected by other economic, business and/or competitive factors; (4) the impact of COVID-19 on the Company’s business; and (5) various other risks and uncertainties. There may be additional risks that the Company considers insignificant or that are unknown. An additional list and description of risks and uncertainties can be found in the company’s most recent Annual Report on Form 10-K, and in all subsequent quarterly filings on Form 10-Q with the Securities and Exchange Commission (the “Commission”), and the Company’s final proxy statement/prospectus filed with the Commission on June 24, 2022. Any forward-looking statements we make in this press release are based solely on information currently available to the Company and do not valid only on the date on which it is manufactured. The Company undertakes no obligation to update publicly any forward-looking statements, written or oral, which may be made from time to time, whether as a result of additional information, future developments or otherwise, except as required by law. requires it.

read more
Prescription drugs

The most and least expensive cities for prescription drugs

As Americans continue to grapple with inflation and its impact on the prices of groceries, gasoline and a number of other essentials, they may also experience rising prices for prescription drugs. A GoodRx study, however, found that this latter impact may largely depend on where they live.

According to an AARP report, prescription drug prices have risen each year, generally faster than inflation. But those prices vary widely by location — and the GoodRx report identifies some of the most surprising.

Notably, Lexington and Little Rock have overtaken San Francisco and Los Angeles as the most expensive cities for prescription drugs. This breaks with the recent past, when cities with higher costs of living — think New York or Chicago — saw drug prices rise.

Lexington’s prices were found to be nearly 16% higher than the national average, with Little Rock just behind at nearly 13%. Los Angeles, New Orleans and New York round out the top five for high prices.

The researchers pointed to inflation as one of the drivers of these increases, but noted that populations in Lexington and Little Rock have high rates of chronic disease (and therefore a significant need for prescription drugs) .

On the other side of the ledger, the cheapest cities remained fairly stable over the four years that GoodRx conducted the research. Denver remained the least expensive city, with drug prices nearly 40% lower than the national average. Atlanta is next with prices nearly 19% lower than the national average, with Houston, Detroit and Tampa rounding out the bottom five.

GoodRx researchers looked at 30 US cities and the prices of the 500 most commonly prescribed drugs. Although some of the price differences can be attributed to the cost of living, the correlation is not ironclad. In Atlanta, the cost of living is high, but medication is cheaper than most other places.

Inflation and rising energy prices also factor into the equation, as many manufacturers spend more money on energy costs in the production process and supply chain. Then there’s the “big box effect,” with some states having more stores, like Walmart, that charge less for prescription drugs.

Of course, in the complicated world of drug pricing, there are other influences at play. Pharmacies often charge different prices for the same drug, depending on the price they paid. Similarly, as pharmacy benefit managers negotiate prices for health insurance companies, a lack of transparency results in widely varying prices.
The passage of the Reducing Inflation Act marks the federal government’s first major step toward reducing drug prices. But while the bill allows Medicare to negotiate prices for some prescription drugs, the impact on drug costs remains limited.

read more
Generic drugs

Pharmaceutical industry eclipses biotech and generic drugs in company reputation survey of patient groups

The Covid pandemic may have shone a spotlight on drugmakers and even contributed to their reputation. But there is still work to be done on pricing and transparency, says UK-based PatientView in its Asia Pharma Reputation Survey.

In fact, the pharmaceutical industry has outperformed its siblings, whether biotech companies or generic drug makers, according to the survey, which covered 300 Asian patient groups. These groups had collectively been in communication with nearly 2.7 million Asian patients in 2021, according to the survey, and about 70% of them had worked with at least one pharmaceutical company that year.

Around 66% of respondents in 2021 thought the reputation of the pharmaceutical industry was “excellent” or “good”, outperforming other healthcare players in the Asian region, including biotech companies (55%) and manufacturers generic drugs (47%). investigation found.

The reputation of pharmaceutical companies has been enhanced by their ability to innovate and bring vaccines to market within a year. “Covid had already given the pharmaceutical industry a huge opportunity in 2020 to prove its worth, by providing direct solutions to the health challenges posed by the pandemic (and, in doing so, to strengthen its corporate reputation),” said said the survey, adding that the storyline continues into 2021.

Explaining the need for an Asia-focused (not global) study, Alexandra Wyke of PatientView, said Activity area, a global study was published in April. However, the needs of patient groups differ significantly globally, and there was added value in looking at regional and national patient perspectives. Twenty-five Indian patient groups also took part in the survey which covered 31 companies in Asia, including India’s Sun Pharma, as well as other major global companies such as AstraZeneca, Pfizer, Novartis, Roche, Gilead, GSK , Eli Lilly and Merck, to name a few. little.

Price disadvantage

The downside for drugmakers was their poor score on issues such as pricing. According to the survey, only 16% of 2021 respondents rated the industry as “excellent” or “good” for having fair pricing policies (compared to 17% in 2020). This was true for patient groups around the world, underscoring the challenge the industry faces in creating pricing policies that patient groups believe are fair, he added. In New Zealand, drugmakers scored zero percent on this indicator in 2021 and 2020.

Price transparency was the other issue they scored low on. And that too was the norm across the world, the survey noted, indicating the industry still had a long way to go in explaining its prices.

An overview of the various rankings includes: Gilead Sciences, Pfizer and ViiV Healthcare, among the top three on business reputation. Interestingly, Pfizer, Roche/Chugai, and Novartis were the top three of 13 “Big Pharma” companies, ranked by overall reputation. Responding to Moderna’s recent allegation about vaccine patents involving Pfizer, the representative clarified that the investigation predated the incident.

PatientView is an independent organization, funding its own research, the rep said. Its revenue comes from selling the reports to industry and drug regulators, she added.

Published on

August 29, 2022

read more
Generic drugs

Generic Drugs Market Research Report 2022-2027: Global Key Companies Analysis, Growth, Outlook, Share, Size, Forecast

Generic drug market expected to reach $482.5 billion by 2027

SHERIDAN, WYOMING, USA, Aug. 29, 2022 /EINPresswire.com/ — IMARC Group’s latest report, titled “Generic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunities and Forecast 2022- 2027,” finds that the global generic drug market size reached US$320 billion in 2021. A generic drug is a drug that contains the same active pharmaceutical ingredient (API) and has an equivalent therapeutic effect as the brand name drug. . It is also identical to brand name drugs in terms of quality, safety strength, dosage, route of administration, intended use, effect, form, quality and side effects. However, it differs in some characteristics such as color, shape and aroma. Compared to patented drugs, generic drugs are cost effective because manufacturers do not have to invest in clinical trials and research and development (R&D) activities to prove the effectiveness of the drug. As a result, these drugs are gaining traction among individuals across the world. Looking ahead, IMARC Group expects the market value to reach US$482.5 billion by 2027, growing at a CAGR of 7% during the forecast period (2022-2027 ).

Get Free Sample Copy of Report at – https://www.imarcgroup.com/generic-drug-manufacturing-plant/requestsample

Global Generic Drugs Market Trends:

In recent years, governments in developed countries have implemented various initiatives to reduce health care costs by promoting the production of generic drugs. In addition to this, hospitals, institutions and various organizations are tackling the shortage of generic drugs across the world. For example, a coalition of seven hospitals and three philanthropic organizations in the United States said they would launch a generic drug company named Civica Rx to address drug shortages. In addition, government authorities in many countries have implemented several programs to encourage doctors and pharmacists to promote generic substitution. This, coupled with the increasing prevalence of chronic diseases such as diabetes, dyslipidemia, hypertension and metabolic syndrome, due to sedentary lifestyles, busy work schedules and changing dietary habits, creates positive market outlook around the world. Additionally, various branded drugs are expected to lose their patent protection in the coming years, which will continue to propel the growth of the market.

Do you know more information, contact our analyst at- https://www.imarcgroup.com/generic-drug-manufacturing-plant

Main generic drug companies in the world:

• Teva Pharmaceuticals Industries Ltd.
• Mylan SA
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Fresenius SE & Co.
• Lupine Limited
• Endo Pharmaceuticals Inc.
• Aurobindo Pharma Limited
• Aspen Pharmacare Holdings Limited

Key Market Segmentation:

Breakdown by therapeutic area:

• Central nervous system
• Cardiovascular
• Dermatology
• Genitourinary/Hormonal
• Respiratory
• Rheumatology
• Diabetes
• Oncology
• Others

Rupture by administration of drugs:

• Oral
• Injectables
• Dermal/Topical
• Inhalers

Breakdown by distribution channel:

• Retail pharmacies
• Hospital pharmacies

Breakdown by region:

• North America (United States, Canada)
• Asia-Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Latin America (Brazil, Mexico, others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, others)

Table of Contents of Generic Drugs Market Research Report:

• Preface
• Scope and methodology
• Summary
• Introduction
• Global generic drugs market
• SWOT analysis
• Value chain analysis
• Price analysis
• Competitive landscape

Browse more research reports:

• https://www.digitaljournal.com/pr/asia-pacific-cold-chain-market-to-reach-us-290-1-billion-by-2027-cagr-of-14-2
• https://www.digitaljournal.com/pr/europe-water-purifier-market-to-reach-us-17-4-billion-by-2027-cagr-of-8
• https://www.digitaljournal.com/pr/gcc-water-purifier-market-grow-at-cagr-of-8-86-during-2022-2027
• https://www.digitaljournal.com/pr/lithium-ion-battery-market-analysis-2022-2027-industry-growth-size-share-price-trends-and-forecast

Who we are:
The IMARC Group is a leading market research firm providing management strategies and market research worldwide. We partner with clients across all industries and geographies to identify their most important opportunities, address their most critical challenges and transform their businesses.

IMARC’s information products include major business, scientific, economic and technological developments for business leaders in pharmaceutical, industrial and high-tech organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverages, travel and tourism, nanotechnology and new processing methods are at the top of the list. company expertise.

Elena Anderson
IMARC Services Private Limited
+1 631-791-1145
write to us here

read more
Medical supplies

Nearly $3 million in medical supplies are heading to Ukrainian healthcare facilities thanks to V6CO’s donation to United Help Ukraine

V6CO donates over 11.5 million syringe kits and medical supplies to support efforts to Ukraine

NEW YORK and GAITHERSBURG, Md., August 29, 2022 /PRNewswire/ — V6CO, a medical device company focused on bringing innovative medical and wellness technologies to patients and consumers, and United Help Ukraine, a nonprofit charity, announced today today that nearly $3 million of medical supplies, including more than 11.5 million syringe kits, are shipped to Ukraine to support relief efforts.

“We are grateful to V6CO for this generous donation which will support countless patients in need of care, in line with our mission to distribute donated food and medical supplies and bring humanitarian aid to the people of Ukraine,” said Maryna Baydiuk, Ph.D., President of United Help Ukraine. “Medical supplies are in high demand as Ukrainian hospitals struggle to replenish supply chains that have been overstretched during the ongoing war.”

Mance ZhuCEO of V6CO added, “At V6CO, we offer our support to people who have been affected by the invasion of Ukraine. As individuals and organizations, we can all do our part to collectively provide support and work to make a difference.”

Kostyantyn VoronaAdvisor, Head of Consular Division at the Embassy of Ukraine in The United States of America said: “As Ukraine continues to resist the invasion of Russiathe need for medical supplies and support for refugees and those who remain in Ukraine is persistent and continuous. We remain grateful for the outpouring of support from dedicated groups around the world in our fight to maintain our independence.”

For more information about United Help Ukraine and how to donate, visit: https://unitedhelpukraine.org/donate

About V6CO

V6CO, LLC is a medical device manufacturer whose mission is to make home wellness sustainable, accessible and easy for everyone. V6CO’s diverse product catalog includes multi-function walking sticks, baby monitors, hearing aids, perpetual health monitoring ring, wearable ECG monitors and diabetic socks. Based at New York City and founded shortly before the onset of the COVID-19 pandemic, the company temporarily shifted its manufacturing to medical supplies such as masks, tests, syringes, needles and gloves. Learn more about https://www.v6co.com.

About United Help Ukraine

United Help Ukraine, Inc. is a non-profit charitable organization that receives and distributes donations, food and medical supplies to Ukrainian IDPs (internally displaced persons), people from Ukraine affected by Russia invasion into Ukrainefamilies of injured or killed for the freedom and independence of Ukraine. Our activities focus on fundraising and crisis awareness events in Ukraine by engaging individuals, organizations, private and governmental institutions and the media in the United States

V6CO Media Contacts

Karen Chase
ICR Westwicke
[email protected]

United Help Ukraine Contacts

Maryna Baydiukdoctorate
[email protected]

Anna Yabluchanskaya
[email protected]

SOURCEV6CO

read more
Generic drugs

Global Generic Inhalation Drugs & Nasal Sprays Industry Expected to Reach $11.2 Billion by 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The report “Inhalation & Nasal Sprays Generic Drugs Market Intelligence Report – Global Forecast to 2027” has been added to from ResearchAndMarkets.com offer.

The global Generic Inhalation Drugs and Nasal Sprays Market is expected to reach USD 11,272.80 Million by 2027, from USD 6,883.36 Million in 2021, at a CAGR of 8.56% during the forecast period.

Market statistics:

The report provides market size analysis and forecasts for 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD and CHF. It helps organizational leaders make better decisions when currency data is readily available.

In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year and the years from 2023 to 2027 as the forecast period.

  • The Americas Generic Inhalation and Nasal Sprays Market size was estimated at USD 2,427.24 million in 2021, is projected to reach USD 2,604.45 million in 2022, and is projected to grow at a CAGR of 8.21% to reach USD 3,898.00 million by 2027.

  • Asia-Pacific Inhalation & Nasal Sprays Generic Drugs Market size was estimated at USD 1,577.49 Million in 2021, is estimated to reach USD 1,746.58 Million in 2022, and is projected to grow at a CAGR of 9.32% to reach 2 USD 693.80 million by 2027.

  • The Europe, Middle East & Africa Generic Inhalation and Nasal Spray Market size was estimated to be USD 2,878.62 million in 2021, is projected to reach USD 3,108.31 million in 2022 and is projected to grow at a CAGR of 8.44% to reach USD 4,680.99 million. by 2027.

Segmentation and market coverage:

The Generic Drugs for Inhalation and Nasal Sprays report identifies key customer attributes to define the potential market and identify various needs in the industry. Understanding the economies and geographies of the potential customer group can help build business acumen for better strategic decision-making.

This market coverage across different industry verticals reveals the hidden truth about the strategies of players in different verticals and helps the organization decide on the target audience. This report gives you a composite view of the sub-markets coupled with comprehensive industry coverage and provides you with the right method of accounting factors such as standards and regulations, culture, to build the right hedging strategy for your market plan. market.

This research report categorizes generic inhalants and nasal sprays to forecast revenues and analyze trends in each of the following submarkets:

Indication:

  • Allergic rhinitis

  • Asthma

  • COPD

Age range:

  • Adults

  • Children 2 to 5

  • Children from 6 to 12 years old

To classify:

  • allergy blocker

  • Anticholinergic

  • Antihistamine

  • Decongestant

  • mast cell inhibitor

  • nasal steroid

Itinerary:

  • Inhalation

  • nasal spray

  • Tropical Lotion

Distribution channel:

  • Hospital medical store

  • Online pharmacy

  • Pharmacy retail

Region:

  • Americas

    • Argentina

    • Brazil

    • Canada

    • Mexico

    • United States

  • Asia Pacific

    • Australia

    • China

    • India

    • Indonesia

    • Japan

    • Malaysia

    • Philippines

    • Singapore

    • South Korea

    • Taiwan

    • Thailand

  • Europe, Middle East and Africa

    • France

    • Germany

    • Italy

    • Netherlands

    • Qatar

    • Russia

    • Saudi Arabia

    • South Africa

    • Spain

    • United Arab Emirates

    • UK

Enterprise Usability Profiles:

  • AbbVie Inc.

  • Akorn, Inc.

  • Altaire Pharmaceuticals Inc.

  • Apotex Inc.

  • AstraZeneca PLC

  • Beximco Pharmaceuticals Ltd.

  • Catalent PharmaSolutions, Inc.

  • Chiesi Farmaceutici SpA

  • Cipla Limited

  • Hikma Pharmaceuticals PLC

  • Nephron Pharmaceutical Company

  • Perrigo Company PLC

  • Favorite Pharmaceuticals, Inc.

  • Sandoz International GmbH

  • Sheffield Pharmaceuticals, LLC

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

  • Viatris inc.

For more information on this report visit https://www.researchandmarkets.com/r/9xy09d

read more
Prescription drugs

Most of Dem Bill’s new prescription drug savings will take years to kick in – NBC Chicago

After decades of failed attempts, Democrats have passed legislation aimed at curbing soaring drug prices for some in the United States.

It will take years for people to realize some of the biggest savings promised in the climate and health care bill that President Joe Biden signed into law this month.

The bill primarily helps the roughly 49 million people who enroll in Medicare drug coverage. But many will be left out of direct savings after lawmakers scrap cost-cutting measures for the majority of people covered by private health insurance.

A look at how some could benefit from the drug savings provisions of the “Cut Inflation Act” and how drugmakers could push back against those efforts.

DRUG NEGOTIATIONS

For the first time, Medicare can negotiate the price of its most expensive drugs.

In the United States, “we’ve never had an entity that negotiated on behalf of such a large group of people before,” said Leigh Purvis, director of cost and healthcare access at the AARP.

This new bargaining power won’t take effect until 2025, when Medicare can negotiate the price of 10 drugs covered by its prescription plan. By 2029, Medicare will be able to negotiate the cost of as many as 60 drugs.

This will take time because the Department of Health and Human Services will have to develop a plan to select the drugs that will be traded. The convoluted rule-making process will take years to devise and will be the subject of intense lobbying and scrutiny from the pharmaceutical industry, which is eager to create loopholes in the new rules.

“The biggest boost is definitely going to be the negotiations because the secretary is setting up a whole new program, and they’re going to be doing a lot of hiring,” Purvis added.

The savings should be huge. The nonpartisan Congressional Budget Office estimates costs could fall by $100 billion over the next decade.

Which drugs Medicare and patients will save on, however, remains a bit of a mystery.

In the first year, Medicare will be allowed to negotiate the cost of the 10 drugs it spends the most money on, provided those drugs have been approved by the Food and Drug Administration for at least nine years and are not have no rival generics. on the market.

Right now, for example, the blood thinner Eliquis, used by 2.6 million Medicare beneficiaries at an annual cost of nearly $10 billion, would likely top the list.

This could encourage pharmaceutical companies to launch new drugs at a higher price, knowing that the cost of the product will be negotiated down for Medicare, warned Arthur Wong, an analyst at S&P Global, a financial research firm.

PhRMA, the trade organization that represents pharmaceutical companies, has acknowledged its intention to push back against the law.

“We are exploring all opportunities – including legislative, regulatory and legal – to ensure that patients have access to the medicines they need and that our industry can continue to develop life-saving cures and treatments,” the carrier said. PhRMA spokesman Brian Newell in a statement emailed to The Associated Press.

___

A CEILING ON THE PRICES OF DIRECT MEDICINES

The bill limits the amount of money Medicare beneficiaries must use for drugs, but, again, it will take some time for these rules to sink in.

In 2024, Medicare will remove a 5% coinsurance required of patients who have reached the catastrophic threshold, which is currently set at $7,050 for out-of-pocket drug costs. Nearly 3 million Medicare patients met that threshold at some point from 2015 to 2019, according to a Kaiser Family Foundation study.

The following year, out-of-pocket drug costs will be capped at $2,000 for Medicare Part D, which generally covers prescription drugs at home.

The Inflation Reduction Act deals with, among other things, climate change, health care and taxes. The final bill is a scaled-down version of what was originally proposed, but Democrats will still have a few talking points for this campaign season, Insider deputy editor Dave Levinthal said. “Even if it’s not all they want, it’s definitely something they can go on,” Levinthal said.

___

HOW WILL DRUG PRICES BE CONTROLLED BY THEN?

The Inflation Reduction Act includes a series of controls aimed at immediately mitigating rising Medicare drug costs. The bill caps copayments for insulin at $35 per month starting in January, but only for Medicare beneficiaries. A limit of $35 per month on out-of-pocket expenses for people with private health insurance has been reduced.

Starting next year, drug companies will also have to pay a rebate to Medicare if they raise the cost of a drug above the rate of inflation. The industry consistently raises drug prices above inflation every year.

A similar rule exists in Medicaid, so the Centers for Medicare and Medicaid have experience running that program, said Rachel Sachs, a law professor at Washington University in St. Louis.

“They were helpful in controlling the rate of increase,” she said of the discounts.

Only Medicare patients will benefit directly. A decision to include in the calculation people with private insurance who are sold overpriced drugs has been removed from the legislation.

Some health policy experts hope this provision, along with the others in the package, will help insurance companies negotiate drug prices for their customers, potentially extending savings to millions of people.

But others are waiting to see if the bill has the opposite effect. Medicare accounts for about a third of the pharmaceutical industry’s market, which means companies could try to squeeze more profits from elsewhere.

“It could be a threat that non-Medicare payers end up having to pay more or at least face tougher negotiations with the pharmaceutical industry,” analyst Wong said.

The House on Friday passed a bill that fights climate change, expands health coverage and raises corporate taxes.

read more
Prescription drugs

Naomi Judd left a suicide note, on several prescription drugs during her death

At Naomi Judd’s Official autopsy report has been made public, and it reveals that she left a suicide note for her family before killing herself.

According to the report obtained by The Blast, Naomi was found in her home after sustaining a “self-inflicted” gunshot wound to the head. The report said she had “a significant medical history for anxiety, depression, bipolar disorder” and other major medical conditions.

Authorities investigating the death revealed in the final report that the family told them Naomi had had “previous suicidal thoughts” and was going through a recent “life stressor” at the time of her death.

Specifically, a weapon and “a note with suicidal connotations” were found near her at the scene.

Naomi Judd was taking multiple prescription medications at the time of her death

Mega

The court documents say the 76-year-old singer was “discovered unresponsive at her home by her family on April 30, 2022. She apparently sustained a gunshot wound and was transported to Williamsson Medical Center where she was pronounced dead. shortly after his arrival.”

Several prescription drugs were found in Judd’s system after investigators performed a toxicology report on his blood. Medications included “etomidate, clonazepam, primidone, venlafaxine, trazodone, and memantine.” The report reveals that the list includes drugs for the treatment of insomnia and seizure disorders and the treatment of Alzheimer’s disease. She was also said to have been taking several antidepressants at the time of her death. No street drugs were detected in his system.

As one can imagine, the report gives a vivid and tragic description of the gunshot wound to the head, which we choose not to describe here. But, the cause of death has been officially ruled as a “gunshot wound to the head” and the manner of death is “suicide”.

Ashley Judd stayed with her mother while waiting for paramedics to arrive

Naomi Judd left a suicide note for her family, on several prescription drugs during her death
MEGA

As we reported, about a month after her mother’s death, her daughter Ashley Judd, 54, appeared on “Good Morning America” ​​and informed Diane Sawyer and the world that her mother had killed herself with a gun.

“My mom used a gun, so that’s the information we’re very uncomfortable sharing,” she said at the time. While the family don’t want this information out in the public eye, they admitted, “But understand we’re in a position where if we don’t say it, someone else will.”

A new court filing published by The Daily Beast earlier this month revealed that Noemie Judd was still alive after discharging the gun, and Ashley had stayed by her mother’s side for thirty minutes while waiting for paramedics to arrive. The documents describe Ashley as being in a state of “clinical shock, active trauma and acute distress” when she spoke to law enforcement officials who arrived at the scene.

Naomi Judd left a suicide note for her family, on several prescription drugs during her death
MEGA

In her interview with GMA, Ashley also opened up about her mother’s struggle with mental health, which the “Love Can Build A Bridge” singer had been very candid about.

“When you’re talking about mental illness, it’s important to distinguish between the loved one and the illness,” Ashley explained, adding, “My mom knew she had been seen and heard in her anguish and that she was escorted home.

Larry Strickland describes Naomi Judd as “fragile” before her death

Naomi Judd 1946-2022
MEGA

Larry Stickland married Naomi Judd in 1989 and they were together for over thirty years. He spoke about his late wife at the Ryman Auditorium in Nashville, Tennessee, during CMT’s “Naomi Judd: A River of Time” special in May.

“Namoi has never met a stranger,” Larry said, as reported by PEOPLE. “To my annoyance, she would strike up a conversation with everyone who looked her in the eye, and we would end up standing 10, 20, 30 minutes on a sidewalk while she talked to a complete stranger about their passions and their dog. .”

He described a time when Naomi flew alone from Austria to Nashville for the Country Music Hall of Fame ceremony, which took place just a day after she took her own life. Larry noted that it was unusual for his wife to fly alone.

“I was really scared to death that she would fly alone from Vienna to Nashville because I knew how fragile she was,” he recalled. Many famous fans and friends continue to mourn his loss in the country music community.

read more
Generic drugs

Novartis Announces $9.6 Billion Spin-off of Sandoz Generic Drugs Biz

By Ashish Sareen (August 25, 2022, 12:59 BST) – Swiss-American pharmaceutical giant Novartis AG on Thursday announced plans to spin off its Sandoz generic drugs division from its core innovative drug development business to form a listed standalone company. in stock exchange. company through a 100% spin-off.

Novartis said the spin-off transaction, which requires final board approval and shareholder approval, is expected to be completed in the second half of 2023.

Details of the law firms acting for Novartis and Sandoz on the deal were not immediately available.

The Sandoz company that will exist after the separation – which Novartis claims would be Europe’s leading generic drug company, with…

Stay one step ahead

In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

  • Access to case data in articles (numbers, filings, courts, nature of lawsuits, etc.)
  • Access to attached documents such as briefs, motions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and more!

TRY LAW360 FREE FOR SEVEN DAYS

read more
Medical supplies

Expanded government meeting to discuss medical supplies

The government of national unity convened a large meeting with regulatory institutions to discuss three issues related to the supply of drugs and the satisfaction of the medical supply needs of the country’s health facilities.

The meeting was attended by the Prime Minister of the National Unity Government, Abdel Hamid Dbeibah, his deputy, the acting Minister of Health, Ramadan Abu Janah, and several officials representing national agencies, programs and large hospitals.

The governor of the Central Bank of Libya and the heads of the Audit Office, the Administrative Control Office, the Internal Security Agency and the Municipal Guard also attended the meeting.

They reviewed the results of the technical committee, made up of specialists from the Ministry of Health and the Homeland Security Agency. The committee was tasked with determining the types of drugs that are effective and of high quality, according to the Health Ministry statement.

The meeting also discussed the strengthening of legal and regulatory procedures of the medicine, and the implementation of a national pharmaceutical policy aimed at strengthening the system to ensure the quality, safety and efficacy of medicines and health products. , and import essential drugs.

He further reviewed the steps taken by the Ministry of Health in coordination with regulatory authorities to implement the state public tender, to meet the medical needs of health facilities across the country. country.

read more
Medical supplies

Recommendations to address drug and medical supply shortages should be assessed: PM | Health

Illustrative image (Photo: VNA)

Hanoi (VNA)
– Prime Minister Pham Minh Chinh asked Acting Minister of Health Dao Hong Lan to consult experts on solutions to address the current shortages of drugs and medical supplies, thereby giving appropriate and timely guidance for this issue in medical examination and treatment facilities.

According to Document No. 514/VPCP-KGVX dated August 24, 2022, Prime Minister Chinh requested the Acting Minister of Health to carefully evaluate expert recommendations to guide the implementation of appropriate solutions.

Recommendations to address drug and medical supply shortages should be assessed: PM hinh anh 2Illustrative image (Photo: VNA)

Previously, the Government Portal hosted a seminar on measures to address shortages of medicines and medical supplies, during which participants highlighted the causes of the
drug shortage and medical supplies, and proposed solutions to the problem.

They stressed the need to assess the extent and situation of drug shortages at all levels, from central health facilities to local facilities, and to determine the cause of drug shortages in each unit.

A number of drug price-related contents in the Pharmacy Law and the provisions of the
auction law must be considered, they said.

The Ministry of Health was reminded to urgently modify and publish soon circulars relating to tender instructions, drug registration and prices; and guidelines for the purchase of medical equipmentpment, including medical supplies.

Issues under the authority of the Ministry of Health, Ministry of Finance and Ministry of Planning and Investment, which remain blocked and affect relevant tendering activities, need to be revisited, the officials said. attendees.

They also stressed the need to improve the capacity and accountability of agencies relating to tender work, to strengthen state governance at all levels and to promote the application of information technology in this work.

According to Dao Khanh Tung, a representative of the United Nations Development Program (UNDP) in Vietnam, the state can significantly save on drug costs the way UNDP supports countries.

Specifically, every two years, UNDP will organize a global tender and then negotiate with manufacturers and suppliers of medicines and medical supplies around the world to help poor and developing countries access the right supply of medicines. generics, brand name drugs and other medical products. at their fair prices.

UNDP support aims to minimize intermediate steps and provide price transparency, thus benefiting not only patients but also countries with already tight budgets, Tung./ said.

read more
Prescription drugs

Will a Medicare Advantage plan with prescription drugs prevent the “extra” Part D premium?

Hello Tony:

I will be 65 in October, I am self-employed and my income is over $250,000. Recently, I received a letter from the Social Security Administration (SSA) advising me that my monthly Medicare Part B premium of $170.10 would be doubled to $340.20 per month due to reported earnings in 2020. This wasn’t a surprise, but Social Security also said the monthly adjustment for prescription drug coverage would be an additional $51.70. What is all this?

I am in excellent health and do not take any prescriptions. What if I don’t apply for Medicare prescription drug coverage? Do I still have to pay the “extra” $51.70?

What happens if a person takes the Medicare Advantage route instead of Original Medicare and a Medicare Supplement? Do they avoid the extra $340.20 per month for Part B and the $51.70 per month extra premium for a Medicare Part D prescription drug plan?

– Mike from Oklahoma City, Okla.

Tony King [ Courtesy of Toni King ]

Mike,

Sorry, Mike, but you can’t avoid additional IRMAA (monthly income-related adjusted amount) premiums if your income exceeds a certain limit, regardless of whether you’re enrolled in original health insurance and supplemental Medicare or a Medicare Advantage plan with prescription drug. It will happen anyway!

Social Security bases your income on you and your spouse (if married), whether or not your spouse is of Medicare age. The MAGI (modified adjusted gross income) amount that is reported on your annual income taxes is what triggers the increase in IRMAA.

Ultimately, if your income exceeds these amounts and you have your Medicare prescription drug plan from a Medicare Advantage prescription drug plan (Part C) or a standalone drug plan on a Medicare (Part D) prescription, you’ll pay the additional IRMAA premium whether you deduct your premiums from your Social Security check or pay Social Security directly (because you haven’t started receiving your Social Security check social).

If you are not enrolled in a Medicare Part D prescription drug plan, whether standalone or with a Medicare Advantage plan, you will not receive the additional Part D IRMAA premium (monthly amount adjusted for revenue). It’s not a wise decision, however, not to enroll in a Medicare Part D plan just because you’re not taking prescriptions when you enroll in Medicare.

Remember, if you are not enrolled in a Medicare Part D prescription drug plan at the right time, not only will you not have prescription drug coverage, but you will also receive an enrollment penalty. late for Part D if you enroll later.

That’s why at Toni Says’ office, we advise everyone to enroll in a Part D prescription drug plan, whether you take no prescriptions or take a lot. No one wants additional punishment.

Track trends affecting the local economy

Track trends affecting the local economy

Subscribe to our free Business by the Bay newsletter

We’ll break down the latest business and consumer news and information you need to know every Wednesday.

You are all registered!

Want more of our free weekly newsletters in your inbox? Let’s start.

Explore all your options

Enrolling in a Medicare Advantage plan instead of Original Medicare with a Medicare/Medigap Supplement and a Medicare Part D plan does not not prevent Medicare or Social Security from charging the additional IRMAA premium for Medicare Parts B and D. The IRMAA Medicare rule for Medicare Part D supplemental IRMAA premiums went into effect on January 1, 2011.

Because the annual Medicare and You Handbook is usually mailed out by October 1, Medicare costs and premiums for that specific year are not included. You should look for annual Medicare costs and premiums that will be released around November 10.

• • •

Toni King is an author and columnist on Medicare and Medicare issues. She has spent over 27 years as a sales leader in the fields. For answers to Medicare questions, email: [email protected] or call 832-519-8664.

read more
Medical products

Utah Medical Products (NASDAQ:UTMD) Stock Price Crosses Above the 200-Day Moving Average of $87.52


Utah Medical Products, Inc. (NASDAQ:UTMDGet a rating) the stock price rose above its 200-day moving average during Tuesday’s session. The stock has a 200-day moving average of $87.52 and is trading as low as $91.11. Shares of Utah Medical Products last traded at $90.32, with a volume of 3,271 shares traded in hands.

Utah medical product inventory performance

The company has a 50-day moving average of $87.35 and a 200-day moving average of $87.52. The company has a market capitalization of $327.41 million, a price-earnings ratio of 20.72 and a beta of 0.26.

Utah Medical Products (NASDAQ:UTMDGet a rating) last released its quarterly earnings data on Tuesday, July 26. The medical device supplier reported EPS of $1.12 for the quarter. The company had revenue of $13.43 million for the quarter. Utah Medical Products had a net margin of 31.18% and a return on equity of 14.69%.

Utah Medical Products Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 5. Shareholders of record on Friday, September 16 will receive a dividend of $0.29 per share. This represents a dividend of $1.16 on an annualized basis and a yield of 1.28%. The ex-dividend date is Thursday, September 15. Utah Medical Products’ dividend payout ratio (DPR) is currently 26.61%.

Institutional entries and exits

A number of hedge funds have recently increased or reduced their stakes in the company. Amalgamated Bank acquired a new position in Utah Medical Products stock during Q1 worth approximately $39,000. Acadian Asset Management LLC acquired a new position in Utah Medical Products during the first quarter valued at approximately $40,000. BNP Paribas Arbitrage SA increased its stake in Utah Medical Products by 97.7% in the second quarter. BNP Paribas Arbitrage SA now owns 779 shares of the medical device supplier valued at $67,000 after buying 385 additional shares last quarter. Lazard Asset Management LLC increased its position in Utah Medical Products shares by 21.3% during the first quarter. Lazard Asset Management LLC now owns 837 shares of the medical device supplier worth $75,000 after purchasing an additional 147 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in Utah Medical Products shares by 57.0% during the 1st quarter. MetLife Investment Management LLC now owns 2,030 shares of the medical device supplier worth $182,000 after buying 737 additional shares in the last quarter. Institutional investors hold 71.44% of the company’s shares.

Utah Medical Products Company Profile

(Get a rating)

Utah Medical Products, Inc. develops, manufactures and distributes medical devices for the healthcare industry. The Company offers fetal monitoring accessories, vacuum assisted delivery systems and other labor and delivery tools; Respiratory hoods for newborns DISPOSA-HOOD; and DELTRAN PLUS blood pressure monitoring systems.

Featured Articles



Receive daily news and reviews for Utah medical products – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Utah Medical Products and related companies with MarketBeat.com’s free daily email newsletter.

read more
Medical supplies

The disposable medical supplies market to see through

The disposable medical supplies market is expected to witness amazing growth shortly. Embedded medical technologies facilitate cloud-based online health records. They thus make way for a well-calibrated care plan and devote less time to assimilating information. This means improving workflows and the medical IoT. The healthcare vertical would therefore take the remotely appropriate automobile route shortly.

Sales of gloves will contribute significantly to the growth of the global market
According to the WHO, 15% of hospitalized patients suffer from nosocomial viral, bacterial and fungal infections. To prevent and reduce the prevalence of nosocomial infections, several measures, such as the use of sterile and disposable products, pre-packaged medical kits, sterile medical devices and disposable gloves, among other disposable medical supplies, are taken.

Healthcare workers use a number of disposable medical supplies and protective equipment, such as surgical drapes, surgical gowns, surgical gloves, eye protection equipment, face masks, etc., during the execution of operations.

Plan ahead? Get Access to Sample Disposable Medical Supplies Market Report! https://www.persistencemarketresearch.com/samples/3242

Company Profiles
• Cardinal Health, Inc.
• Covidien plc.
• 3M Healthcare Ltd.
• Halyard Health, Inc.
• Molnlycke Health Care AB
• Medline Industries Inc.
• Sempermed USA, Inc.
• Ansell Healthcare LLC
• Nipro Corp.
• McKesson Corp.

Disposable Medical Supplies Market: Key Dynamics Impacting Growth
The increased awareness of nosocomial infections and the crucial role played by disposable medical supplies are the two factors preventing the rapid spread of these infections. The European Center for Disease Prevention and Control (ECDC) has reported that one in 18 patients in European hospitals suffers from a hospital-acquired infection (HAI).

On average, approximately 3.2 million patients per year suffer from IAS. Disposable medical supplies are used in the treatment of numerous infectious diseases, which is expected to drive the growth of the disposable medical supplies market over the forecast period.

An increasing number of surgeries performed globally is another significant factor expected to drive the disposable medical supplies market. Likewise, the rising focus of governments of various countries on regularizing the healthcare profession by implementing strict guidelines will further enhance the disposable medical supplies market revenue. Various hygiene awareness programs in various regions promote the use of disposable medical supplies, such as gloves, gowns and sheets.

The continuous innovations of disposable medical supplies manufacturers, the lucrative marketing strategies used by companies, and the development of disposable medical supplies with better protection quality, such as disposable gowns, sheets, gloves, feeding tubes and others, etc are expected to further boost the Disposable Medical Supplies Market.

How about revitalizing the strategy-driven funnel to stay ahead of the disposable medical supplies market? https://www.persistencemarketresearch.com/methodology/3242

Some disposable medical supply products, such as procedure kits and trays, reduce workload and allow for a simple and efficient workflow. The global disposable medical supplies market is expected to be driven by the growing number of end users, rising healthcare expenditure per capita, and increasing number of surgeries.

The rapid growth in the healthcare industry is the major driver of growth in the global disposable medical supplies market. Rising demand for disposable gloves and growth in the healthcare sector will in turn propel the growth of the disposable medical supplies market.

According to a latest report published on NCBI, of the total surgical gowns consumed in the United States, more than 80% are disposable. The use of disposable surgical gowns is also increasing in the emerging regions of APAC and MEA due to increased hospital budget and improved living standard of people in these regions.

However, pricing pressure and saturation of the disposable medical supplies market are the two factors that will limit the growth of the disposable medical supplies market over the forecast period.

Thinking of introducing an offbeat product/technology to the disposable medical supplies market? Go to “Buy Now” to get our disposable medical supplies market report! https://www.persistencemarketresearch.com/checkout/3242

Disposable Medical Supplies Market: Segment Insights
The disposable medical supplies market is segmented on the basis of product type and end users. Based on product type, the disposable medical supplies market is segmented into surgical drapes, feeding tubes, gloves, gowns, and procedure kits and tray.

On the basis of end users, the disposable medical supplies market is segmented into Tier 1 hospitals (>500 beds), Tier 2 hospitals (250-500 beds) and Tier 3 hospitals (

Contact us:
Address – 305 Broadway, 7th Floor, New York, NY 10007 USA
Telephone in the United States – +1-646-568-7751
USA-Canada Toll Free – +1 800-961-0353
Sales – [email protected]
Website – https://www.persistencemarketresearch.com

About Us:
Persistence Market Research is here to provide businesses with a one stop solution when it comes to improving customer experience. It is committed to gathering appropriate feedback after going through personalized customer interactions to add value to the customer experience by acting as the “missing” link between “customer relationships” and “business results”. The best possible yields are guaranteed.

This press release was published on openPR.

read more
Prescription drugs

The non-prescription drug market will receive a crushing rise

Medicines without a prescription

Global Non-prescription Drugs Market research report provides key analysis on the state of the Non-prescription Drugs market with best facts and figures, meaning, definition, SWOT analysis, expert opinions and insights. latest developments around the world. The report also calculates the market size, sales, price, revenue, gross margin, market share, cost structure, and growth rate. The report considers the revenue generated from the sales of this report and technologies by various application segments and browse the market data tables.

The Non-Prescription Drugs Market report covers the various market scenarios which have a direct impact on the growth of the market. The Non-Prescription Drugs report study includes insights into market factors such as market dynamics, including drivers, restraints, challenges, threats, potential growth opportunities, market trends, development models, financial information, latest technologies, innovations, main competitors and regions. market analysis.

Request more information about this report (use corporate email id for higher priority): https://www.worldwidemarketreports.com/sample/720473

The following key players are mentioned in this document:

✤Pfizer
✤ Rock
✤Sanofi
✤Johnson & Johnson
✤ Merck & Co (MSD)
✤ Novartis
✤ AbbVie
✤ Gilead Sciences
✤ GlaxoSmithKline (GSK)
✤ Amgen
✤ Astra Zeneca
✤ Bristol Myers Squibb
✤ Eli Lily
✤ Teva
✤ Bayer

Non-prescription Drugs Market Analysis by Type

✤ Brand name drugs
✤ Generic drug

Non-prescription Drugs Market Analysis by Application

✤ Hospital
✤ Clinic

Get a sample to understand more details about Non-Prescription Drugs Market segments: https://www.worldwidemarketreports.com/sample/720473

Regional Analysis For Non-prescription Drugs Market:

North America (USA, Canada)
Europe (UK, Italy, Germany, France, Rest of EU)
Asia-Pacific (India, Japan, China, South Korea, Australia, rest of APAC)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa, Rest of MEA)

(*NOTE: To achieve customization to your liking, you can ADD/remove key players, regions, and any other segments as needed.)

How Covid 19 has affected the non-prescription drug market

Since the outbreak of the COVID-19 virus in December 2019, the disease has spread to almost every country in the world, with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already beginning to be felt and will significantly affect the non-prescription impact medication market in 2020. The COVID-19 outbreak has impacted many aspects, such as flight cancellations. , travel bans and quarantines, restaurants closed, all indoor/outdoor events restricted, state of emergency declared in over forty countries, massive supply chain slowdown, stock market volatility, declining business confidence, growing panic among the population and uncertainty about the future.

Obtain specified sample containing COVID 19 details: https://www.worldwidemarketreports.com/sample/720473

In this segment, we will give you the impact of COVID-19, how it has affected the non-prescription drug market and how it will change the future of the industry based on the current government, private and public situation. Our expert analysts keep an eye out for any situations that could alter the flow of the industry, helping you make the best possible decision for your business.

The objective of the study is to define the Non-Prescription Drugs market size of different segments and countries in previous years and to forecast the values ​​to the next Five years. The report is designed to incorporate qualified qualitative and quantitative aspects of the industry with respect to each region and country involved in the study. Furthermore, the report also provides detailed information about crucial aspects such as drivers and restraining factors which will define the future growth of the Non-prescription Drugs market.

You can buy this report here: https://www.worldwidemarketreports.com/buy/720473

Report cover

• Provides a comprehensive understanding of Non-Prescription Drugs Market using informed market outlook, opportunities, challenges, trends, size and growth, competitive analysis, top competitors and top five analysis by Porter
• Identifies key growth drivers and challenges for key industry players. Also, assesses the future impact of propellants and restraints on the market
• Discover potential market demands
• Porter’s analysis identifies competitive forces in the market
• Provides information on historical and current market size and future market potential
• Provides size of key regional markets using process, segment, product, end user, technology, etc. criteria. (if applicable)
• Highlights the competitive scenario of the market, major competitors, market share, benchmarking, investments and merger acquisitions

Why Choose Non-Prescription Drugs Market Report?

• Unbiased conclusions and market overview
• Customer service available 24/7 to answer customer questions
• Highly efficient and experienced team of analysts striving to create top quality reports
• Our reports have facilitated the growth of more than 500 companies
• A systematic and methodical market research process

Contact us:

Global Market Reports,
Tel: USA +1-415-871-0703
UK +44-203-289-4040
Japan +81-50-5539-1737
Email: [email protected]
Website: https://www.worldwidemarketreports.com/

About WMR:

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by a long list of publishers around the world. We offer reports on virtually every domain and an extensive list of subdomains under the sun. In-depth market analysis by some of the most experienced analysts provides our diverse range of clients across all industries with essential decision-making insights to plan and align their market strategies with current market trends.

This press release was published on openPR.

read more
Medical products

Zavation Medical Products Receives 510(k) Clearance from the FDA for the Varisync Anterior Cervical Plate and Spacer System





Two- and four-hole Varisync plates (Zavation)

Zavation Medical Products has received 510(k) clearance from the United States Food and Drug Administration (FDA) for Varisync, a cervical intervertebral fusion device.

The newest addition to the Zavation cervical spine portfolio, Varisync has been tested and approved for independent and synchronized use of its plate and spacer components. This allows surgeons to use plate and spacer options together as a system or pair individual components with one of Zavation’s existing cervical portfolio options.

The Varisync plate has attributes that include visual and tactile lock confirmation, ideal screw angulation, multiple insertion devices, and optimal spacer placement in the disc space, according to the company.

Jeffrey Johnson, CEO of Zavation, said, “Our product development team’s dedication to creatively combining simplicity and precision in robust product design has produced a product that we believe is the new benchmark in facilitating the merging of patients in a transparent and simplified procedure.

“With the many interbody offerings from Zavation, it makes sense that we would develop a device that allows surgeons to easily integrate and place a plate and spacer combination of their choice. This product is an example of Zavation’s commitment to Zavation to offer innovative and differentiated products in conjunction with market-leading customer service to better serve our surgeons and distributor network.








read more
Medical supplies

Ivy Tech Fort Wayne/Warsaw donates medical supplies to One World Medics charity

read more
Medical supplies

Medical supplies sent from Swindon warehouse to help Ukrainian refugees

PILES of hygiene products and medical equipment have been sent from a warehouse in Swindon to help Ukrainian refugees.

Mitie has shipped life-saving PPE and other supplies to the GE Operator Humanitarian Center in Warsaw, which will be used for essential medical care and general hygiene for those fleeing the war-torn country.

Equipment, including sanitizer, gloves and coveralls, was transported to the GE Operators Humanitarian Center in Warsaw from Mitie’s warehouse in Swindon.

The center in Poland provides temporary shelter and assistance to people displaced by war in Ukraine and has so far supported over 52,000 refugees by providing a safe place to stay, medical care and psychological support, as well as help to organize their trip to the countries. through Europe.

Mitie, who previously ran the UK government’s Covid-19 testing centers throughout the pandemic, collected excess stock of PPE stored in its warehouse in Swindon and repurposed it for rescue and relief efforts following to an increase in demand for support at the Ukrainian border.

With the help of humanitarian partner Stronghold Global, Mitie packed and shipped an articulated truck full of disinfectant, toilet cleaner, wipes, spill kits, coveralls, gowns, masks, face shields and gloves in the Polish capital, answering the call for vital supplies by the humanitarian centre.

Mark Donnelly directed the project for Mitie with Stuart Bleazard and Iain Taylor.

Mark explained: “The Global Humanitarian Center in Poland is a huge venue equivalent to the size of the NEC in Birmingham which is quickly filling up with people in need.

“As the numbers increase, the demand for cleaning products at the center increases. Hygiene in the camp is vital, especially as the number of refugees increases.

“The center was reaching out to UK businesses for donations of cleaning supplies and I knew Mitie could step in and answer the call for help.

“The truck has now arrived in Warsaw, and we are honored to have been able to make a small difference for those fleeing war in Ukraine.”

Krzysztof Szczęsny from the center of Warsaw said: “PPE and hygiene equipment are so important for us to provide the necessary medical support and treatment to the people in our care and to ensure that we have a safe place and hygienic for Ukrainians fleeing the war. Thank you Mitie for answering the call – it will make a substantial difference in our humanitarian efforts.

Donate to www.poland4you.org

read more
Medical products

Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoRevealTM Dx Colon Cancer Test | Company

read more
Medical products

Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoRevealTM Dx Colon Cancer Test | Nation/World

NATICK, Mass.–(BUSINESS WIRE)–August 22, 2022–

Biosciences Pillar, the leader of Decision Medicine™, developers and distributors of next-generation sequencing (NGS) assays that localize testing and reduce time to treatment initiation and overall testing costs, today announced that its oncoReveal assay TM Dx Colon Cancer Assay has received approval from China National Medical Products Administration (NMPA). The IVD test is now commercially available in China, the United States and Europe as a companion diagnostic (CDx) to identify colorectal cancer patients whose tumors express wild-type KRAS status and may benefit treatment with specific targeted therapies.

“The oncoReveal™ Dx Colon Cancer Test localizes NGS testing and efficiently provides a highly accurate genetic profile of KRAS mutations in patients with metastatic colorectal cancer,” said Randy Pritchard, CEO of Pillar Biosciences. “This approval is important for oncologists across China who need a more streamlined, efficient and accurate way to identify the right treatment for their individual patients. By making testing more widely available and enabling faster results, we can significantly reduce the time it takes to initiate treatment and enable patients to continue with more confidence throughout their life course.

The oncoReveal™ Dx Colon Cancer Test is a companion diagnostic test that identifies patients with metastatic colorectal cancer who have KRAS wild-type tumor status and may benefit from treatment with approved therapies, Erbitux® (cetuximab) or Vectibix® (panitumumab). The test uses Pillar’s highly accurate and sensitive SLIMamp® NGS test technology to generate data that optimizes the selection of precision therapies for cancer patients. It is the company’s first NMPA-approved diagnostic product. Pillar’s oncoReveal™ Dx Lung & Colon Cancer Assay previously received CE-IVD certification in Europe in April 2020 and Premarketing Approval (PMA) from the U.S. Food and Drug Administration (FDA) in July 2021.

About Pilar Biosciences

Pillar Biosciences is the leader in Decision Medicine™, which uses highly accurate and sensitive next-generation sequencing (NGS) assay technology to generate data that optimizes the selection of precision therapies for cancer patients, from profiling of the tumor to therapy selection and recurrence monitoring. Pillar’s NGS testing solutions, including the FDA-cleared oncoReveal™ Dx lung and colon cancer test, are powered by the company’s proprietary SLIMamp® and PiVAT® technologies, and decentralize the testing process, reducing diagnostic costs and improving access and efficiency of complex NGS tests for pathologists, prescribers and patients worldwide. The company has more than 20 NGS test products available in IVD or RUO formats, and several more in various stages of development, including an oncoReveal™ CDx pan-cancer test and two liquid biopsy offerings. Pillar’s patented technologies have been shown to deliver accurate, actionable data in as little as 48 hours, allowing physicians to select appropriate therapies and monitor patient response. Pillar Biosciences has operations in Natick, MA and Shanghai, China. For more information, visit www.pillar-biosciences.com.

Show source version on businesswire.com:https://www.businesswire.com/news/home/20220822005134/en/

CONTACT: Investor Contact:

Dawn Schottlandt

Slang Partners

212-600-1902

[email protected]

Media Contact:

Joshua R. Mansbach

Slang Partners

212-600-1902

[email protected]

KEYWORD: MASSACHUSETTS CHINA UNITED STATES NORTH AMERICA ASIA PACIFIC

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICALS MEDICAL SUPPLIES ONCOLOGY GENERAL HEALTH HEALTH GENETICS CLINICAL TRIALS

SOURCE: Biosciences Pillar

Copyright BusinessWire 2022.

PUBLISHED: 08/22/2022 07:00 / DISK: 08/22/2022 07:02

http://www.businesswire.com/news/home/20220822005134/en

Copyright BusinessWire 2022.

read more
Medical supplies

Volunteers Provide Medical Supplies – Knox County VillageSoup

CAMDEN— On a beautiful summer Saturday morning, August 20, when many were thinking about going for a swim or “triage,” a group of local residents volunteered their time to sort medical supplies from a warehouse on the street Mount Battie.

Supplies are being directed to places of great need, including war-torn regions such as Ukraine, Syria, Liberia and Mali.

Elizabeth McLellan of Partners for World Health, left, sorts medical supplies in Camden with Anna Rich, centre, and Kate Rich. Kate is a nurse at Pen Bay Medical Center. Photo by Daniel Dunkle

The volunteer effort in Camden began a few years ago when Alison McKellar started collecting supplies for NuDay Syria, to help refugees displaced by war in that country. Now the volunteers are working with Partners for Global Healthwhich was founded by Elizabeth McLellan, a Camden native and nurse.

The donated goods, some of which are still deposited on McKellar’s porch in Camden, go to several countries. The biggest difference in the operation, according to volunteer Angeline Ferris from Camden, is that it now only takes donations of medical supplies, although Beanie Babies are also welcome.

Alison McKellar from Camden moves medical supplies through a warehouse in Mount Battie Street. The supplies will be donated to people in other countries in need. Photo by Daniel Dunkle

McLellan, McKellar and a team of about 10 volunteers worked to sort through medical supplies which included hospital gowns, IV equipment, walkers, wheelchairs, beds and many other items. Supplies will be trucked to Partners for World Health headquarters in Portland and from there delivered to those in need around the world.

Our hospitals and medical facilities often throw away medical supplies that can still be used in other countries, and this organization captures those items and keeps them from being wasted.

The organization has five warehouses in Maine and out-of-state facilities as well.

McLellan said he receives help from as many as 800 volunteers.

She added that medical missions to Bangladesh and Nepal are planned for October and the group still needs a medical oncologist and a gynecological surgical oncologist. Those interested in helping can call 207-774-5555.

The Mount Battie Street warehouse is owned by Michael Mullins. The group said it helped them provide them with space, use of a forklift and trash cans.

Wendy Rich from Camden helps sort out donated medical supplies to help people overseas. Photo by Daniel Dunkle

Alison McKellar’s dog, Timber, offers moral support during the sorting party at a warehouse in Camden on Saturday August 20. Photo by Daniel Dunkle

” Previous

Next ”


read more
Prescription drugs

Prescription drugs: “Make science work for America”

The availability of promising new drugs to improve or even save our lives depends on an important but little-known federal law, the Prescription Drug User Fee Act (PDUFA). This law will expire in September if Congress does not renew it this summer.

As someone who works with biomedical researchers and as a patient, I know firsthand how important PDUFA is to providing Americans with new drugs safely and in a timely manner. Before PDUFA, it often took years for a promising new drug to go through the government approval process, unnecessarily pushing treatments away from patients whose lives could be better with them. With the establishment of PDUFA over the past 30 years, the biopharmaceutical industry and the FDA have enjoyed a constructive relationship that has eliminated undue delays while ensuring drug safety and efficacy.

PDUFA’s drug screening and approval process works. We do not want the return of delays that deprive patients of the means to improve their lives. As an advocate and as a patient, I believe Congress should take action and reauthorize PDUFA as soon as possible, so we can continue to make science work for America.

Ken Gordon, Seattle, Executive Director, Northwest Association, Biomedical Research

read more
Prescription drugs

County vigil to shed light on addictive prescription drugs

The Hope and Remembrance Memorial was established in 2020 to remember those who lost their lives to the disease of addiction.

Camden County will host its sixth annual Memorial Vigil of Remembrance and Hope in memory of those who lost their lives to drug overdoses on August 31, International Overdose Awareness Day.

“When we launched our Opioid Addiction Task Force (in 2014), one of our goals was to educate the public about the problem of substance use disorders and also to try to remove the stigma associated with trouble,” County Commissioner Louis Capelli said.

“We believed that by recognizing those who had tragically lost their lives to substance abuse disorders, we could remove the stigma and educate the public at the same time.”

Cappelli noted that factors driving the number of overdoses include addictive prescription drug abuse.

“When the makers of these pills went to doctors, they said the pills are not addictive, so our medical community has come to rely heavily on opioids for pain treatment,” Cappelli explained. . “Unfortunately, the pills are addictive. The manufacturers were aware and so we need to educate the public about the dangers of taking these prescribed drugs.

A slide show during the vigil will identify those who have lost their lives to overdose and feature speakers who will address the impact of overdose on loved ones. New cobblestones will also be added to the memorial site.

The CDC estimates that more than 100,000 people in the United States have died of drug overdose between April 2020 and April 2021, an increase of 56,000 from the previous year. According to nj.gov, New Jersey recorded 3,124 suspected drug overdoses in 2021, including 335 in Camden County.

The vigil’s keynote speaker will be Mantua resident Tanya Niederman, whose 19-year-old son Justin died earlier this year from fentanyl poisoning.

“I hope we can find ways to make this (reality) more real so that people can kind of understand,” Niederman said, noting that her son was a recreational cocaine user. “I feel like every opportunity I have to tell a story and what happened to him, and our family is an opportunity to save a life.

“The reality is that nothing I do or say will bring it back, but we can try to prevent it from happening to anyone else.”

Camden County offers many mental health and addictions resources, including a fentanyl awareness campaign and a substance abuse task force that recommends policies and initiatives. Cappelli said a policy to make narcan more widely available in schools and buses is in the works.

The Memorial Vigil of Remembrance and Hope will be held at 7:30 p.m. at Timber Creek Park in Blackwood. Those interested in having their loved one featured in the slideshow should submit their name and photo to https://bit.ly/3dA89L8. People who have submitted photos in the past will need to submit again for this year.

People struggling with addiction can call the county helpline at (877) 266-8882. To learn more about addiction resources, visit https://www.camdencounty.com/service/mental-health-and-addiction/addiction-resources/

read more
Medical products

Sorrento Therapeutics Announces China National Medical Products Administration (NMPA) IND Clearance for STI-1558, an Oral Mpro Inhibitor for Phase I Trial in Patients with COVID-19

  • STI-1558, an oral major protease of SARS-CoV-2 (Mpro), which can block viral replication, is specifically designed as a stand-alone treatment for COVID-19 without ritonavir as a booster.
  • The single ascending dose (SAD) portion of the phase I study in healthy subjects was completed in Australia with the maximum dose of 2000 mg. There were no serious adverse events (SAEs) or treatment-related serious adverse events (TEAEs) and the pharmacokinetics (PK) were dose-proportional.
  • In the phase I trial in China authorized by the NMPA, STI-1558 will be administered to subjects with COVID-19 in multiple ascending doses (MAD) with three dose cohorts, including 300 mg BID, 600 mg BID and 800 mg BID, to assess safety, tolerability and efficacy, to be conducted alongside the MAD portion of the study in healthy subjects in Australia.

SAN DIEGO, Aug. 19, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced NMPA clearance for a Phase I study of its oral lead viral protease (Mpro) inhibitor, STI-1558, in subjects with COVID-19 in a MAD study in China.

In a previously announced Australian phase I study in healthy subjects, the SAD part with four dose cohorts (300 mg, 600 mg, 1200 mg and 2000 mg) was completed. The MAD portion of the study is commencing and STI-1558 has been well tolerated to date with only a few associated adverse events, which have been transient and mild in severity. The PK profile matched predicted values ​​based on animal studies and confirms that STI-1558 is readily absorbed by humans with high bioavailability and no need for ritonavir, a potent cytochrome P450 3A4 inhibitor, to block metabolic clearance in order to maintain effective blood circulation. levels. In the NMPA-authorized Phase I trial, STI-1558 will be administered to subjects with COVID-19 with mild or no symptoms in this MAD study, allowing evaluation of safety, tolerability and the efficacy of STI-1558 as a stand-alone treatment without ritonavir as a booster.

In the double-blind, placebo-controlled MAD study, a total of 56 patients with mild or no symptoms will be enrolled in three dose cohorts (active: placebo, 3:1), 300 mg BID (n=8), 600 mg BID (n=24) and 800 mg twice daily (n=24). In addition to the safety and tolerability assessment, viral load in patients will be examined to assess the antiviral activity of STI-1558 treatment in subjects with COVID-19 compared to placebo treatment. The trial will support the application for an Emergency Use Authorization (EUA) approval in China and will be conducted by ACEA Therapeutics, Inc., a Sorrento company, and Shenzhen Third Hospital in Shenzhen, China. Dr. Lu Hangzhou, professor and fellow of the American Academy of Microbiology and president of Shenzhen Third Hospital, is leading the trial in China.

“The trial in China will allow us to assess the antiviral activity of STI-1558 in patients as well as the safety, tolerability and pharmacokinetics at different doses. We look forward to seeing results in patients with COVID-19, which should facilitate our planned Phase II/III trials of STI-1558 in Mexico and the United States,” said Henry Ji, Ph.D. ., President and CEO of Sorrento. .

About Sorrento Therapeutics, Inc.

Sorrento is a clinical and commercial-stage biopharmaceutical company developing novel therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. Sorrento’s multi-modal, multi-pronged approach to fighting cancer is enabled by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), immunocellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”) and oncolytic viruses (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and coronavirus vaccines, including Abivertinib, COVISHIELD™ and COVI-MSC™; and diagnostic testing solutions, including COVIMARK™.

Sorrento’s commitment to therapies that improve patients’ lives is also demonstrated by our efforts to advance a first-in-class, non-opioid pain management small molecule (TRPV1 agonist), resiniferatoxin (“RTX”) and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a new viscous gel formulation of a corticosteroid widely used for epidural injections to treat lumbosacral radicular pain, or sciatica, and to market ZTlido® (topical lidocaine system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a phase II trial in refractory pain associated with cancer and a phase II trial in patients with osteoarthritis. Positive final results from the CLEAR program of the pivotal Phase III trial for SEMDEXA™, its new non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. ZTlido® was approved by the FDA on February 28, 2018.

For more information, visit www.sorrentotherapeutics.com

Forward-looking statements

This press release and all statements made for and during any presentation or meeting contain forward-looking statements relating to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties. which could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding STI-1558, including the potential antiviral profile of STI-1558 with respect to SARS-CoV-2 and its variants; preclinical testing of STI-1558; the potential safety and efficacy of STI-1558; the possibility that no co-administration is necessary with STI-1558; the oral bioavailability of STI-1558; the potential success of Phase I trials in Australia and China; phase II/III trials in Mexico and the United States; the possibility that the trial will help obtain EUA approval in China; the position of STI-1558 and Sorrento in the antiviral industry; the expected formulation, dosage and/or route of administration for STI-1558; and preparing for a worldwide commercial supply of STI-1558. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements include, but are not limited to: risks relating to Sorrento’s technologies and prospects, including, but not to limit the risks associated with the safety and effectiveness of STI-1558 and seek regulatory approval for STI-1558; clinical development risks, including risks relating to the progress, timing, cost and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; the risks that the results of a clinical study may not meet any or all of the clinical study endpoints and that the data generated by such studies may not support a regulatory submission or approval; the risks that the results of prior tests, studies and trials, including PK modeling and values ​​obtained therefrom, will not be replicated in ongoing or future studies and trials; risks associated with the manufacture and supply of pharmaceutical products; the risks of using the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in executing its product candidate strategies; risks related to the global impact of COVID-19; and other risks described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission and Exchange Commission, including the risk factors set forth in those documents. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, and we undertake no obligation to update any forward-looking statements in this press release unless the law requires it.

Media and investor relations
Contact: Brian Cooley
E-mail: [email protected]

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVIMARK™ and Fujovee™ are registered trademarks of Sorrento Therapeutics, Inc.

SEMDEXA™ (SP-102) is a registered trademark of Semnur Pharmaceuticals, Inc. Proprietary name review by the FDA is pending.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

©2022 Sorrento Therapeutics, Inc. All rights reserved.


main logo

read more
Generic drugs

Branded generic drugs: counterfeit judged by the ANDA file

by Dennis Crouch

By Pharm., Inc. c. Eagle Pharm., Inc., No. 2021-2342, – F.4th – (Fed. Cir. Aug. 18, 2022)

In 2018, Eagle filed its Abbreviated New Drug Application (ANDA) with the FDA to market a generic version of Par’s vasopressin injection product (Vasostrict) used for the emergency treatment of blood pressure. Par had listed two patents in the Orange Book as covering its product and, as required, Eagle’s ANDA included a certification in paragraph IV that both patents were either (1) invalid or (2) would not be infringed . 35 USC § 355(j)(2)(A)(vii)(IV).

In order to facilitate the resolution of trademark generic patent disputes, the patent laws include a form of paper infringement – a legal fiction that the mere filing of an ANDA and Paragraph IV certification counts as a form of patent infringement. . This gives the brand name drug maker (here PAR) the ability to immediately take legal action to keep the generic off the market (if the patent proves enforceable). But, these Hatch-Waxman lawsuits are considered a form of declaratory relief and no actual damages are available. This configuration also means that these cases are not “common law suits” and therefore the Seventh Amendment right to a jury trial does not apply. Thus, ANDA patent lawsuits are usually decided by a bench trial – and usually by one of the Delaware District Court judges. In patent law, an injunction has been difficult to obtain, but under the Hatch-Waxman Act, the FDA will automatically delay any marketing approval for 30 months if the trademark patent holder files a lawsuit.

Vasopressin is a naturally occurring mammalian hormone and has been widely known for decades. As its name suggests, the chemical has been known ever since its naming for its ability to constrict blood vessels – the same use claimed by Par’s patents. Par’s two patents here cover a particular composition of vasopressin (9,750,785) and a method of treatment using the composition (9,744,209).

Both Par patents include a pH requirement: “wherein the unit dosage form has a pH of 3.7 to 3.9”. In its ANDA, Eagle was careful to specify that its product would have a slightly different pH range: 3.4 to 3.6. Eagle then argued that this difference was sufficient to avoid infringement.

Despite its nominal specifications, Par presented evidence that (he claims) the pH of Eagle’s product “varied” as it sat on the shelf. He combined this evidence with the very slight difference between Eagle’s product and Par’s patent to argue that Eagle’s product “would inevitably drift into the range claimed by Par”. Slip Op. The District Court (Judge Connolly) held a three-day trial and ultimately entered a judgment of non-infringement. In particular, Judge Connolly concluded that the evidence did not prove an upward drift in pH, but rather merely “minor fluctuations” with “no discernible trend”. Identifier. On appeal, the Federal Circuit upheld — seeing no “obvious error” in the district court’s factual findings.

I mentioned above that this form of violation of the ANDA filing is a legal fiction created by Congress to facilitate a more competitive marketplace. A problem then is that there is no actual product to inspect. We have the ANDA file, but there are still substantial design choices before the final release. The prophetic inquiry therefore looks at what the “probable ANDA product” is and asks whether this probable product would be in violation if it were actually produced.

Yet the main guide is the ANDA documents as a source of infringement in this highly regulated area. Sometimes a court may consider other relevant evidence, but only when the ANDA filing fails to “speak clearly and directly to the issue of infringement”. Instead, the court assumes that the ANDA registrant “will act in full compliance with its representations to the FDA.” In re Brimonidine Patent Litigation., 643 F.3d 1366, 1378 (Fed. Cir. 2011).

Here, the ANDA documents clearly state that the product does not infringe. The pH range in Eagle’s ANDA document is different from that claimed by Par. And, ANDA filings also indicate that the pH range will remain stable throughout the shelf life of the product. Thus, the ANDA documents do not indicate any drift in the protected space of Par.

No declaratory judgment of infringement. (No court decisions deal with the doctrine of equivalents.)

I have not thought through all of the claims exclusion issues. But, once the product is released, Par may be barred from suing again under res judicata and Kesler Doctrine.

===

Judges: Moore, Prost, Hughes
Review by: Moore
Lawyers: Martin Black (Dechert) for patentee Par with Sharon Gagliardi, Brian Goldberg, Luke Reilly, Robert Rhoad, Daniel Roberts and Jonathan Loeb. John O’Quinn (Kirkland) for Eagle with Bill Burgess, Bryan Hales, Benjamin Lasky and Jenna Wacker.

read more
Prescription drugs

Helping the elderly get rid of prescription drugs Ayudar a los adultos mayores a desechar los medicamentos recetados

Ayudar a los adultos mayores a desechar los medicamentos recetados

El nuevo esfuerzo tiene como objetivo prevent los eventos adversos de los medicamentos.

A nuevo servicio claims to ayudar a los adultos mayores a desechar de forma segura los medicamentos recetados caducados.

La Oficina del estado de Nueva York para el Envejecimiento (NYSOFA, por sus siglas en inglés), la Oficina de Servicios y Apoyo a las Adicciones (OASAS, por sus siglas en inglés) y otros socios están ayudando a distribuir 100,000 bolsas Deterra de deactivation y eliminación de medicamentos a los proeedores de services para que las distribuyan a los adultos mayores de todo el estado.

Las bolsas Deterra están designed to destroy los medicaments not used or caducados de form segura y permanent, así no pueden usarse equivocadamente ni ingerirse de form accidental. Una vez activadas, las bolsas pueden desecharse en la basura normal.

Hasta ahora se han enviado 69,000 bolsas a todo el estado. The restaurant will be distributed in futuras rounds según lo soliciten los proveedores que necesiten reabastecerse.

The object of this initiative is to prevent adverse drug effects, which cause approximately 1.3 million visits to emergency services and 350,000 hospitalizations for seguir el tratamiento cada año, según los Centros para el Control y la Prévención de Enfermedades (CDC, por sus siglas en inglés) of Estados Unidos.

Las bolsas se están proporcionando para su distribución a adultos mayores en todo el estado.

Según los CDC, los adultos mayores corren un mayor riesgo de sufrir efectos adversos de los drugs debido a combination of metabolic factors and al mayor potencial de interaction between drugs, ya que tienden a tener más drugs recetados y, port tanto, es más probable que tengan restos de medicamentos o medicamentos caducados.

“El adulto mayor promedio en nuestra lista de casos tiene cuatro o más condiciones crónicas. Estas afecciones may require more of a document of recetado drugs, with places of rest and lapsing that overlap and cambios of doses determined by medical professionals, lo that increase el riesgo de que se produzcan efectos adversos or interactions entre los medicaments”, dijo NYSOFA Director Greg Olsen. “This complejidad requires soluciones sencillas. Estamos orgullosos de trabajar con la OASAS para llevar métodos de eliminación de medicaments faciles, seguros, científicamente probados y respects con el medio ambiente a miles de adults mayores de todo el estado de Nueva York que no pueden acudir a los points de venta de la comunidad para los días de devolución de medicamentos”.

The commission of OASAS Chinazo Cunningham.

Both the NYSOFA and the OASAS también están trabajando en varias asociaciones para ayudar a los adultos mayores con la seguridad de los medicaments, incluyendo interventions con base en la evidencia y examenes relacionados con el mal use de las drugs o el alcohol.

“This innovadora iniciativa es una gran manera de promover la eliminación segura de los medicaments recetados y de ayudar a preventive el mal use de estos medicamentos. población que tiende a tener muchos medicamentos recetados y está en riesgo de efectos adversos”, dijo la comisionada de la OASAS, Chinazo Cunningham. create awareness sober and possible bad use of los medicaments, reduce the risk of sobredosis and save más vidas”.

If necessary ayudar has an adult mayor to desechar sus medicamentos recetados, póngase in contacto con sur oficina local de NYSOFA en aging.ny.gov/local-offices.

read more
Medical supplies

Medical supply company CCS innovates on the frontline of diabetes treatment at home

Home medical supply provider CCS is expanding to better support patients with chronic needs at home.

Specifically, it seeks to transform the way diabetes patients are cared for at home. To do this, CCS is expanding its patient education, monitoring and coaching services to “unify the patient experience”.

The Dallas-based CCS serves more than 200,000 people across the country living with diabetes or other chronic conditions.

The medical device supplier now has two main divisions: CCS Medical and CCS Health.

CCS Health assists patients at home with their medical devices for disease management. CCS Medical corresponds more to the daily bread of the company. It provides patients with cutting-edge technology and products to monitor diabetes and other chronic diseases.

As a macro trend, the push toward home care — particularly since the onset of the COVID-19 pandemic — has been good for CCS’s business. A second macro trend that CCS has made sure to follow is the evolution and innovation of diabetes treatment and care.

Between these two trends, CCS has tried to bridge the gap of a “broken patient experience” when it comes to rolling out the right kind of diabetes care, said CCS CEO Tony Vahedian.

“We’ve been doing this for 25 years, we’ve known people with diabetes forever and we have a very trusting relationship with them,” Vahedian said.

CCS’s ability to respond to both macro-trends is conveniently “exactly what the patient needs,” he added. With a new focus on data and technology, CCS’ mission for the new model is to simplify the overall patient experience.

Too often, patients are sent home and have to fend for themselves and learn on their own with medical devices when they are sent home, Vahedian said. CCS wants to change that.

“Once they’re diagnosed, they can come to us and we can give them whatever device they want,” Vahedian said. “We can coach them on the device, charge the device and we can monitor them. It’s actually the most streamlined experience a patient can have, compared to the fragmented one they see today. .

CCS also created a new strategic advisory board and added three members to the board, Francine Kaufman, Christos Cotsakos and Jean-Claude Saghbini.

“On the CCS Medical side, since we are at the top of all the relationships around this patient,” Vahedian said. “The trick is making sure we have all the right relationships with all the right players to be able to serve that patient in the right way.”

read more
Prescription drugs

Colorado moves closer to importing prescription drugs from Canada

Colorado has taken another step towards importing lower-cost prescription drugs from Canada, after signing contracts with companies on both sides of the border that will handle the transaction.

The state hopes that importing everyday prescription drugs from Canada, where they are sold at a lower price than the United States, will help reduce drug costs for people here. . On Thursday, the state announced that it had signed agreements with three companies: AdiraMedica, a wholesaler with a subsidiary in Canada that will act as an exporter; Premier Pharmaceuticals, an Idaho-based wholesaler that will act as an importer and distributor; and Rocky Mountain Poison and Drug Safety, which will lead a program to collect drug safety reports.

“We have taken an important step in terms of importation, and that is, if you will, the establishment of the path and the partnership contracts in order to allow importation. said Kim Bimestefer, executive director of Colorado’s Department of Health Care Policy and Funding, which oversees the import program.

How will it work

The Department of Bimestefer administers Medicaid in Colorado. But the drug import program is not intended to reduce state government prescription drug spending, which amounts to about $1 billion a year, Bimestefer said.

The explanation for this is contained in a report released by the department last year which found that, due to federal rebates and regulations, the prices Medicaid pays for drugs are already comparable to drug prices in Canada. Bimestefer said Medicaid drug spending has remained flat in recent years, while it has continued to climb for people with private insurance.

As a result, the state set up the importation program with the aim of helping private policyholders, with imported drugs eventually ending up in local pharmacies.

Lauren Reveley, who leads the HCPF’s drug importation program, said AdiraMedica will work with the state to negotiate the purchase of drugs from manufacturers in Canada. AdiraMedica will then purchase the drugs and resell them to Premier Pharmaceuticals. Premier will contract with a lab to test the drugs and make sure they are what they claim to be, then repackage and relabel the drugs and distribute them to participating pharmacies in Colorado, who will sell them to consumers.

During this time, Rocky Mountain Poison and Drug Safety will implement a program to monitor adverse events and other safety issues, so the state can detect problems in the supply chain.

Reveley said the system is designed to be market-driven, meaning the state will facilitate it but not need to fund it with taxpayers’ money. So far, Colorado has spent about $1.5 million to set up the program, Reveley said.

Apply for Federal Approval

Colorado has not yet identified the drugs it will seek to import. Some – biologics, like insulin, for example – are excluded due to federal regulations. For others, it depends on how negotiations with manufacturers go, Reveley said. But the state is expected to finalize its list in the coming months, as it is a requirement to gain federal approval for the program.

Photo illustration by freestocks on Unsplash

Bimestefer said the state plans to submit its application to the federal Food and Drug Administration this fall. After that, it’s unclear how long authorities will take to review it.

State drug import programs were made possible under rules passed under the Trump administration and continued under the Biden administration. But, so far, no state program has been approved. Florida was the first state to file a request with the federal government, but, nearly two years later, it still has no response.

A Polis priority

Colorado’s drug import program is a major part of Gov. Jared Polis’ health care agenda, which has taken on even greater importance in an election year as Polis touts his efforts to save money. money to people.

In a statement, Polis called Thursday’s announcement of the program’s contractors “a major building block in place to make drugs more affordable.”

“I’m proud to see the progress of the program and the strides being made in making healthcare cost reduction a reality across Colorado and look forward to delivering real results and savings,” Polis said.

In her own statement, four-time cancer survivor Lieutenant Governor Dianne Primavera referenced her personal experiences trying to pay for lifesaving drugs and said the administration is “committed to creating new and innovative ways to ensure that all Coloradans have access to high quality and affordable health care.

Navigating Canadian Concerns

Even though the program receives federal approval, it still faces significant hurdles. Among the most important: will Canada really follow?

For years, officials and advocacy groups in Canada have raised concerns about the impact of large-scale export of drugs to the United States on the price and supply of drugs in Canada. This resulted, at the end of 2020, in a rule blocking the export of medicines in shortage.

“Our health system is a symbol of our national identity and we are committed to defending it,” said Canada’s Minister of Health. said at the time.

But, for Bimestefer and other Colorado officials, that’s not exactly a no.

Bimestefer said she has held meetings with the Canadian consulate to better understand Canada’s position, and she believes Colorado can build its program in a way that doesn’t harm Canada’s pharmaceutical supply. The state, she said, will only seek to import drugs that are not in short supply — and many of the most commonly used drugs are not.

“We are committed to monitoring and not importing drugs in a way that would impede any of their supplies,” Bimestefer said, referring to the need “to be a very good partner for our friends in the north.”

“I believe they have come down in a way that allows us to do that.”

Beat Industry Opposition

If Canada accepts, only one obstacle remains: the pharmaceutical industry, which has fiercely opposed it.

In 2020, the industry filed a lawsuit seeking to stop the implementation of federal rules for state import programs. That lawsuit is still ongoing — Florida earlier this year filed an amicus brief in support of the federal rules; Colorado did not do the same, according to federal court records.

The industry has also opposed a bill in Congress that would enshrine federal rules on state import programs into law.

“Drugs entering the United States through drug import programs would bypass FDA review and approval of our drug supply,” said Priscilla VanderVeer, group vice president of public policy. of pharmaceutical industry PhRMA, in a statement following a committee hearing on the federal government. invoice.

Proponents of importation, including Bimestefer, said the programs will have many safeguards, including a requirement that drugs be purchased directly from manufacturers. But these requirements also make opposition from the pharmaceutical industry more substantial – essentially giving the industry a veto over the programs.

Still, Bimestefer said she’s optimistic that some manufacturers will want to work with Colorado to export Canadian drugs.

“We are about to be able to do what is right and about to be able to face those who would prevent us from bringing savings to Coloradans,” she said.

“We will find manufacturers who are willing to negotiate. If we didn’t think we could find manufacturers willing to negotiate, we wouldn’t pursue this. »


We believe vital information should be seen by those affected, whether it is a public health crisis, investigative reporting, or holding lawmakers accountable. This report depends on the support of readers like you.

read more
Generic drugs

Differences between biosimilars and generic drugs

Roy M. Fleischmann, MD: What are the main differences between a biosimilar medicine and a generic small molecule medicine?

Joel M. Gelfand, MD, MSCE, FAAD: That’s an excellent question. This is an important nuance. As clinicians, we have been used to generic drugs for some time. In dermatology, a drug called doxycycline is used for acne, which has other indications. Most of us don’t even think twice about which generic or brand name drug will be dispensed to the patient. That’s largely because the molecule itself is really identical, and what may vary are the excipients, or the color of the pill, or things of that nature. For the most part, as clinicians, you can usually get away with it without any problems.

There may be unusual circumstances where a patient has an allergy to any of the ingredients in the generic drug package, or perhaps a rare circumstance where the PK [pharmacokinetics] may not be the same for a drug like cyclosporine. But biosimilars are not the same product. They are nearly identical, especially in the areas that matter most in terms of where the biological binds to the target – at the cytokine level for example – but there may be some variation in protein structure, glycosylation and other aspects of the antibody itself.

Roy M. Fleischmann, MD: It’s exactly that. A biosimilar is not exactly the same as a generic pill. There are differences between them.

Transcript edited for clarity

read more
Medical products

Zavation Medical Products, LLC, Receives 510K Clearance from the FDA for Varisync™ Anterior Cervical Plate and Spacer System to Complement its Cervical Spine Portfolio

FLOWOOD, Miss., August 18, 2022 /PRNewswire/ — Zavation Medical Products (“Zavation” or the “Company”), an innovative designer and manufacturer of high-quality spinal implants, instruments, MIS procedure kits and biologics, headquartered in in Flowood, MS, announced FDA 510K clearance of Varisync™, a cervical intervertebral fusion device.

Varisync™, the newest addition to Zavation’s cervical spine portfolio, has been tested and approved for independent and synchronized use of its plate and spacer components. This allows Zavation partner surgeons to use these plate and spacer options together as a system or pair individual components with one of Zavation’s existing cervical portfolio options. The Varisync™ Plate has been carefully designed and has attributes that include visual and tactile lock confirmation, ideal screw angulation, multiple insertion devices, and optimal spacer placement in the disc space.

Zavation’s market share and active surgeon base continue to grow rapidly given the company’s ability to adapt to surgeon/patient needs, constantly upgrade instruments and design devices with simplicity. and unparalleled precision. Zavation’s continued investment in research and development will further improve its technologies and accelerate market share and base earnings of active surgeons.

“Our product development team’s dedication to creatively blending simplicity and precision into robust product design has produced a product that we believe is the new benchmark in facilitating patient fusion in the setting of ‘a seamless and streamlined procedure,’ said Jeffrey Johnson, Managing Director, ‘With the many interbody offerings Zavation has to offer, it only makes sense that we would develop a device that allows surgeons to easily integrate and place a combination plate and spacer of their choice. “This product is an example of Zavation’s commitment to offering innovative and differentiated products in conjunction with market-leading customer service to better serve our surgeons and distributor network.”

INDICATIONS FOR USE

The VariSync™ Plate is intended for anterior screw fixation to the cervical spine (C2-C7) for the following indications: Degenerative disc disease (as defined by cervical pain of disc origin with disc degeneration confirmed by patient history and radiographic studies), trauma (including fractures), tumors, deformity (defined as kyphosis, lordosis or scoliosis), non-union, anterior fusion failure, spondylolisthesis and spinal stenosis.

The VariSync™ spacer is an interbody fusion device intended for use in mature skeletal patients with degenerative disc disease (DDD) of the cervical spine (C2-T1) at one level. DDD is defined as disc pain with disc degeneration confirmed by history and radiographic studies. These patients must be skeletally mature and have had at least six (6) weeks of non-operative treatment. The VariSync™ spacer should be filled with autograft or allogeneic bone graft consisting of cancellous and/or corticocellous bone graft in skeletally mature patients. These devices are intended for use with an additional fixation such as the Zavation VariSync™ Plate, Zavation Midline Plate, Zavation EZ Plate, or Zavation Cervical Plate Systems. When used with the VariSync™ plate, the assembly mirrors the indications of the VariSync™ spacer, with the VariSync™ plate serving as an additional fixation.

ABOUT ZAVATION MEDICAL PRODUCTS, LLC.

Based in Flowood, MS, Zavation designs, engineers and manufactures a portfolio of spinal hardware and biologics covering key areas including cervical, thoracolumbar, interbody fusion, interventional spine and minimally invasive surgery. Founded in 2012, Zavation has experienced exceptional growth and created a nationwide network of numerous distributors across the United States. The Company has marketed more than 25 product families since its creation. Zavation operates a new 75,000 square foot vertically integrated facility in Flowood, MS. To learn more about Zavation and the company’s product line, visit www.zavation.com.

Related links
www.zavation.com

SOURCE Zavation Medical Products, LLC.

read more
Generic drugs

Ivermectin among generic drugs that didn’t help COVID-19 patients avoid hospitalization, large study finds

A new study has found that three generic drugs – fluvoxamine, which is often prescribed to treat depression, the controversial antimalarial ivermectin and the diabetes drug metformin – failed to prevent the type of COVID-19 serious that leads to a visit to the emergency room or hospitalization.

The research, published Wednesday in the New England Journal of Medicine, examined whether any of three drugs benefited 1,323 patients when prescribed in the early days of a COVID-19 infection. Some of the study participants received a combination of metformin and fluvoxamine or metformin and ivermectin, most were vaccinated, and all were overweight. The randomized, placebo-controlled phase 3 study was conducted from December 2020 to January this year by researchers at the University of Minnesota.

“None of the drugs showed any impact on the primary outcome, which included low oxygen measured on a home oxygen monitor,” said Dr. Carolyn Bramonte, the study’s principal investigator and assistant professor. internal medicine and pediatrics at the University. from the Minnesota Medical School.

Low blood oxygen, or hypoxemia, is a common reason that patients with COVID-19 end up seeking emergency care, being hospitalized, or dying.

Until the Food and Drug Administration clears Pfizer’s PFE,
-1.18%
the antiviral Paxlovid and the MRK from Merck,
+0.50%
Lagevrio at the end of 2021, there was no authorized treatment for people who tested positive for the virus but were not yet sick enough to go to hospital. Repurposed drugs – which are cheap, readily available and have decades of safety data, including in children and pregnant women – have had particular appeal for regulators and clinicians since the early days of the pandemic. .

Each of the three generic drugs has been touted as a possible COVID-19 drug, particularly ivermectin, which has gained a cult following during the pandemic despite well-documented issues with flawed science that in some cases has fraudulently touted the benefits of the drug. Yet, so far, none have been shown in robust clinical trials to actually help treat people with COVID-19.

A long-awaited double-blind, randomized, placebo-controlled study conducted by Duke University School of Medicine and funded by the United States concluded in June that ivermectin did not improve the duration of symptoms in COVID-19 patients. with mild to moderate forms of the disease. The same research found that the drug did not reduce hospitalizations or deaths.

Some of the same University of Minnesota researchers petitioned the FDA last year to clear fluvoxamine as a COVID-19 treatment, based on an earlier set of clinical data. The regulator declined to grant emergency authorization this spring, saying the data did not show the drug’s ability to treat COVID-19.

There is a possible silver lining in the study results, at least for metformin. When researchers looked at the study’s secondary endpoints, they found that metformin reduced emergency room visits, hospitalizations or deaths by 40%, even though the pill did not show an impact on hypoxemia. That said, the researchers say more studies need to be done before clinicians start prescribing metformin to their COVID-19 patients.

“We are really happy that our study adds to the knowledge we are gaining around this pandemic in this virus,” Bramonte said. “At this point, some doctors may see our results and see metformin as providing easily accessible treatments for some patients. However, as a medical researcher, I see the need for further studies to replicate these results as the primary outcome of a study.

read more
Prescription drugs

Changes made to reduce the cost of prescription drugs

LANSING, Mich. (WILX) — This is a big step toward lowering prescription drug prices for seniors. President Joe Biden signed into law the Cut Inflation Act on Tuesday afternoon.

The new law brings two major changes. First, it allows Medicare to negotiate prices with drug companies. Second, it will lower the cost of insulin for diabetics on Medicare.

“It feels good. It’s heartwarming. It’s one less thing I can take off the relevant checklist. It should never be there in the first place,” Delta Township Trustee Fonda Brewer said.

Fonda Brewer was recently diagnosed with diabetes. She’s not on insulin yet, but if that changes, she’s grateful the new law caps the price at $35 a month.

“Not having to figure out if I’m going to pay this bill or get the medication I desperately need,” Brewer said.

More than two million Michiganders are on Medicare and a third of them have diabetes. And with a monthly insulin supply of up to $1,000 right now, the new law is going to be a huge relief.

Senator Debbie Stabenow hopes this will be an example for the health care industry.

Related: Major reforms to reduce prescription drug costs announced by Stabenow, Slotkin

“So the first step is health insurance for the elderly and the disabled and at every opportunity we will take that further,” Stabenow said. “And if the insurance companies want to do the right thing, the drug companies want to do the right thing, they’ll do what Medicare does.”

The law also limits out-of-pocket spending on Medicare patients’ prescriptions to $2,000 per year starting in 2025. Future increases in drug prices will be limited to the rate of inflation.

The law allows Medicare to begin negotiating drug prices in 2026, but only for the 10 specific drugs it spends the most money on. This list will increase to 20 drugs per year by 2029.

Next:

Copyright 2022 WILX. All rights reserved.

Subscribe to our News newsletter 10 and get the latest local news and weather straight to your email every morning.

read more
Medical supplies

Revolutionizing healthcare: Bengaluru start-up begins delivering medical supplies to Arunachal Pradesh – VIDEO

zeenews.india.com understands that your privacy is important to you and we are committed to being transparent about the technologies we use. This Cookie Policy explains how and why cookies and other similar technologies may be stored on and accessed from your device when you use or visit the zeenews.india.com websites that link to this Policy (collectively, “ the sites “). This cookie policy should be read in conjunction with our privacy policy.

By continuing to browse or use our sites, you agree that we may store and access cookies and other tracking technologies as described in this policy.

What are cookies and other tracking technologies?

A cookie is a small text file that may be stored and accessed from your device when you visit one of our sites, provided you consent. Other tracking technologies work similarly to cookies and place small data files on your devices or monitor your website activity to allow us to collect information about how you use our sites. This allows our sites to recognize your device among those of other users of our sites. The information provided below on cookies also applies to these other tracking technologies.


How do our sites use cookies and other tracking technologies?

Zeenews.com uses cookies and other technologies to store information in your web browser or on your mobile phone, tablet, computer or other devices (collectively “devices”) that allow us to store and receive certain information whenever you use or interact with our applications and sites zeenews.india.com. These cookies and other technologies help us identify you and your interests, remember your preferences and track usage of zeenews.india.com We also use cookies and other tracking technologies to control access to certain content on our sites, to protect the sites, and to process all requests that you send to us.
We also use cookies to administer our sites and for research purposes, zeenews.india.com has also contracted with third party service providers to track and analyze statistical usage and volume information of users of our site . These third-party service providers use persistent cookies to help us improve user experience, manage our site content, and analyze how users navigate and use the sites.

Proprietary and third-party cookies

Proprietary cookies

These are cookies that belong to us and that we place on your device or those set by a website visited by the user at that time (eg cookies placed by zeenews.india.com)

Third-party cookies

Certain features used on this website may involve a third party sending a cookie to your computer. For example, if you view or listen to embedded audio or video content, you may receive cookies from the site where the embedded content is hosted. Similarly, if you share content from this website via social networks (for example by clicking on a Facebook “Like” button or a “Tweet” button), you may receive cookies from these websites. We do not control the setting of these cookies, so please check the websites of these third parties for more information about their cookies and how to manage them.

Persistent cookies
We use persistent cookies to improve your experience of using the sites. This includes recording your acceptance of our cookie policy to remove the cookie message that first appears when you visit our site.
Session cookies
Session cookies are temporary and deleted from your machine when your web browser closes. We use session cookies to help us track internet usage as described above.
You may refuse to accept browser cookies by activating the appropriate setting on your browser. However, if you select this setting, you may not be able to access certain parts of the Sites. Unless you have adjusted your browser settings to refuse cookies, our system will check whether cookies can be captured when you direct your browser to our sites.
The data collected by the sites and/or through Cookies likely to be placed on your computer will not be kept longer than necessary to fulfill the purposes mentioned above. In any case, this information will be kept in our database until we obtain your explicit consent to delete all stored cookies.

We categorize cookies as follows:

Essential cookies

These cookies are essential to our site in order to allow you to move around it and use its features. Without these essential cookies, we may not be able to provide certain services or features and our site will not function as well as we would like. These cookies, for example, allow us to recognize that you have created an account and logged in/out to access content on the site. They also include Cookies that allow us to memorize your previous actions within the same browsing session and to secure our sites.

Analytical/performance cookies

These cookies are used by us or our third party service providers to analyze how the sites are used and how they are performing. For example, these cookies track the most frequently visited content, your viewing history and where our visitors come from. If you subscribe to a newsletter or register with the Sites, these cookies may be correlated to you.

Functionality cookies

These cookies allow us to operate the sites in accordance with the choices you make. These cookies allow us to “remember you” between visits. For example, we will recognize your username and remember how you have customized the Sites and Services, such as by adjusting text size, fonts, languages ​​and other parts of web pages that are modifiable, and offer you the same personalizations during your next visits.

Advertising cookies

These cookies collect information about your activities on our sites and other sites to provide you with targeted advertising. We may also allow our third-party service providers to use cookies on the Sites for the same purposes identified above, including collecting information about your online activities over time and across different websites. Third-party service providers that generate these cookies, such as social media platforms, have their own privacy policies and may use their cookies to target advertisements to you on other websites, based on your visit to our sites.

How do I refuse or withdraw my consent to the use of Cookies?

If you do not want cookies to be placed on your terminal, you can adjust the settings of your Internet browser to refuse the setting of all or part of the cookies and to alert you when a cookie is placed on your terminal. For more information on how to do this, please refer to the “help” / “tool” or “edit” section of your browser for your browser’s cookie settings, which may be Google Chrome, Safari, Mozilla Firefox , etc.
Please note that if your browser settings are already configured to block all cookies (including strictly necessary cookies), you may not be able to access or use some or all of our sites or features.
If you wish to delete previously stored cookies, you can manually delete cookies at any time from your browser settings. However, this will not prevent the sites from placing further cookies on your device unless and until you adjust your internet browser settings as described above.
For more information on the development of user profiles and the use of targeting/advertising cookies, please see www.youronlinechoices.eu if you are located in Europe or www.aboutads.info/choices if in the United States.

contact us

If you have any further questions about our cookie policy, please contact us at:
If you need any information or clarification regarding the use of your personal information or this privacy policy or complaints regarding the use of your personal information, please email us at [email protected] .

read more
Generic drugs

Savings could be made with more generic drugs on the Croatian market

August 16, 2022 – Replacements of some drugs are expected to hit the Croatian market as cost savings become extremely necessary in the weakened Croatian healthcare system.

As Poslovni Dnevnik/Josipa Ban writes, counting the pennies in the wider Croatian healthcare system, especially in the consumption of medicines, is now more necessary than ever. We have been witnessing for decades accumulated debts for medicines which, after numerous attempts at rehabilitation by the Ministry of Finance, are still far from being reduced. In fact, they only increased enough to reach just over six billion kuna at the end of April this year.

HUP – the Pharmaceutical Manufacturers Association has been warning about some of these debts for some time, noting that they can certainly be reduced. The annual savings of the Croatian healthcare system could increase from the current 300 million to one billion kuna if consumption were to increase and if the procedure for including generic drugs in the HZZO drug list for the Croatian market was finally accelerated.

Some substitute drugs enter the Croatian market when the original drug’s patent rights expire. As bringing them to the Croatian market means more competition, the price of the drug also drops at the same time. The situation here, at least according to 2019 data, is that 61% of the volume of prescription drug consumption in the Republic of Croatia is generic drugs, and they only account for 5% of total healthcare. sector budget.

“Although this percentage has increased over the years, it is still a bit below the EU average of 67%. This shows us that there is still great potential for the use of medicines generic in this country,” they pointed out. of HUP – the Association of Drug Manufacturers, whose members invested a total of 5.4 billion kuna between 2010 and 2020. With regard to biosimilar drugs, the situation is much worse, and in 2019 they occupied a modest 13% of the Croatian market.

A complicated process…

One of the reasons for the low uptake of generic and biosimilar drugs, which leads to higher spending on these drugs, is the process manufacturers must follow to get on the HZZO drug formulary.

Jerko Jaksic, chairman of the board of directors of PharmaS and president of the HUP association of drug manufacturers, explained that the process of bringing a generic drug to the Croatian market takes about one to two years.

“The first step is the registration of the medicine with HALMED or, for biosimilar medicines, with the European Medicines Agency (EMA). After approval by HALMED or EMA, it takes up to six months at HZZO to get drugs on their list. Although it’s a bit better than it was a decade ago, this part of HZZO could and should be accelerated, what I mean by that is is that after the approval of HALMED and EMA, these drugs should automatically be included in the drug lists, without any additional administrative steps because there is no need for them. Unfortunately, here too, we have an example of resistance to changes and adaptation of the system, as well as the classic slowness of administration,” stressed Jaksic, adding that the automatic inclusion would speed up the processes and the arrival of medicines on the Croatian market, while like drug therapies less expensive for patients in three to six months.

“It would also bring savings of several tens of millions of kuna at the annual level for the entire Croatian market,” said the Chairman of the Board of Directors of PharmaS. HUP noted that the role of generic and biosimilar medicines is extremely important both for the healthcare system and for the patients themselves.

“In fact, these drugs are making many key therapies available to more patients, and at the same or lower cost than before they were introduced. For example, two to three boxes of prescription drugs dispensed in Croatia come from the generic industry, and the Share of generic drugs in the cost of all drugs is only 27%.If we look at the pharmaceutical system, the share of generic drugs is 65%, and this represents less than 40% of the drug budget,” they explained.

Great potential

In addition to all the above, there is no fear for the patient because prescription drugs and generic drugs are the most organized part of the healthcare system. Jerko Jaksic noted that their importance has long been recognized by general practitioners. However, hospital doctors have yet to follow suit.

“Hospital doctors have a lower level of knowledge of generic and especially biosimilar therapies, they also lack a developed awareness of the financial savings they can allow. There is great untapped potential here, especially in the sense of use cheaper generic and biosimilar therapies in order to reduce costs for hospitals,” Jaksic said.

There are therefore several mechanisms that we need to change in order to speed up the introduction of generic and biosimilar medicines on the Croatian market, and thus contribute to significant savings.

“There is a need to consistently implement existing regulations for drug pricing, to include generic drugs on the HZZO drug list more quickly, and to enable faster penetration of generic and biosimilar drugs into the system. hospital in the broad sense,” said the HUP association. of drug makers believes.

With these measures, together with measures of treatment outcomes, they say, savings in the healthcare system can reach up to 1 billion kuna per year. So the ruling party has a solution. But is the will there?

To learn more, be sure to check out our dedicated lifestyle section.

read more
Generic drugs

Judges said generic drugs were at risk from lean label ruling

By Ryan Davis (August 15, 2022, 7:31 p.m. EDT) – The generic drug industry on Friday urged the United States Supreme Court to overturn a Federal Circuit decision upholding a $235 million patent judgment against Teva, claiming it would drive up drug prices by exposing generic manufacturers using so-called skinny labels to the risk of “extraordinary liability”.

Generic drug industry group the Association for Accessible Medicines, along with two companies and dozens of professors, told judges that the ruling that Teva infringed patents on the heart disease drug Coreg by GlaxoSmithKline would lead to disastrous consequences.

“This tribunal’s review is urgently needed to address one of the most important, damaging and misguided issues…

Stay one step ahead

In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

  • Access to case data in articles (numbers, filings, courts, nature of lawsuits, etc.)
  • Access to attached documents such as briefs, motions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and more!

TRY LAW360 FREE FOR SEVEN DAYS

read more
Prescription drugs

US Senator Sherrod Brown: Lowering prescription drug costs – The Tribune

U.S. Senator Sherrod Brown: Reducing prescription drug costs

Posted at 12:00 p.m. on Saturday, August 13, 2022

Right now, Ohioans are struggling with high prices, and prescription drugs are among the most expensive items that many families are forced to pay for each month. Americans pay more than three times what people in other countries pay for the same drugs.

Retirement shouldn’t mean a choice between putting food on the table and getting the prescriptions you need.

Now, after years of battling opposition from Big Pharma and politicians still bidding on their lobbyists, we are finally on the verge of making progress.

The Cut Inflation Act forces drug companies to cut drug prices, especially for Americans on Medicare, and will make so many things we’ve been fighting for for years a reality. And with the cost of living hitting American retirees on fixed incomes particularly hard, now is the time to do so.

My entire career I’ve pushed for allowing Medicare to negotiate directly with drug companies for lower prices. Currently, the Secretary of Health and Human Services is prohibited from negotiating for better prices for people on Medicare, as VAs or private companies do. This bill will finally change that, allowing Medicare to negotiate lower drug prices for American seniors and even forcing the Secretary to negotiate the price of the most expensive drugs.

This bill would also impose a $2,000 cap on prescription drug costs for older Americans and create an inflation rebate, which would force pharmaceutical companies that raise the price of their drugs beyond the rate of inflation to pay a rebate to Medicare.

It is not a mistake that the current law protects the profits of big pharmaceutical companies at the direct expense of patients. The pharmaceutical companies were there when this law was written, and I have been fighting to fix it ever since.

Very often, these companies do not create new drugs or invest in innovation. They simply buy the rights to existing drugs from other companies, lay off workers, increase prices by eight, nine or ten times – and then expect patients, hospitals and taxpayers to foot the bill. If drug companies raise prices at twice the rate of inflation for no reason other than to pay their bottom line, then they have to pay that money back.

We know high drug costs are a problem, and we know how to fix it: we let Medicare negotiate, we cap out-of-pocket spending, and we penalize companies that price-gouging. With this bill, we are finally on the verge of taking on the lobbyists of pharmaceutical companies and taking action.

Sherrod Brown is a Democrat and the senior United States Senator representing Ohio. His office can be reached at 212-224-2315.

read more
Generic drugs

Global Generic Drugs Market Report 2022-2026

Dublin, Aug. 12, 2022 (GLOBE NEWSWIRE) — The Generic Drugs – Global Market Trajectory & Analytics report has been added to ResearchAndMarkets.com’s offer.

Global generic drug market to reach $507.8 billion by 2026

Amid the COVID-19 crisis, the global generic drug market estimated at US$402.9 billion in 2022 is expected to reach a revised size of US$507.8 billion by 2026, growing at a CAGR of 5.6% over the analysis period.

A key advantage for generic drug manufacturers is that they do not need to invest time and money in drug R&D and marketing efforts, as generic drug prices are significantly lower compared to their branded counterparts.

Generic small molecules, one of the segments analyzed in the report, is expected to grow at a CAGR of 5.2% to reach US$325.7 billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and the induced economic crisis, the growth of the biosimilars segment is readjusted to a revised CAGR of 6.3% for the next 7-year period.

This segment currently accounts for a 37.7% share of the global generic drug market. With several factors encouraging growth contributing to wider adoption, biosimilars are poised to increase their share of the global generic drug market in the coming years. The rise of biosimilars has notably reduced overall drug spending in recent years, a trend that is expected to continue for the foreseeable future.

The emergence of biosimilars in the market leads to increased competition, the next generation of biologics under development aims to improve safety, efficacy and cost factors compared to the drugs of the previous generation, which further adds to the competitive heat in the market.

The US market is estimated at $121.8 billion in 2022, while China is expected to reach $91.2 billion by 2026

The generic drug market in the United States is estimated to be worth US$121.8 billion in 2022. The country currently accounts for a 30.46% share of the global market. China, the world’s second largest economy, is expected to reach an estimated market size of US$91.2 billion in 2026 growing at a CAGR of 7.2% over the analysis period.

Other noteworthy geographic markets include Japan and Canada, each forecasting growth of 3.8% and 5% respectively over the analysis period. In Europe, Germany is expected to grow at a CAGR of approximately 4.3%, while the rest of the European market (as defined in the study) will reach US$97.6 billion by the end of the outlook period. ‘to analyse.

The market is expected to be driven by the ever increasing risk of various chronic diseases such as hypertension, obesity and diabetes. Although pharmaceutical companies continue to develop branded drugs due to the shortage of new blockbuster drugs coming to market, generic drugs are expected to continue to meet the majority of these therapeutic needs of the population, especially the elderly population. in expansion.

With the high cost of brand name drugs becoming a financial burden on people, efforts have intensified to develop cost-effective generic variants. Many branded drugs are unable to extend their exclusivity, resulting in the loss of patents and making way for affordable generics to be manufactured. Major application areas of generic drugs include cardiology, anti-infection, anti-arthritis, CNS, anti-cancer, and respiratory, among others.

Generic drugs for cardiovascular diseases currently represent the dominant segment, accounting for the majority share of the overall market. Cardiovascular diseases such as heart failure, high blood pressure, circulatory disorders, dyslipidemia, cholesterol, arrhythmias, strokes and angina pectoris are the leading causes of death worldwide.

The cardiovascular segment is expected to cover a larger portion of the global generic drugs market owing to several patent expirations of these drugs. Generic drugs for infectious diseases would gain popularity over the next few years, mainly due to the increasing number of cases around the world.

The COVID-19 pandemic has emerged as a significant growth driver for the generic drug market over the past year. As nations’ economies collapsed due to rising unemployment, the demand for cheaper substitutes for brand name drugs grew.

What’s new for 2022?

  • Global competitiveness and percentage market shares of main competitors
  • Market presence in multiple geographies – Strong/Active/Niche/Trivial
  • Peer-to-peer collaborative online interactive updates
  • Access to digital archives
  • Free updates for one year

Main topics covered:

I. METHODOLOGY

II. ABSTRACT

1. MARKET OVERVIEW

  • Generic drugs – Percentage of market share of the main global competitors in 2022 (E)
  • Progress on vaccinations, why should companies care?
  • These are times when questions abound and answers are few.
  • With the IMF’s upward revision of global GDP forecasts for 2021, most businesses are optimistic about a global economic comeback.
  • A strong economic rebound in 2021 based on pent-up demand comes as relief for struggling industries and markets
  • How has the healthcare industry been and continues to be impacted by the pandemic and what is the new normal?
  • With the COVID-19 pandemic exposing the lack of global health care preparedness, policies are increasingly focused on restarting health systems around the world: current and required health expenditure as % of GDP
  • Impact of the COVID-19 crisis on the generic drugs market
  • Demand for generic painkillers is increasing
  • A prelude to generic drugs
  • The generic drug market is poised for rapid growth
  • US dominates, Asia-Pacific shows fastest growth
  • India – An important market
  • Market constraints
  • Competition
  • Recent market activity

2. FOCUS ON CERTAIN PLAYERS (Total 42 Featured)

  • Abbott Laboratories
  • Apotex Inc.
  • ASKA Pharmaceutical Co., Ltd.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca Plc
  • Baxter International Inc.
  • Dr. Reddy’s Laboratories Limited
  • Eli Lilly and company
  • Endo International plc
  • Fresenius Kabi
  • GlaxoSmithKline Plc.
  • H.Lundbeck A/S
  • Hospira
  • Lupine Pharmaceuticals, Inc.
  • Mylan S.A.
  • Novartis International SA
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche SA
  • Sandoz International GmbH
  • Sanofi-Aventis US LLC
  • STADA Arzneimittel AG
  • Sun Pharma
  • Teva Pharmaceutical Industries Ltd.

3. MARKET TRENDS AND DRIVERS

  • Patent expirations expected to expand potential generic drug market
  • Expiry of patents for certain drugs in 2020
  • Expiry of patents for certain drugs in 2021
  • Expiry of patents for certain drugs in 2022
  • Expiration of patents for certain major drugs in the United States: 2020-2022
  • High demand for pharmaceutical drugs drives demand for generic drugs
  • Cost containment measures focus on generics
  • Small molecule generics are the dominant segment
  • Increased demand for biosimilars, driven by expiring patents for key biopharmaceutical drugs
  • Expiration of patents for major biopharmaceutical drugs in the United States and Europe
  • A progressive regulatory framework accelerates product approvals and subsequently market revenue
  • Specific guidelines for biosimilars in various countries with year of publication
  • Biosimilar regulators in selected regional markets
  • US biosimilar approvals (as of February 2021)
  • Biosimilar approvals in Europe (from January 2021)
  • Rising healthcare costs drive demand for generic drugs
  • An aging population to propel demand for generic drugs
  • Growing prevalence of chronic diseases is driving demand for generic drugs
  • Global cost of chronic diseases (in billions of US dollars) for the years 2018 and 2030
  • Deaths by heart disease – Estimated percentage distribution for cardiovascular disease, ischemic heart disease, stroke and other

4. GLOBAL MARKET OUTLOOK

III. REGIONAL MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/q8s3o4

  • Global Generic Drugs Market


        
read more
Generic drugs

Expert: OGD on track to approve more generic drugs in FY22

Regulatory news

| August 12, 2022 | By Joanne S. Eglovitch

The United States Food and Drug Administration (FDA) Office of Generic Drugs (OGD) will most likely approve a higher number of generic drugs in fiscal year 2022 compared to the previous year, and the number of generic applications received could continue to exceed the DMO’s review capacity, said Robert Pollock, senior consultant at Lachman Consultants.

Pollock, who writes regularly about generic FDA approvals, spoke with Regulatory guidance and shared these observations in his recent blog. His predictions were based on the FDA’s Monthly Business Report for July 2022.

He estimates that, based on current trends, the FDA will approve about 877 generic drugs, of which 695 will be full approvals and 182 tentative approvals.

In fiscal year 2021, the FDA approved 836 generic drugs, with 669 full approvals and 157 tentative approvals, Pollock said. This could reverse the overall downward trend in generic drug approvals, according to OGD’s annual report released earlier this year. (RELATED: Generic drug approvals continued to decline in 2021Regulatory guidance February 16, 2022)

Through July, the FDA has approved 731 generic drugs, with 579 full approvals and 152 tentative approvals.

He further projected that the number of receipts could continue to exceed OGD’s review capacity, and the agency will receive 842 submissions in fiscal year 2022, up from 809 in fiscal year 2021. delta between ANDA approvals and receipts in fiscal year 2021 was 130 and, if the numbers hold for fiscal year 2022, we expect the delta to be 147; the gap widened by 26 in 2019 and increased in fiscal years 2020 (128) and 2021 (130),” he wrote.

Another notable trend, Pollock said, is the high number of complete response (CR) letters issued in July, which are issued to applicants for deficient applications. The OGD issued 171 CR in July, which was the second highest number behind issuing 195 CR in January.

Yet the total number of CRs issued by other government departments has continued to decline over the past five years, from 2,648 in fiscal year 2018 to 2,310 in fiscal year 2019, to 2,010 in in fiscal 2020 and 1,851 in fiscal 2021, with 1,833 CR expected in fiscal 2022.

At the same time he was telling Regulatory Focus, the number of RTRs has started to “rise” over the past three years, which Pollock attributes to new entrants to the generic market. He said he hopes this doesn’t indicate a “backsliding” of the industry or “the OGD is getting stricter with new requirements”.

The agency also appears poised to approve more first-time generics compared to previous years, and has already approved 100 so far this year, surpassing the first 93 generics approved in fiscal year 2021. Early generics provide access to therapies where no competition previously existed.

Lachman said this bump “is not unexpected” since first-time generics are given priority review and can therefore be reviewed more quickly. Another reason: Due to the rush for first approval, companies “pay more attention to the details of the initial submission or response to a first CRL.”

FDA

© 2022 Society of Regulatory Affairs Professionals.


read more
Generic drugs

Opinion: The FDA should ban imports of dangerous generic drugs now

More than 131 million Americans take prescription drugs every day. And almost all of these prescriptions are filled with generic drugs at local pharmacies.

What is deeply concerning is that the largest domestic supplier of these generic drugs, Aurobindo Pharma 524804,
+3.10%,
has been repeatedly cited by the Food and Drug Administration for unsafe manufacturing practices at its factories in India. However, despite more than a decade of contamination issues, product recalls and safety issues, Aurobindo continues to meet the daily medication needs of millions of Americans.

Earlier this year, the FDA issued a warning letter to Aurobindo citing “significant deviations from current good manufacturing practices (CGMP) for active pharmaceutical ingredients.” At the same time, Auromedics Pharma LLC, a subsidiary of Aurobindo, was forced to recall shipments of an injectable antibiotic.

The FDA has had issues with Aurobindo since 2011. And in 2019, federal regulators warned the company of “repeated failures” to address safety issues, including “contamination at levels above the acceptable limit” and “inadequate cleaning procedures”.

If that’s not enough, Aurobindo recently received three new notices from the FDA for potential violations of the Drugs and Cosmetics Act (FD&C).

Despite these repeated safety concerns, the FDA has just granted Aurobindo’s subsidiary, Eugia Pharma Specialties Ltd., approval for an injectable drug used to treat certain types of cancer.

Aurobindo is not the only overseas drugmaker with a history of safety concerns. Pharmaceutical manufacturers in China and India regularly receive warning letters from the FDA regarding production safety violations. These include carcinogenic ingredients in drugs as well as manufacturing processes that can “lead to life-threatening infections in a wide range of patients”. Incredibly, however, the FDA has not conducted in-person inspections at many of these facilities in recent years and has not visited any drug manufacturing plants in China since 2019.

The United States has become heavily dependent on these foreign drugmakers, particularly in China and India, for essential life-saving generic drugs. This is the result of heavily subsidized foreign drug producers artificially lowering their prices to bankrupt many American pharmaceutical companies. As a result, the United States now depends on imports for at least two-thirds of its generic drug needs. And nearly 90% of the active pharmaceutical ingredients the United States needs to manufacture drugs are also produced overseas.

This is a serious concern – that the United States is dependent on imports for its drug needs. In fact, during the COVID pandemic, China and other countries have banned exports of essential medicines, including antibiotics and antivirals, to maintain needed supplies at home. As a result, American hospitals have scrambled to deal with shortages of basic drugs.

The FDA continues to allow producers of substandard and dangerous drugs to export generic drugs to US consumers. Federal regulators have repeatedly issued warning letters, but taken no further action. It is the equivalent of simply endorsing poor quality drug manufacturing methods. And the numbers at stake are staggering as the United States imported $127.6 billion worth of pharmaceuticals in 2019 alone.

The answer is that the FDA visits and inspects drug manufacturers in China and India. There is an urgent need to test the drugs supplied to American patients and to fully insist on safe manufacturing facilities. Until the FDA can do that, it must hold foreign drug producers accountable and ban dangerous products.

The American people agree. A recent poll by Morning Consult found that 84% of voters want the FDA to stop imports of generic drugs from foreign manufacturers that have received warning letters. And 72% of voters say they oppose importing generic drugs from China. That makes sense, given that contaminated batches of the anticoagulant heparin from China killed 81 Americans in 2008.

The United States once led the world in the manufacture of pharmaceuticals. But today the United States no longer manufactures penicillin and has virtually no capacity to produce antibiotics, among many other life-saving drugs. This overreliance on foreign production has left America deeply vulnerable. It is high time to rebuild national drug manufacturing capacity – and to do so before another health crisis endangers the lives of other Americans.

Michael Stumo is CEO of the Coalition for a Prosperous America, a bipartisan advocacy organization representing farmers, ranchers, manufacturers, and labor organizations that make and grow things in the United States. Follow him on @michael_stumo

read more
Prescription drugs

High school seniors playing contact sports more likely to abuse prescription drugs in their 20s – The Hill

The story at a glance


  • Researchers collected data from more than 4,000 high school students from 2006 to 2017, then followed them for a decade to measure the relationship between sports participation and prescription drug abuse.

  • The team looked at contact, semi-contact and non-contact sports, and found that athletes are more likely than non-athletes to abuse prescription stimulants.

  • About 31% of people aged 17 to 18 reported abusing prescription drugs in the last year of the study period.

High school students who play sports are more likely than non-athletes to abuse prescription stimulants during their 20s, but those who play contact sports are even more likely than their peers to do so, according to a new study.

Researchers at the University of Michigan collected data from 4,777 12e students from 2006 to 2017 and then followed them for a decade to measure the relationship between high school sports participation and prescription drug abuse.

The team looked at contact, semi-contact and non-contact sports, and found that athletes are more likely than non-athletes to abuse prescription stimulants. They found that seniors who play contact sports are 50% more likely than those who haven’t played contact sports to abuse prescription stimulants over the next decade.

Additionally, the percentage of athletes involved in contact athletics who reported using prescription stimulants as seniors increased by 7% between the ages of 21 and 22. About 31% of people aged 17 to 18 reported abusing prescription drugs in the last year of the study period. .

America is changing faster than ever! Add Change America to your Facebook Where Twitter stream to stay up to date with the news.

The study’s lead author, Philip Veliz, an associate research professor at the University of Michigan School of Nursing, said that while opioid use among athletes in contact sports was higher , participation did not trigger any abuse.

Veliz said the abuse of opioids and stimulants has declined over the decade, “the study found that certain types of former high school athletes are at greater risk of abusing these drugs and initiate in early adulthood”.

The researchers said the study results “strengthen screenings” for monitoring drug abuse among high school athletes.

“Increased abuse of prescription stimulants after high school warrants continued monitoring into adulthood, especially in athletes,” Sean Esteban McCabe, lead author and director of DASH, the Center for the Study of Drug, Alcohol, Smoking, and Health from the University of Michigan. School of Nursing, said in the statement.

Posted on August 11, 2022

read more
Generic drugs

Global Generic Drugs Market Report 2022: Market to Reach $507.8 Billion by 2026

DUBLIN, August 11, 2022 /PRNewswire/ — The “Generic Drugs – Global Market Trajectory and Analysis” report has been added to ResearchAndMarkets.com’s offer.

Research and Markets Logo

Global generic drugs market to reach $507.8 billion by 2026

Amid COVID-19 Crisis, Global Generic Drugs Market Estimated at US$402.9 billion in 2022, is expected to reach a revised size of US$507.8 billion by 2026, growing at a CAGR of 5.6% over the analysis period.

A key advantage for generic drug manufacturers is that they do not need to invest time and money in drug R&D and marketing efforts, as generic drug prices are significantly lower compared to their brand counterparts.

Generic small molecules, one of the segments analyzed in the report, is expected to grow at a CAGR of 5.2% to reach US$325.7 billion at the end of the analysis period. After a thorough analysis of the business implications of the pandemic and the induced economic crisis, the growth of the biosimilars segment is readjusted to a revised CAGR of 6.3% for the next 7-year period.

This segment currently accounts for a 37.7% share of the global generic drug market. With several factors encouraging growth contributing to wider adoption, biosimilars are poised to increase their share of the global generic drug market in the coming years. The rise of biosimilars has notably reduced overall drug spending in recent years, a trend that is expected to continue for the foreseeable future.

The emergence of biosimilars in the market leads to increased competition, the next generation of biologics under development aims to improve safety, efficacy and cost factors compared to the drugs of the previous generation, which further adds to the competitive heat in the market.

The US market is estimated at $121.8 billion in 2022, when China is expected to reach $91.2 billion by 2026

The generic drug market in the United States is estimated at US$121.8 billion in 2022. The country currently accounts for a 30.46% share of the global market. Chinaworld’s second largest economy, is expected to reach an estimated market size of US$91.2 billion in 2026 with a CAGR of 7.2% over the analysis period.

Other notable geographic markets include Japan and Canada, each predicting growth of 3.8% and 5% respectively over the analysis period. In Europe, Germany is expected to grow at around 4.3% CAGR while the rest of the European market (as defined in the study) will reach US$97.6 billion at the end of the analysis period.

The market is expected to be driven by the steadily increasing risk of various chronic diseases such as hypertension, obesity and diabetes. Although pharmaceutical companies continue to develop branded drugs due to the shortage of new blockbuster drugs coming to market, generic drugs are expected to continue to meet the majority of these therapeutic needs of the population, especially the elderly population. in expansion.

With the high cost of brand name drugs becoming a financial burden on people, efforts have intensified to develop cost-effective generic variants. Many branded drugs are unable to extend their exclusivity, resulting in the loss of patents and making way for affordable generics to be manufactured. Major application areas of generic drugs include cardiology, anti-infection, anti-arthritis, CNS, anti-cancer, and respiratory, among others.

Generic drugs for cardiovascular diseases currently represent the dominant segment, accounting for the majority share of the overall market. Cardiovascular diseases such as heart failure, high blood pressure, circulatory disorders, dyslipidemia, cholesterol, arrhythmias, strokes and angina pectoris are the leading causes of death worldwide.

The cardiovascular segment is expected to cover a larger portion of the global generic drugs market owing to several patent expirations of these drugs. Generic drugs for infectious diseases would gain popularity over the next few years, mainly due to the increasing number of cases around the world.

The COVID-19 pandemic has emerged as a significant growth driver for the generic drug market over the past year. As nations’ economies collapsed due to rising unemployment, the demand for cheaper substitutes for brand name drugs grew.

What’s new for 2022?

  • Global competitiveness and percentage market shares of main competitors

  • Market presence in multiple geographies – Strong/Active/Niche/Trivial

  • Peer-to-peer collaborative online interactive updates

  • Access to digital archives

  • Free updates for one year

Main topics covered:

I. METHODOLOGY

II. ABSTRACT

1. MARKET OVERVIEW

  • Generic drugs – Percentage of market share of the main global competitors in 2022 (E)

  • Progress on vaccinations, why should companies care?

  • These are times when questions abound and answers are few.

  • With the upward revision of the IMF’s global GDP forecast for 2021, most businesses are optimistic about a global economic comeback.

  • A strong economic rebound in 2021 based on pent-up demand comes as relief for struggling industries and markets

  • How has the healthcare sector been and continues to be impacted by the pandemic and what is the new normal?

  • With the COVID-19 pandemic exposing the lack of global health care preparedness, policies are increasingly focused on restarting health systems around the world: current and required health expenditure as % of GDP

  • Impact of the COVID-19 crisis on the generic drugs market

  • Demand for generic painkillers is increasing

  • A prelude to generic drugs

  • The generic drug market is poised for rapid growth

  • The United States dominates, Asia Pacific to show the fastest growth

  • India– A large market

  • Market constraints

  • Competition

  • Recent market activity

2. FOCUS ON CERTAIN PLAYERS (Total 42 Featured)

  • Abbott Laboratories

  • Apotex Inc.

  • ASKA Pharmaceutical Co., Ltd.

  • Aspen Pharmacare Holdings Limited

  • AstraZeneca Plc

  • Baxter International Inc.

  • Dr. Reddy’s Laboratories Limited

  • Eli Lilly and company

  • Endo International plc

  • Fresenius Kabi

  • GlaxoSmithKline Plc.

  • H.Lundbeck A/S

  • Hospira

  • Lupine Pharmaceuticals, Inc.

  • Mylan S.A.

  • Novartis International SA

  • Novo Nordisk A/S

  • F. Hoffmann-La Roche SA

  • Sandoz International GmbH

  • Sanofi-Aventis US LLC

  • STADA Arzneimittel AG

  • Sun Pharma

  • Teva Pharmaceutical Industries Ltd.

3. MARKET TRENDS AND DRIVERS

  • Patent expirations expected to expand potential generic drug market

  • Expiry of patents for certain drugs in 2020

  • Expiry of patents for certain drugs in 2021

  • Expiry of patents for certain drugs in 2022

  • Expiration of patents for certain major drugs in the United States: 2020-2022

  • High demand for pharmaceutical drugs drives demand for generic drugs

  • Cost containment measures focus on generics

  • Small molecule generics are the dominant segment

  • Increased demand for biosimilars, driven by expiring patents for key biopharmaceutical drugs

  • Expiration of patents for major biopharmaceutical drugs in the United States and Europe

  • A progressive regulatory framework accelerates product approvals and subsequently market revenue

  • Specific guidelines for biosimilars in various countries with year of publication

  • Biosimilar regulators in selected regional markets

  • US Biosimilar Approvals (as of February 2021)

  • Biosimilar Approvals in Europe (from January 2021)

  • Rising healthcare costs drive demand for generic drugs

  • An aging population to propel demand for generic drugs

  • Growing prevalence of chronic diseases is driving demand for generic drugs

  • Global cost of chronic diseases (in billions of US dollars) for the years 2018 and 2030

  • Deaths by heart disease – Estimated percentage distribution for cardiovascular disease, ischemic heart disease, stroke and other

4. GLOBAL MARKET OUTLOOK

III. REGIONAL MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/7otw89

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Quote

Quote

View original content: https://www.prnewswire.com/news-releases/global-generic-drugs-market-report-2022-market-to-reach-507-8-billion-by-2026—cost – lockdown-measures-emphasizing-generics-301604275.html

SOURCE Research and Markets

read more
Medical products

Fake test kits, seized medical products

Police show off falsely labeled ATKs, face masks and other goods seized in raids on premises in Nakhon Pathom and Nonthaburi on Thursday. (Photo: Wassayos Ngamkham)

Fake Covid-19 antigen test kits and other medical equipment, worth around 2 million baht, were seized in raids by police in Nakhon Pathom and Nonthaburi provinces on Thursday.

Teams of Consumer Protection Police Division (CPPD) officers and Food and Drug Administration (FDA) officials first searched a commercial building in tambon Naraphirom of Bang Len district in Nakhon Pathom .

They seized tens of thousands of antigen test kits (ATKs) that were falsely labeled with brand names such as Testsealabs Gica, Testsealabs Nex and Zybio, along with face masks and other products.

A woman identified only as Anusara admitted to owning the goods and the building, Central Bureau of Investigation Commissioner Lt. Gen. Jirabhob Bhuridej said.

The second raid took place at a tambon Bang Khen house in Muang district of Nonthaburi. There they seized ATKs falsely labeled as Testsealab Gia, Testsealabs Nex, Greenspring, Singclean, Seinofy, Hip, Deepblue, Humansis, Bioteke and Ustar, as well as medical gloves, oximeters and Chinese herbal products.

A woman identified only as Patyaphorn admitted to owning the house and property.

The items seized from the two locations were worth around 2 million baht in total, the CIB chief said.

The raids followed complaints that unscrupulous people were selling unapproved products falsely labeled with FDA-approved brand names.

CPPD Branch 4 Chief Pol Col Neti Wongkulab said a police investigation revealed that falsely labeled ATKs were being sold at low prices through Facebook accounts run by the two women since April. They sold ATKs for 40 to 45 baht each, cheaper than brands normally sold, Pol Col Neti said.

The police posed as customers, buying the ATKs from a shop near the site of the first raid in Nakhon Pathom. They then searched the nearby commercial building and found the same products packaged and ready for distribution. This led to the raid on the house in Nonthaburi.

Pol Col Neti said the next step would be to arrest the Chinese national who allegedly supplied these counterfeit products. Investigators believed at least four people were involved.

FDA Secretary General Paisarn Dunkum said oximeters and ATKs are medical devices. Tampering with medical equipment affects quality and safety and poses a danger to medical staff and patients.

Tampering with medical equipment is punishable by up to 10 years in prison and/or a fine of one million baht, Dr Paisarn said.

read more
Medical supplies

Key to Automated Payments for Medical Supplies

PYMNTS recently met with two of the players in the health sector.

On the purchase side, Huntington Healthwhich is affiliated with the Cedars-Sinai Health System in California, shared how faster and more efficient delivery of vital medical supplies is occurring despite limited supplies and other recently exposed system weaknesses.

From a financial point of view, American Express shared his perspective on the history, status quo and future of digitization and automation of payments in the healthcare sector, which accounts for nearly 20% of gross domestic product (GDP).

Read more: B2B Payments in Healthcare Tracker®

The buy side

Like many other health systems, Huntington Health faces payment issues when purchasing medical supplies, seeking faster and more efficient payment processes instead. Embracing technology and trusted financial partnerships can ease friction.

Huntington buys about $100 million worth of supplies and equipment a year – even bandages. The pandemic has tested purchases with a mad rush for specialized types of equipment, such as N95 masks and ventilators, which are not normally stocked in bulk or available in large quantities from medical supply suppliers. trusted or even government stocks.

The pandemic presented a unique day-to-day scenario where the hospital needed to be prepared to write a check or quickly transfer money outside of its normal purchasing systems, which required manual billing, shipping, and Accounts Payable (AP) .

Slowly, this is changing as hospitals are beginning to see the benefits of using enterprise resource planning (ERP) solutions to streamline different processes and work towards achieving overall organizational efficiency. Still, it takes time to implement new technologies in large healthcare organizations, and Huntington is about three years away from full adoption.

The use of electronic payments is also growing. The number of ACH healthcare payments in the second quarter of 2022 was 113.7 million, an increase of 5.3% compared to the 108 million ACH healthcare payments in the second quarter of 2021, according at Nasha.

Yet while providers prefer ACH payments and direct deposits, their customers are making up to 85% of their payments by check or other paper-based methods, as shown in the B2B Payments in Healthcare Tracker, a collaboration between PYMNTS and American Express.

The healthcare industry is also facing staffing shortages in many different disciplines. Huntington is working to adopt artificial intelligence and robotics technology that can help reduce the need for human effort.

The Financial Sector Perspective

American Express believes that automation can improve medical supplies procurement and supplier relationships. The shape of things to come implies a future in which automation will continue as procurement ensures supply chain efficiency.

Healthcare is particularly sensitive to pandemic issues, and many back-office employees are still inclined to work from home. Digital access to physical assets, such as ledgers, invoices and checks, widely adopted during shutdowns, continues to enable this trend, helping to address labor shortages while reducing workforces by maximizing efficiency and effectiveness.

Remote back office work also frees up facility space for clinical and wellness revenue generating uses.

See also: Health accounts for 20% of GDP which desperately needs payment efficiency

Automated billing creates a backbone of supply support to deliver critical medical supplies on time. Fully automated AP and Accounts Receivable (AR) processes with electronic invoicing can eliminate friction by correcting discrepancies.

Hospitals have embraced AP automation solutions, which conversely have vendors looking for AR solutions and payment portals to maximize receivable collection rates and treasury applications while using solutions supply chain finance.

The challenges of travel

The journey to the promised land necessarily requires a trek through the desert. Supply is challenged by a myriad of factors, especially when visibility into hospital inventory is poor.

Internally, data management can be difficult when working on decentralized legacy systems. Teams that can still take very manual steps to place orders will cause delivery delays, further blurring visibility into inventory levels, orders, and delivery schedules.

Externally, ongoing changes in regulatory requirements are impacting on-demand medical supplies that need to be stocked. Additional tension occurs when demand spikes, bidding processes lack transparency, and supply chain procurement logistics come to a halt.

Concentration remains a problem. While nothing focuses the mind quite as wonderfully as the prospect of a pandemic, hospitals and healthcare systems are still focused on other priorities, including clinics, compliance, revenue cycle management, and consolidation. after the merger and acquisition.

A common goal

Huntington looks forward to the time when direct payments to overseas suppliers can be made by machines that can instantly account for supply chain delays. By using pre-authorized payment methods such as virtual cards, machines can ensure a steady flow of supplies and pay for them in local currency.

Meanwhile, American Express envisions the convergence of buyers and suppliers under the umbrella of automation. FinTechs and financial institutions will be instrumental in providing the healthcare industry with the payment digitization and automation solutions it needs to succeed in this matter of life and death.

For all PYMNTS B2B coverage, subscribe daily B2B Newsletter.

——————————

NEW PYMNTS SURVEY FINDS 3 IN 4 CONSUMERS HAVING HIGH DEMAND FOR SUPER APPS

About: Results from PYMNTS’ new study, “The Super App Shift: How Consumers Want To Save, Shop And Spend In The Connected Economy,” a collaboration with PayPal, analyzed responses from 9,904 consumers in Australia, Germany, UK and USA. and showed strong demand for one super multi-functional app rather than using dozens of individual apps.

read more
Medical supplies

✦ Medical supplies fly to African skies

Before we dive into the nitty-gritty, a programming note: your regular member briefing will take a vacation next Wednesday, but will be back on Wednesday August 17th.

Hi Quartz Africa members!

One of the problems with providing quality health care in many African communities is the poor condition of essential infrastructure like roads.

During emergencies, it is so difficult to reach patients with life-saving supplies that people often die of generally treatable illnesses or injuries. Coupled with the dearth of health facilities with robust storage systems, a government’s ability to manage supplies and coordinate distribution between sites is often limited. This is the case for essential drugs, vaccines and equipment, but undoubtedly the most crucial when it comes to blood products.

Delivering blood efficiently is a matter of life and death, especially for women in sub-Saharan Africa, who suffer from the highest maternal mortality rate in the world. Most deaths are due to complications related to pregnancy or childbirth, especially postpartum haemorrhage. But blood products are also needed in other urgent medical procedures, such as treating major accidents and performing surgery. As such, companies that can provide logistics to circumvent transportation challenges have a huge market opportunity.

When it comes to rapid transport, nothing beats an air vehicle. But where planes carry humans and heavy cargo, unmanned aerial vehicles, also known as drones, have emerged over the past decade as a flexible, safe and reliable sweet spot for direct-to-home deliveries. . Amazon, FedEx, UPS and Walmart have all started experimenting with drone deliveries as part of a move towards greater efficiency. When it comes to delivering medical products like blood, four startups are catching up with an industry leader born in the United States, raised in Rwanda and entering new markets in Africa.


Checklist

💡 The Opportunity: Communities that live in places that are difficult to access by road find it difficult to receive medical care when they need it. Drone deliveries can bridge this access gap and also use digital technology to effectively anticipate demand.

🤔 The challenge: Unmanned aerial vehicles are expensive to procure and require high levels of expertise for operations, especially when dealing with medical products that are sensitive to time, temperature, and other storage conditions. Additionally, national security considerations often make it difficult to obtain licenses for drone operations.

🌍 The roadmap: Identify health care providers who need to improve the distribution of medical products. Develop a system that centralizes these products in distribution centers, from where they can be quickly flown to medical facilities.

💰 The speakers: Government regulators who must approve drone operating licenses, healthcare providers who hold medical products in stock but need efficient distribution, and patients who ultimately receive needed care.


By the numbers

30%: The proportion of roads in Nigeria that are paved.

50%: The proportion of maternal deaths in sub-Saharan Africa caused by postpartum haemorrhage.

$185 billion: Expected revenue for the global healthcare logistics market by 2030.

5000000: Vaccine units delivered by Zipline using its drones.


The case study

Last name: Zipline

Based: 2014

HQ: UNITED STATES

Founders: Keller Rinaudo, Keenan Wyrobek and Will Hetzler

Last assessment: $2.75 billion (June 2021)

Zipline is not a health technology company, but a logistics company like FedEx. Zipline has spent a decade working with African governments to deliver lifesaving blood products, vaccines and medicines, using its own unmanned drones.

Zipline has flown 300,000 flights since first in Rwanda in 2016. Its work in Rwanda served as a model for its operations in Ghana in 2019 and in Nigeria this year. Its operations are simple: Zipline receives medical products from government stock and stores them in a distribution center that also serves as an airfield from where drones take off and deliver the products to hospitals. Zipline is contracted and paid for by a federal or state government, but the company’s systems interact with hospital staff, receiving requests from doctors at those hospitals via text, WhatsApp, phone, or the Internet.

The not-so-simple part is that Zipline’s drones must be carefully designed to deliver sensitive medical products, rather than books or groceries. And while the business value lies in flying over rugged areas, drones need to drop off packages where medical personnel can safely retrieve them. Drones do not land on the ground during deliveries; they momentarily suspend the air, deposit the package and return to the base from which they took off.

Luke Dray/Stringer

After delivering packages to more than 2,000 hospitals in Rwanda, Ghana and the United States, the company has unveiled technology that allows its drones to detect other aircraft in real time and prevent possible accidents. Zipline now boasts its ability to perform in harsh conditions as its main selling point. “We bring instant logistics of essential medical products to [Nigeria]one of the most logistically challenging states,” Daniel Marfo, the company’s senior vice president for Africa, told Quartz.

Powered by nearly $500 million in funding, Zipline has the financial muscle to design and build its drones in-house. Large capital outlay, the need for government contracts, and the complexity of drone regulations can be a significant hurdle for new entrants. But again, Zipline has only scratched the surface of a problem that exists in 54 countries across the continent. Another innovator might just give them a hard time.


In conversation with

Daniel Marfo is Zipline’s senior vice president for Africa. Quartz spoke to him ahead of the company’s launch in Nigeria this year:

⚠️ Why does Zipline go to communities with difficult terrain?

Due to the incidence of banditry, to move some medical supplies from Kaduna town (North West Nigeria) to West Kaduna, they need a military convoy. I have been to health facilities in Kaduna which have been closed because medical supplies are not reaching them due to the danger of traveling on certain roads. So for us, those are the types of places that need it the most.

🤝 How dependent is Zipline on government health contracts??

Our main customers in Rwanda and Ghana are the federal governments of each country, but they are not our only customers. Our system can be applied to other use cases. For example, in Rwanda, we transport artificial semen from farm animals under cold chain to farmers in rural areas. Our work of delivering medical products is the most important and it creates the greatest impact, [but] it’s not our only revenue model.


Similar offers we are 👀

LifeBank, the blood delivery startup in Nigeria, received a $250,000 grant in 2019 after winning the African Netpreneur Prize Initiative run by the Jack Ma Foundation. Founded in 2016, the company uses motorcycles to deliver blood and, more recently, oxygen products to hospitals just in time for use by patients.


More from Quartz Africa

🚁 Zipline needs Nigeria to support its medical drone delivery service

🇳🇬 Zipline is launched in Kaduna State

💰 The true cost of medical drone delivery services in Africa


🎵 This brief was produced by listening Tarihindaby Cécile Kayirebwa (Rwanda)

Have a very motivated weekend,

—Alexander Onukwue, West Africa Correspondent


A 🩸 thing

In October 2016, Zipline began delivering blood products to 21 Rwandan hospitals on demand, reducing delivery time from four hours by road to less than 20 minutes, using drones that travel up to 100 km per hour at a time.

read more
Generic drugs

Global Generic Drugs Market Research Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Generic Drugs – Global Market Trajectory and Analysis” report has been added to from ResearchAndMarkets.com offer.

Global generic drug market to reach $507.8 billion by 2026

Amid the COVID-19 crisis, the global generic drug market estimated at US$402.9 billion in 2022 is expected to reach a revised size of US$507.8 billion by 2026, growing at a CAGR of 5.6% over the analysis period.

A key advantage for generic drug manufacturers is that they do not need to invest time and money in drug R&D and marketing efforts, as generic drug prices are significantly lower compared to their branded counterparts.

Generic small molecules, one of the segments analyzed in the report, is expected to grow at a CAGR of 5.2% to reach US$325.7 billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and the induced economic crisis, the growth of the biosimilars segment is readjusted to a revised CAGR of 6.3% for the next 7-year period.

This segment currently accounts for a 37.7% share of the global generic drug market. With several factors encouraging growth contributing to wider adoption, biosimilars are poised to increase their share of the global generic drug market in the coming years. The rise of biosimilars has notably reduced overall drug spending in recent years, a trend that is expected to continue for the foreseeable future.

The emergence of biosimilars in the market leads to increased competition, the next generation of biologics under development aims to improve safety, efficacy and cost factors compared to previous generation drugs, which further adds to the competitive heat in the market.

The US market is estimated at $121.8 billion in 2022, while China is expected to reach $91.2 billion by 2026

The generic drug market in the United States is estimated to be worth US$121.8 billion in 2022. The country currently accounts for a 30.46% share of the global market. China, the world’s second largest economy, is expected to reach an estimated market size of US$91.2 billion in 2026 growing at a CAGR of 7.2% over the analysis period.

Other noteworthy geographic markets include Japan and Canada, each forecasting growth of 3.8% and 5% respectively over the analysis period. In Europe, Germany is expected to grow at a CAGR of approximately 4.3%, while the rest of the European market (as defined in the study) will reach US$97.6 billion by the end of the outlook period. ‘to analyse.

The market is expected to be driven by the ever increasing risk of various chronic diseases such as hypertension, obesity and diabetes. Although pharmaceutical companies continue to develop branded drugs due to the shortage of new blockbuster drugs coming to market, generic drugs are expected to continue to meet the majority of these therapeutic needs of the population, especially the elderly population. in expansion.

With the high cost of brand name drugs becoming a financial burden on people, efforts have intensified to develop cost-effective generic variants. Many branded drugs are unable to extend their exclusivity, resulting in the loss of patents and making way for affordable generics to be manufactured. Major application areas of generic drugs include cardiology, anti-infection, anti-arthritis, CNS, anti-cancer, and respiratory, among others.

Generic drugs for cardiovascular diseases currently represent the dominant segment, accounting for the majority share of the overall market. Cardiovascular diseases such as heart failure, high blood pressure, circulatory disorders, dyslipidemia, cholesterol, arrhythmias, strokes and angina pectoris are the leading causes of death worldwide.

The cardiovascular segment is expected to cover a larger portion of the global generic drugs market owing to several patent expirations of these drugs. Generic drugs for infectious diseases would gain popularity over the next few years, mainly due to the increasing number of cases around the world.

The COVID-19 pandemic has emerged as a significant growth driver for the generic drug market over the past year. As nations’ economies collapsed due to rising unemployment, the demand for cheaper substitutes for brand name drugs grew.

What’s new for 2022?

  • Global competitiveness and percentage market shares of main competitors

  • Market presence in multiple geographies – Strong/Active/Niche/Trivial

  • Peer-to-peer collaborative online interactive updates

  • Access to digital archives

  • Free updates for one year

Main topics covered:

I. METHODOLOGY

II. ABSTRACT

1. MARKET OVERVIEW

  • Generic drugs – Percentage of market share of the main global competitors in 2022 (E)

  • Progress on vaccinations, why should companies care?

  • These are times when questions abound and answers are few.

  • With the upward revision of the IMF’s global GDP forecast for 2021, most businesses are optimistic about a global economic comeback.

  • A strong economic rebound in 2021 based on pent-up demand comes as relief for struggling industries and markets

  • How has the healthcare industry been and continues to be impacted by the pandemic and what is the new normal?

  • With the COVID-19 pandemic exposing the lack of global health care preparedness, policies are increasingly focused on restarting health systems around the world: current and required health expenditure as % of GDP

  • Impact of the COVID-19 crisis on the generic drugs market

  • Demand for generic painkillers is increasing

  • A prelude to generic drugs

  • The generic drug market is poised for rapid growth

  • US dominates, Asia-Pacific shows fastest growth

  • India – An important market

  • Market constraints

  • Competition

  • Recent market activity

2. FOCUS ON SELECT PLAYERS (Total 42 Featured)

  • Abbott Laboratories

  • Apotex Inc.

  • ASKA Pharmaceutical Co., Ltd.

  • Aspen Pharmacare Holdings Limited

  • Astra Zeneca Plc

  • Baxter International Inc.

  • Dr. Reddy’s Laboratories Limited

  • Eli Lilly and company

  • Endo International plc

  • Fresenius Kabi

  • GlaxoSmithKline Plc.

  • H.Lundbeck A/S

  • Hospira

  • Lupine Pharmaceuticals, Inc.

  • Mylan AG

  • Novartis International AG

  • Novo Nordisk A/S

  • F. Hoffmann-La Roche SA

  • Sandoz International GmbH

  • Sanofi-Aventis US LLC

  • STADA Arzneimittel AG

  • Sun Pharma

  • Teva Pharmaceutical Industries Ltd.

3. MARKET TRENDS AND DRIVERS

  • Patent expirations expected to expand potential market for generic drugs

  • Expiry of patents for certain drugs in 2020

  • Expiry of patents for certain drugs in 2021

  • Expiry of patents for certain drugs in 2022

  • Expiration of patents for certain major drugs in the United States: 2020-2022

  • High demand for pharmaceutical drugs drives demand for generic drugs

  • Cost containment measures focus on generics

  • Small molecule generics are the dominant segment

  • Increased demand for biosimilars, driven by expiring patents for key biopharmaceutical drugs

  • Expiration of patents for major biopharmaceutical drugs in the United States and Europe

  • A progressive regulatory framework accelerates product approvals and subsequently market revenue

  • Specific guidelines for biosimilars in various countries with year of publication

  • Biosimilar regulators in selected regional markets

  • US biosimilar approvals (as of February 2021)

  • Biosimilar approvals in Europe (from January 2021)

  • Rising healthcare costs drive demand for generic drugs

  • An aging population to propel demand for generic drugs

  • Growing prevalence of chronic diseases is driving demand for generic drugs

  • Global cost of chronic diseases (in billions of US dollars) for the years 2018 and 2030

  • Deaths by heart disease – Estimated percentage distribution for cardiovascular disease, ischemic heart disease, stroke and other

4. GLOBAL MARKET OUTLOOK

III. REGIONAL MARKET ANALYSIS

IV. COMPETITION

For more information on this report, visit https://www.researchandmarkets.com/r/63hic2

read more
Prescription drugs

Passage of the Cut Inflation Act includes cutting the cost of prescription drugs

AARP in the Virgin Islands

AARP – in the Virgin Islands shares a statement released by AARP CEO Jo Ann Jenkins following the historic vote to pass the Cut Inflation Act. The message was released on August 7 immediately after the Senate vote. The Senate voted to pass the Cut Inflation Act of 2022, a bill that includes several key provisions to drive down prescription drug prices. AARP thanked all of the senators who voted to support this essential legislation and move closer to real relief for seniors.

The Inflation Reduction Act includes key AARP priorities that will go a long way in reducing drug prices and out-of-pocket costs. AARP fought for provisions in the bill that:

  • Finally allow Medicare to negotiate drug prices
  • Cap annual prescription drug spending in Medicare Part D at $2,000
  • Hold drug companies accountable when they raise drug prices faster than the rate of inflation, and
  • Cap the insulin co-pay to a maximum of $35 per month in Part D.

Jo Ann Jenkins, executive director of AARP, released a statement in reaction to the Senate vote:

“Since AARP’s inception, we have fought to ensure seniors have access to affordable health care, including prescription drugs. And we’ve worked for nearly two decades to allow Medicare to negotiate the price it pays for drugs. Thanks to today’s historic vote in the Senate, millions of Americans over 50 are one step closer

to real relief from runaway prescription drug prices. This bill will save Medicare hundreds of billions of dollars and give seniors peace of mind knowing there is an annual limit on what they have to pay out of pocket for drugs. Lowering prescription drug prices is a top priority for Americans, with more than 80% of people from all political parties supporting the measure. We thank all senators who voted today to lower drug prices.

“We are also thrilled that the bill will keep health insurance affordable for millions of Americans who buy their coverage in the market, especially consumers between the ages of 50 and 64, including more than one million got more affordable options.

Printable, PDF and email version
read more
Medical products

Growing medical device maker with 110 new jobs in Houston County

Mark Fellows, vice president of GRI-APS, said the additional 110 jobs in Houston County will increase over the next 90 days.

“These growth plans for Global Resources International and Advanced Product Solutions represent a significant development for the Wiregrass region,” said Greg Canfield, Secretary of the Alabama Department of Commerce.

“This expansion will enhance domestic production of much-needed products for Alabama and nationwide customers, while strengthening GRI-APS’ presence in Wiregrass.”

GROWTH PLANS

In a joint statement, Dothan Mayor Mark Saliba and Houston County Commission Chairman Mark Culver praised GRI-APS’ continued investment and said they are “incredible examples of partners community trade”.

Columbia Mayor Cas Haddock said the GRI-APS project is a “breath of fresh air” for the Houston County community of 800.

“We are grateful that they chose Columbia, Alabama for this sophisticated operation,” he added.

GRI, headquartered in Flowery Branch, Georgia, is a privately held manufacturing and supply company specializing in the design, manufacture, sterilization and distribution of products for the healthcare, medical and medical markets. industry and animal care.

A long-standing GRI affiliate, based in Ashland, Alabama Eastern Technologies Inc.. produces protective equipment for workers in industries such as nuclear power, chemicals and defence. (Learn more about ETI’s efforts at the start of the pandemic.)

A broad partnership of state and local agencies supported the project. At the state level, these include the governor’s office; the Alabama Department of Commerce; AIDT, the state’s main workforce development agency; and Southeastern Alabama works.

The City of Dothan, Houston County Commission, City of Columbia, Dothan Industrial Development Council, and Dothan Chamber/Grow Dothan Development Team also supported the project, as did Dothan Utilities, Alabama Municipal Electric Authority. and Southeast Gas.

read more
Medical supplies

Global Medical Supplies Market Report 2022, Trends and Opportunities to 2030 – Shanghaiist

published by researchreports.xyz

Comprehensive analyzes of the fastest growing medical supplies market provide insights that help stakeholders identify opportunities and challenges. The 2022 markets could be another big year for medical supplies. This report provides an overview of the company’s activities and financial situation (a company profile is required if you want to raise capital or attract investors), recent developments (mergers and acquisitions) and recent SWOT analyses. This report focuses on the medical supplies market over the assessment period 2030. The report also provides an analysis of the growth of the medical supplies market which includes Porter’s five factor analysis and analysis of the Supply Chain.

Click here to access the sample report: researchreports.xyz/Request-For-Sample-Report?/Medical-Supplies&id=9403

This Medical Supplies analysis report also provides in-depth insights into other upcoming trends and challenges that will have a tremendous effect on the growth of the market. Get detailed insights into trends and challenges, which will help businesses assess and develop strategies for growth.

Who are the main suppliers of medical supplies?

Medtronic plc (Ireland), Cardinal Health, Inc. (USA), Becton, Dickinson and Company (USA), Johnson & Johnson (USA), B. Braun (Germany), Boston Scientific Corporation (USA), USA), Thermo Fisher Scientific (USA), Baxter International Inc. (USA), Halyard (USA), 3M (USA)

Detailed segmentation:

By TypeDiagnostic ProductsDialysis ConsumablesTrauma ConsumablesRadiation Related ConsumablesInfusion Related ProductsBy ApplicationUrologyWound CareRadiologyAnesthesiaSterilizationCardiologyOphthalmologyOther ApplicationsBy End UsersHospitalsClinicsOtherBy Distribution ChannelOnline ChannelOffline Channel

Get 30-50% off various types of licenses when buying it now (use corporate email id for higher priority) @researchreports.xyz/Check-Discount-On-Report?/ Medical-Supplies&id=9403

Competitive landscape highlighting important parameters players are gaining with market shifts and developments:

• % market share, SWOT analysis, segment revenue for each company profile.
• Overview of the activity and classification of the products or services.
• Latest developments (product launches, technological advances, manufacturing, expansion plans and research and development)
• Matrix of products or services.
• Capacity, consumption and production of players.

Quantitative data:

1. Market Revenue and Growth Rate by Type (Historical and Forecast)
2. Market revenue and growth rate by application, such as food, beverage, pharmaceutical, industrial & chemical, cosmetic & personal care, agriculture, etc.
3. Market Revenue, Growth Rate, Volume, Type and Application by Each Country (Historical and Forecast)
4. Revenue, volume and annual growth rate per player (reference year).

Qualitative data:

It contains sections related to market dynamics and trending factors that are influencing or driving market growth. To list some names of the sections covered:

• Overview of the global medical supplies industry.
• Global market growth drivers, opportunities and restraints.
• Gaps and opportunities in the medical supplies market
• Market entropy (suppression of aggressiveness and strategic moves by industry players).
• Analysis of Porter’s five forces (potential new market entrants, competitive competitors, alternative customers and products).
• PESTLE analysis (360 degree view of the market).
• Analysis of trademarks and patents.
• Competitive analysis (of each player and manufacturer featured in the report) SWOT analysis display).
• Medical supplies market developments and insights innovations, and new product or service launches.
• Investment and project feasibility study.

We also offer customization of reports based on specific customer requirements:

– Free country-level analysis for the 5 countries of your choice.
– Free competitive analysis of 5 key market players.
– 40 hours of free analysis to cover any other data point.

For a custom report, click @ researchreports.xyz/Reports-Description-And-Details?/Medical-Supplies&id=9403

All of the reports we list tracked the impact of COVID-19. The upstream and downstream of the entire supply chain were taken into account during this operation. Additionally, where possible, we will provide an additional COVID-19 update supplement/report to the third quarter report, please check with the sales team.

About Us:

researchreports.xyz is the credible source for getting the research reports that will provide you with the direction your business needs. The market is changing rapidly with the continuous expansion of the industry. Technological advancements have provided today’s businesses with multi-faceted benefits driving daily economic changes. Thus, it is very important for a business to understand the patterns of market movements in order to better strategize. An effective strategy gives companies a head start in planning and an advantage over their competitors.

Contact us

Research reports

Phone (UK): +44 141 628 5998

Email: [email protected]

Web: https://www.researchreports.xyz

read more
Medical products

UPS acquires medical products company Bomi

United Parcel Service has agreed to acquire Bomi Group, an Italian distributor of medical products.

Why is this important: COVID-19 has highlighted the importance of reliable and efficient distribution of medical products. Bomi plays in an important and growing sector of the increasingly targeted market: temperature-controlled transport.

  • Pharmaceutical and biologic therapies rely on cold chain systems that monitor temperature and extend shelf life during transport.

Details: Via Bomi, UPS gains temperature-controlled facilities in 14 countries, inheriting a fleet of more than 350 temperature-controlled vehicles and four million square feet.

  • Bomi facilitates the delivery of pharmaceuticals and medical supplies to hospitals, clinics, laboratories, pharmacies and patients at home.
  • The company employs 3,000 people and serves more than 150 multinational customers worldwide.
  • Financial terms were not disclosed. JP Morgan Securities advised UPS.

The context: UPS Healthcare has already doubled its global footprint since 2020 to meet increased demand, according to a press release.

  • The division has new healthcare facilities built in Germany and Australia, and expanded footprints in Hungary and the Netherlands.
  • It recently beefed up its UPS Premier technology-driven tracking service to improve the quality of logistics.

State of play: Bomi has been carried away by a global logistics strategy, but many private equity investors are also building players in temperature-controlled transportation.

  • In June, EQT and Mubadala purchased Envirotainer — a world leader in active cold chain technologies for the air transport of pharmaceuticals — in a $3 billion deal.
  • CSafe Global, backed by Thomas H. Lee and Frazier Healthcare Partners, in December purchased Softbox Systemswhich produces passive temperature-controlled packaging systems.
  • Global packaging company Sonoco is also playing in the field of passive cold chain logistics with its ThermoSafe unit.

Yes and: Investors invest their money in health care infrastructure in other ways as well.

  • Medline, a giant in the distribution of uncomplicated products to hospitals such as scrubs or sterilized trays — last year ordered an enterprise value of $34 billion with its leveraged buyout by Hellman & Friedman, Carlyle and Blackstone.
  • Shortly thereafter, Bain Capital acquired PartSource, which can be likened to a “healthcare Amazon” from a B2B perspective, in a transaction valued at $1.25 billionsources then told Sarah.

read more
Prescription drugs

Hyperlipidemia Prescription Drugs Market Research Report 2022

Global Prescription Drugs for Hyperlipidemia Market is expected to grow at a CAGR of 14.5% to reach xx Million USD through 2029

Prescription drugs for hyperlipidemia Market overview

The Prescription Drugs for Hyperlipidemia market research report includes all the necessary details. By providing accurate data to its clients, it helps them make important decisions and gives market forecasts. This study, which combines primary and secondary research, provides market size, share, trends and forecasts for important segments and sub-segments. This market research monitors all the latest developments and changes in the industry. It provides information on the obstacles encountered when starting a business and offers advice on how to deal with impending difficulties.

Browse the full report at:

https://pharmaresearchconsulting.com/reports/hyperlipidemia-prescription-drugs-market-global-growth-trends-and-forecast-2022-2029-by-type-hmg-coa-reductase-inhibitors-fibric-acid-derivatives- nicotinic-acid-by-hospital-clinical-application-and-by-regions

Report scope

The research analysis of the Global Prescription Drugs for Hyperlipidemia Market takes a close look at the market size, trends, and potential opportunities. By offering in-depth details of technology expenditure for the projection year, this research provides a unique perspective on the global Prescription Hyperlipidemia Drugs market across various categories. Clients can learn more about the potential and limitations of the industry by reading the study on Global Prescription Drugs for Hyperlipidemia Market. The study discusses in detail a number of factors that have been identified as influencing the growth trajectory of the market. The issues facing the market are also identified in the study.

Profile of key companies in the report:

Amgen, are Eli Lilly, GlaxoSmithKline Pharmaceuticals, Isis Pharmaceuticals, Merck, Dr. Reddy’s Laboratories, Immuron Limited, Esperion Therapeutics and Pfizer, Formac Pharmaceuticals and others.

Prescription drugs for hyperlipidemia Market segmentation :

By Type, it is segmented into

HMG COA reductase inhibitors

Fibric acid derivatives

nicotinic acid

Bile acid sequestering agents

Cholesterol absorption inhibitors

Combination drug therapy

By Application, it is segmented into

Hospital

Clinical

Others

Regional Analysis Of Prescription Drugs For Hyperlipidemia Market

The research mentions the regional scope of the market, mainly focusing on the following areas:

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa)

Points covered in the report

It includes a detailed description of each company. Along with these factors, the study also covers their capacity, production, price, revenue, cost, gross margin, sales volume, revenue, consumption, growth rate, import , their exports, supply, future plans and technological advancements. This study forecast and reviewed data for the past 12 years.

There is a detailed discussion of the market growth factors, along with a detailed explanation of each of the market end users.

The data and information is broken down by market player, region, type, application etc. and also by custom

Prescription drugs for hyperlipidemia Market Players and Competitor Analysis:

The research includes company profile, product specifications, production/sales capacity, revenue, price and gross margin 2022-2029, and sales by type for major market players.

Regional and global market research Global and regional market status and outlook for 2022-2029 are included in the report. The report also includes breakdown information for each region and country it covers. identifying the number of sales and revenue projections, as well as its production, consumption, imports and exports.

Market analysis by product type: The study covers the majority of product types used in the Prescription Drugs for Hyperlipidemia market, along with product details for each major player, volume and sales by volume and value.

Market analysis by type of application: The market is further subdivided into numerous key applications of its industry based on the Prescription Hyperlipidemia Drugs market and its applications. It offers market size, CAGR, and forecast information for each application in the industry.

Market trends: Two major market trends are the escalation of competition and continuous innovation.

Main highlights of the Prescription drugs for hyperlipidemia Market report:

– Overall assessment of the parent market
– Evolution of the significant aspects of the market
– Industry-wide survey of market segments
– Assessment of the value and volume of the market over the past, present and forecast years (2022-2029)
– Market share assessment
– Tactical approaches from market leaders
– Money-making strategies to help companies strengthen their position in the market

Click the link for a free sample copy of the report:

https://pharmaresearchconsulting.com/reports/veterinary-therapeutics-market-global-growth-trends-and-forecast-2022-2029-by-type-by-distribution-channel-by-regions-by-key-players- zoetis-inc-merck-animal-health-elanco-animal-health-boehringer-ingelheim-gmbh/request

Contents:

Chapter 1: Introduction, Market Driver Product Research and Research Objectives Scope of Prescription Drugs for Hyperlipidemia Market

Chapter 2: Exclusive Summary – Basic Information on the Prescription Drugs for Hyperlipidemia Market.

Chapter 3: Revealing Market Dynamics – Drivers, Trends and Challenges

Chapter 4: Prescription drugs for hyperlipidemia Introducing Porters Five Forces Market Factor Analysis, Supply/Value Chain, Pestel Analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: View by Type, End User and Region 2022-2029

Chapter 6: Evaluating Hyperlipidemia Prescription Drugs Market Key Manufacturers Including Competitive Landscape and Company Profiles

Chapter 7: To assess the market by segments, countries and manufacturers, with revenue sharing and sales by key countries for these various regions.

Chapters 8 and 9: Appendix, methodology and data source display

About Us

Pharma Research Consulting (An Improve Digital Consultancy Pvt Ltd Group Company) provides

syndicated market research reports to industries, organizations or even individuals to help them

their decision-making process

Contact us: –

Phone number+1 (704) 266-3234 | [email protected]

read more
Generic drugs

Generic Inhalation and Nasal Spray Market Segmentations, Trends, Share, Size, Major Key Players and Forecast to 2030 – Instant Interview

The Generic Inhalation and Nasal Spray market report is provided here in USD Million. The report will provide insightful data related to the growth rates represented in terms of CAGR % over the projected years. The report will discuss which strategies to adopt after COVID-19, along with a comprehensive analysis of the growth factors, types, applications, impending challenges, competitive landscape, key trends to watch, PEST analysis and overall market dynamics. The main objective of the Inhalation And Nasal Spray Generic Drugs market report is to analyze the impact of COVID-19 on the market and the opportunities to be exploited in the future. The Generic Inhalation and Nasal Spray Drugs Market study examines the market performance for the top 20 countries and understands the growth potential in these countries.
For More Details, Download Free Sample of Generic Inhalation and Nasal Spray Drugs Market: https://healthcaremarketreports.com/sample-request/inhalation-and-nasal-spray-generic-drugs-market/170/

Global Generic Inhalation and Nasal Spray Drugs Market: Major Key Players
Novartis AG (Sandoz International GmbH)
cipla ltd.
Allergan AG
Nephron Pharmaceutical Company
Ranbaxy Laboratories Ltd.
Teva Pharmaceutical Industries Ltd.
Beximco Pharmaceuticals
Mylan AG
Roxane Laboratories, Inc.

Global Generic Inhalation and Nasal Spray Drugs Market by Types
Generic Nasal Spray Drugs
Generic inhaled drugs

Global Generic Drugs for Inhalation and Nasal Spray Market: By Applications
Asthma
COPD
Allergic rhinitis

Global Generic Drugs for Inhalation and Nasal Spray Market by Country
United States
Canada
Germany
UK
France
Italy
Spain
Russia
China
Japan
South Korea
Australia
Thailand
Brazil
Argentina
Chile
South Africa
Egypt
United Arab Emirates
Saudi Arabia

The global healthcare industry has been growing at a CAGR of around 5% and is expected to produce even more in the future. The healthcare industry is growing at a steady pace and is expected to move up the growth ladder in the future. The healthcare sector consists of several main areas including healthcare services and facilities, hospital supplies, medical equipment, pharmaceuticals and drugs and we provide comprehensive information on these sectors with utmost accuracy. .

Healthcare organizations are now working in a dynamic environment, undergoing seismic transformations following the introduction of innovative medical treatments and increased use of the internet. This, combined with unrivaled online access to incredible amounts of information, has made astute patients more cautious. As a result, the demand for smart, affordable and personalized healthcare services has exploded. The COVID-19 pandemic has further led to an increase in demand for healthcare and related products and services, further bolstering the performance of the entire healthcare industry.
Our specialized reports offer information tailored to the unique needs of all important stakeholders. Our reports come with market assessments that provide our clients with useful information on market size, current competition, and other factors. The reports also estimate the burden of common and unusual medical conditions based on prevalence and cost of care. The reports also include an executive-level market plan and valuable insights to help establish effective expansion plans. Healthcare reports also provide an in-depth look at the research and development landscape of a market. These data pointers and analytics provide in-depth research of pipeline product distribution by clinical trial stage, therapeutic region, indication and other factors.

Buy Direct Inhalation and Nasal Spray Generic Drugs Market Research Report: https://healthcaremarketreports.com/purchase/inhalation-and-nasal-spray-generic-drugs-market/170/

FAQs
• What is the driving factor for the growth of the Inhalation And Nasal Spray Generic Drugs market?
• What impact will COVID-19 pandemic have on demand and consumption for the Inhalation And Nasal Spray Generic Drugs Market?
• What is the major application area of ​​the Inhalation And Nasal Spray Generic Drugs market?
• Who are the manufacturers of generic inhalers and nasal sprays in the world?
• Which geographical area is predominant in the Inhalation And Nasal Spray Generic Drugs market?
• Who are the leading industry players in the Generic Inhalation and Nasal Spray Drugs Market?

About Us:
The healthcare industry is certainly facing disruption, with global economies placing great importance on individual health. In this scenario, we expect our customers to get deep insights to propel their innovations in the right direction. We have closely followed the changes and modifications that occur in the field of health. According to our understanding, these alterations are active and unexampled.

read more
Prescription drugs

Senate lawmaker weakens plan of Senate prescription drug bill, climate change initiatives remain intact

WASHINGTON– On Saturday, the Senate congressman struck a blow to the Democrats’ plan to cut drug prices, but left the rest of their sprawling economic bill largely untouched as party leaders geared up for early votes on a package containing many of President Joe Biden’s major national goals.

Elizabeth MacDonough, the nonpartisan arbiter of the chamber rules, said lawmakers must remove language imposing stiff penalties on drugmakers who raise prices above inflation in the private insurance market. . These were the bill’s main rate protections for the roughly 180 million people whose health coverage comes from private insurance, either through work or purchased on their own.

Other important provisions remained intact, including giving Medicare the power to negotiate what it pays for pharmaceuticals for its 64 million elderly beneficiaries, a longtime goal for Democrats. Penalties on manufacturers for overshooting inflation would apply to drugs sold to Medicare, and there is a $2,000 annual cap on free drug and vaccine costs for Medicare beneficiaries.

RELATED | Democrats say they have reached an agreement on the climate and the tax bill

His decisions came as Democrats planned to begin votes in the Senate on Saturday on their sweeping agenda covering climate change, energy, health care costs, taxes and even deficit reduction. Party leaders said they believe they have the unity they will need to push the legislation through the Senate 50-50, with Vice President Kamala Harris’s deciding vote and a strong Republican opposition.

“This is a major victory for the American people,” Senate Majority Leader Chuck Schumer, DN.Y., said of the bill, which both parties are using in their election campaigns to blame the worst period of inflation in four years. decades. “And a sad commentary on the Republican Party as it actively fights cost-cutting provisions for the American family.”

In response, Senate Minority Leader Mitch McConnell, R-Ky., said Democrats are “misinterpreting the outrage of the American people as a mandate for another reckless fiscal and spending spree.” He said Democrats “have already robbed American families once through inflation and now their solution is to rob American families a second time.”

Abandoning penalties on drugmakers reduces incentives for pharmaceutical companies to restrict what they charge, which increases costs for patients.

RELATED | PACT Act: Senate passes healthcare for veterans exposed to toxic burning stoves amid protests

Erasing that language will reduce the $288 billion in 10-year savings that Democrats’ blanket drug restrictions were meant to generate — a reduction of perhaps tens of billions of dollars, analysts say.

Schumer said MacDonough’s private insurance price cap decision was “an unfortunate decision.” But he said the lingering drug pricing language represented “a major victory for the American people” and that the overall bill “remains largely intact.”

The decision followed a 10-day period in which Democrats resurrected key elements of Biden’s agenda that seemed dead. In quick deals with the Democrats’ two most unpredictable senators — first conservative Joe Manchin of West Virginia and then Arizona centrist Kyrsten Sinema — Schumer pieced together a vast package that, although a fraction of earlier versions bigger than Manchin has derailed, would give the party a feat in the context of the legislative elections this fall.

The parliamentarian also signed a levy on excess emissions of methane, a potent contributor of greenhouse gases, from oil and gas drilling. She also left environmental grants to minority communities and other carbon reduction initiatives, said Senate Environment and Public Works Committee Chairman Thomas Carper, D-Del.

She approved a provision requiring union-wide wages to be paid if energy efficiency projects are to qualify for tax credits, and another that would limit electric vehicle tax credits to cars and trucks. assembled in the USA.

The blanket measure faces unanimous Republican opposition. But assuming Democrats fight an unbroken “vote-a-rama” of amendments — many of which are designed by Republicans to derail the measure — they should be able to force the measure through the Senate.

The switch to the House could take place when that House returns briefly from recess on Friday.

“What the vote-a-rama will look like. It’ll be like hell,” Sen. Lindsey Graham of South Carolina, the top Republican on the Senate Budget Committee, said Friday of the approaching GOP amendments. He said that by supporting the Democratic bill, Manchin and Sinema are “strengthening legislation that will make life harder for the average person” by forcing energy costs with tax increases and making it harder for businesses to hire workers.

The bill proposes spending and tax incentives to switch to cleaner fuels and support coal with help to reduce carbon emissions. The expiration of subsidies that help millions pay private insurance premiums would be extended by three years, and $4 billion is earmarked to help Western states fight drought.

There would be a new minimum tax of 15% on certain corporations that earn more than $1 billion a year but pay significantly less than the current corporate tax of 21%. There would also be a 1% tax on companies buying back their own shares, traded after Sinema refused to back higher taxes for private equity firm executives and hedge fund managers. The IRS budget would be inflated to strengthen its tax collections.

While the final costs of the bill are still being determined, overall it would spend more than $300 billion over 10 years to slow climate change, which analysts say would be the country’s biggest investment in this. effort, and billions more for health care. This would raise more than $700 billion in taxes and government drug cost savings, leaving about $300 billion for deficit reduction – a modest portion of projected 10-year deficits of several trillions of dollars. dollars.

Democrats are using special procedures that would allow them to pass the measure without having to achieve the 60-vote majority that legislation often needs in the Senate.

It is the parliamentarian’s job to decide whether parts of the legislation should be dropped for violating these rules, which include the requirement that the provisions are intended primarily to affect the federal budget, not to impose new policy.

Copyright © 2022 by The Associated Press. All rights reserved.

read more
Generic drugs

Global generic drug market to reach $631.58 billion by 2027

DUBLIN, August 5, 2022 /PRNewswire/ — The report “Global Generic Drugs Market (2022-2027) by Category, Applications, End User, Geography, Competitive Analysis and Covid-19 Impact with Ansoff Analysis” has been added to from ResearchAndMarkets.com offer.

The global generic drug market is estimated at $374.14 billion in 2022 and should reach $631.58 billion by 2027 at a CAGR of 11.04%.

Market segmentation

The global generic drugs market is segmented on the basis of category, applications, end-user, and geography.

  • By category, the market is categorized into biosimilars and small molecule generics.
  • By applications, the market is categorized into Anti-Arthritis Drugs, Anti-Cancer Drugs, Anti-Infection Drugs, Cardiovascular Drugs, Central Nervous System Drugs, and Respiratory Drugs.
  • By end-user, the market is categorized into pharmacies, hospitals, pharmacies, private clinics, and retail pharmacies.
  • By geography, the market is categorized into Americas, Europe, Middle East & Africa and Asia Pacific.

Countries studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United StatesRest of the Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Swiss, UKRest of Europe)
  • Middle East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emiratesrest of the MEA)
  • Asia Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, TaiwanRest of Asia Pacific)

Competitive quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and assess the position of companies based on their industry position score and market performance score. The tool uses various factors to classify players into four categories. Some of these factors considered for analysis are financial performance over the past 3 years, growth strategies, innovation score, new product launches, investments, market share growth, etc

Ansoff analysis

The report presents a detailed analysis of the Ansoff matrix for the global generic drugs market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design business growth strategies. The matrix can be used to assess approaches in four strategies viz. Market development, market penetration, product development and diversification. The matrix is ​​also used for risk analysis to understand the risk associated with each approach. The analyst analyzes the global generic drugs market using the Ansoff Matrix to provide the best approaches a company can take to improve its position in the market. Based on the SWOT analysis done on the industry and industry players, the analyst has designed appropriate strategies for market growth.

Why buy this report?

  • The report offers a comprehensive assessment of the global generic drugs market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and market size projections. Projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The main research is done through interviews, surveys and observations of renowned personnel in the industry.
  • The report includes in-depth market analysis using Porter’s 5 forces model and Ansoff’s matrix. Additionally, the impact of Covid-19 on the market is also presented in the report.
  • The report also includes the regulatory scenario in the industry, which will help you to make an informed decision. The report discusses the major regulatory bodies and major rules and regulations imposed on this industry across various geographies.
  • The report also contains competitive analysis using Positioning Quadrants, the analyst’s proprietary competitive positioning tool.

Report Highlights:

  • A comprehensive analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current and projected market size based on value and volume
  • Market shares and strategies of the main players
  • Recommendations for companies to strengthen their presence in the market

Market dynamics

Drivers

  • Low cost of generic drugs compared to brand name drugs
  • Robust M&A activity in the generic drug market
  • Growing incidences of chronic diseases

Constraints

  • Strong commercialization of brand name drugs eclipses generic drugs

Opportunities

  • 3D manufacturing technology boosts
  • Increase collaboration on generic drug research

Challenges

  • Inactive ingredients or excipients are different

Main topics covered:

1 Description of the report

2 Research methodology

3 Executive summary

4 Market dynamics

5 Market Analysis

6 Global Generic Drugs Market, by Category

7 Global Generic Drugs Market, by Applications

8 Global Generic Drugs Market, By End User

9 Americas Generic Drugs Market

ten Europe Generic drugs market

11 Middle East and africa Generic drugs market

12 APAC Generic Drugs Market

13 Competitive landscape

14 company profiles

15 Appendix

Companies cited

  • Abbott Healthcare Pvt. ltd.
  • Allergan PLC
  • Amneal Pharmaceuticals, Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Aurobindo Pharma Ltd.
  • Baxter International Inc.
  • Cipla inc.
  • Eli Lilly and company
  • Endo Pharmaceuticals Inc.
  • Fresenius medical care
  • GSK-API
  • Apotex Inc.
  • Lupine Ltd.
  • Mylan AG
  • Novartis International
  • Pfizer Inc.
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/7zc1v9

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

read more
Medical supplies

Medical supplies market worth $163.5 billion by 2027 –

Chicago, Aug. 05, 2022 (GLOBE NEWSWIRE) — The medical supplies market is expected to grow from USD 138.4 billion in 2022 to USD 163.5 billion by 2027, at a CAGR of 3.4% from 2022 to 2027 according to a new report from MarketsandMarkets™. The growth of this market can be attributed to the expanding geriatric population, increasing investment in research, high volume of surgical procedures, and high prevalence of chronic diseases.

Download the PDF brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64344238

Browse the in-depth table of contents at “Medical supplies market
174 – Tables
39 – Numbers
281 – Pages

In 2021, intubation and ventilation supplies accounted for the largest share of the medical supplies market, by type.

By Type, the medical supplies market is segmented into diagnostic supplies, dialysis consumables, wound care consumables, radiology consumables, disinfectants, infusion and injectable supplies, intubation and ventilation supplies, personal protective equipment , sterilization consumables, catheters, sleep apnea consumables and other medical equipment. In. The intubation and ventilation supplies segment held the highest share, which is attributed to its massive demand amid the novel coronavirus outbreak. The overwhelming influx of COVID-19 patients has created a huge demand for intubation and ventilation supplies which has fueled the market share.

By other application accounted for the largest market share in 2021.

Based on application, the medical supplies market is segmented into urology, wound care, radiology, respiratory, infection control, cardiology, IVD and other applications. The other application segment held the largest share. Other application areas include dentistry, neurology, gastroenterology, orthopedics and waste management applications. The segment market share is driven by high number of surgeries and increasing prevalence of neurological disorders, dental diseases, gastrointestinal disorders and others.

By end user, hospitals accounted for the largest market share in 2021.

Based on end-user, the market is segmented into hospitals, clinics/doctor’s offices, and other end-users. In 2021, the hospital segment accounted for the largest market share. This can be attributed to increased investment in healthcare and state-of-the-art infrastructure.

Request sample pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=64344238

North America was the largest regional market for the medical supplies market in 2021.

The medical supplies market is segmented into five major regions, namely North America, Europe, Asia Pacific and Rest of the World. North America held the largest market share in 2021, followed by Europe. The largest North America market share is driven by high incidence of strong presence of industry players, high prevalence of chronic and infectious diseases and advanced healthcare infrastructure in the region.

Some of the major players operating in the medical supplies market are Medtronic plc (Ireland), Cardinal Health (US), BD (US), Johnson & Johnson, Inc. (US), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (US ), Thermo Fisher Scientific, Inc. (USA), Baxter (USA), 3M (USA), Smith & Nephew (Ireland), Convatec Inc. (UK), Abbott (USA) , Cook Medical (USA), Merit Medical Systems (USA), Stryker (USA), Terumo Corporation (Japan), Teleflex Incorporated (USA), Fresenius Medical Care AG & Co. KGaA (Germany) , Coloplast Group (Denmark), Hamilton Medical (Switzerland), ACell, Inc. (USA), Invacare Corporation (USA), Medline Industries, LP. (USA), DeRoyal Industries, Inc. (USA), Shenzhen MedRena Biotech Co., Ltd. (China), Kerecis (USA) and Whiteley (Australia).

Get 10% free customization on this report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=64344238

Browse the adjacent market: Research reports and advice on the medical device market

Related reports:

Infection Control Market by product [Sterilization (Steam, Hydrogen Peroxide, EtO), Disinfection (Wipes, Liquids, Disinfectors), Services, E-beam, Face Masks]End user (Hospitals, Pharmaceutical companies) (2022 – 2026)


        
read more
Medical products

Inequalities in access to COVID-19 medical products persist as corporate power expands : Peoples Dispatch

Cases of COVID-19 persist around the world, raising particular concern in regions with low immunization rates due to unequal access to vaccines. As the pandemic continues, analyzes of the global response continue to underscore the dangers of prevailing multi-partisan campaigns. One of the latest of these analyzes is a report published by Transnational Institute and Friends of the Earth International in July. It examines how transnational corporations (TNCs) seized the opportunity to gain more power over international institutions and expand markets during the COVID-19 pandemic.

During the launch of the report, Lauren Paremoer of the People’s Health Movement pointed out that the capture of the multilateral system by TNCs and private philanthropies was already underway before the pandemic, but extraordinary circumstances have led to an unforeseen expansion. In the report itself, Harris Gleckman, former head of the New York office of the United Nations (UN) Conference on Trade and Development, highlights how a response to the pandemic is building on multi-stakeholder initiatives such as the The COVID-19 Tool Access Accelerator (ACT-A) has essentially resulted in an international response driven by TNC interests rather than global solidarity.

As demonstrated in previous instances, the report says the COVID-19 pandemic has been a source of record profits for major pharmaceutical and biotech producers. Most strikingly, this suggests that the inclusion of TNCs in pandemic response mechanisms, in combination with their quest to protect and expand markets, has resulted in the prioritization of market opportunities over people’s lives.

In addition to issues around access to COVID-19 vaccines in the Global South, the report highlights examples of inequitable access to COVID-19 tests, personal protective equipment (PPE) and therapeutics – from Essential products highly inaccessible in developing countries due to prohibitive prices. Also among those products is medical oxygen, which about 15% of all COVID-19 patients need while on treatment, according to the nonprofit organization PATH.

In low- and middle-income countries, this translates to around 500,000 people needing a million cylinders of oxygen every day, an amount that exceeds what was defined in contracts signed before the start of COVID-19. . Since the start of the pandemic, oxygen shortages have been recorded in Jordan, Nigeria, Pakistan and Zimbabwe, among others. And although the shortages presented a direct threat to the health and lives of thousands of people in the Global South, some oxygen producers continued to insist on contractual clauses prohibiting the supply of oxygen from other sources. sources, including local extraction.

Among other things, ACT-A was supposed to examine and close the gaps between oxygen supply and need through an emergency task force coordinated by Unitaid, an intergovernmental funding agency, and the Wellcome Foundation based United Kingdom. But instead of developing approaches that would ensure rapid and accessible deployments of supplemental oxygen supplies when needed, the task force “focused on arranging grants and loans from OECD countries, from the World Bank, regional development banks and private foundations to enable local health authorities to purchase supplemental oxygen.

According to the report, there is concern that a similar procedure may have been put in place with regard to the purchase and distribution of PPE through ACT-A. A strategic plan from October 2021 to October 2022 remains silent on the more practical aspects of delivering PPE to the 92 priority countries. Reviewing the oxygen supply experience, the report states that it is “reasonable to assume that this objective and the related market expansion would be achieved, if at all, by increased debt or grants to institutions in developing countries”.

As Gleckman pointed out at the launch, this is a well-known pattern of the COVID-19 vaccine procurement process: countries that lacked the resources to pay the high prices set by producers vaccines were forced to take out loans around the world. Bank and the International Monetary Fund. This means that they will have to allocate even more money to debt service instead of strengthening health and social security systems, which will compromise their ability to respond to future crises.

Due to the effects of loans from international financial institutions on the stability of health systems in developing countries, debt and debt cancellation should be a major focus in future phases of the COVID-19 discussion, suggested Lauren Paremoer. With this element missing from the conversation, developing countries face the same grim no-access scenario they faced in the case of vaccines.

Read more articles from the latest edition of the People’s Health Dispatch and subscribe to the newsletter here.

read more
Generic drugs

Global Generic Drugs Market Report (2022-2027): Low Cost of Generic Drugs Compared to Branded Drugs and Robust M&A Activities in Generic Drugs Market Driving Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Generic Drugs Market (2022-2027) by Category, Applications, End User, Geography, Competitive Analysis and Covid-19 Impact with Ansoff Analysis” report has been added to from ResearchAndMarkets.com offer.

The global generic drugs market is estimated at USD 374.14 billion in 2022 and is projected to reach USD 631.58 billion by 2027, growing at a CAGR of 11.04%.

Market segmentation

The global generic drugs market is segmented on the basis of category, applications, end-user, and geography.

  • By category, the market is categorized into biosimilars and generics of small molecules.

  • By applications, the market is categorized into Anti-Arthritis Drugs, Anti-Cancer Drugs, Anti-Infection Drugs, Cardiovascular Drugs, Central Nervous System Drugs, and Respiratory Drugs.

  • By end-user, the market is categorized into pharmacies, hospitals, pharmacies, private clinics, and retail pharmacies.

  • By geography, the market is categorized into Americas, Europe, Middle East & Africa, and Asia-Pacific.

Countries studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

  • Middle East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and assess the position of companies based on their industry position score and market performance score. The tool uses various factors to classify players into four categories. Some of these factors considered for analysis are financial performance over the past 3 years, growth strategies, innovation score, new product launches, investments, market share growth, etc

Ansoff analysis

The report presents a detailed analysis of the Ansoff matrix for the global generic drugs market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design business growth strategies. The matrix can be used to assess approaches in four strategies viz. Market development, market penetration, product development and diversification. The matrix is ​​also used for risk analysis to understand the risk associated with each approach. The analyst analyzes the global generic drugs market using the Ansoff Matrix to provide the best approaches a company can take to improve its position in the market. Based on the SWOT analysis done on the industry and industry players, the analyst has designed appropriate strategies for market growth.

Why buy this report?

  • The report offers a comprehensive assessment of the global generic drugs market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and market size projections. Projections are calculated using proven research methodologies.

  • The report has been compiled through extensive primary and secondary research. The main research is done through interviews, surveys and observations of renowned personnel in the industry.

  • The report includes in-depth market analysis using Porter’s 5 forces model and Ansoff’s matrix. Additionally, the impact of Covid-19 on the market is also presented in the report.

  • The report also includes the regulatory scenario in the industry, which will help you to make an informed decision. The report discusses the major regulatory bodies and major rules and regulations imposed on this industry across various geographies.

  • The report also contains competitive analysis using Positioning Quadrants, the analyst’s proprietary competitive positioning tool.

Report Highlights:

  • A comprehensive analysis of the market, including the parent industry

  • Important market dynamics and trends

  • Market segmentation

  • Historical, current and projected market size based on value and volume

  • Market shares and strategies of the main players

  • Recommendations for companies to strengthen their presence in the market

Market dynamics

Drivers

  • Low cost of generic drugs compared to brand name drugs

  • Robust M&A activity in the generic drug market

  • Growing incidences of chronic diseases

Constraints

  • Strong commercialization of brand name drugs eclipses generic drugs

Opportunities

  • 3D manufacturing technology boosts

  • Increase collaboration on generic drug research

Challenges

  • Inactive ingredients or excipients are different

Main topics covered:

1 Description of the report

2 Research methodology

3 Executive Summary

4 Market dynamics

5 Market Analysis

6 Global Generic Drugs Market, by Category

7 Global Generic Drugs Market, by Applications

8 Global Generic Drugs Market, By End User

9 Americas Generic Drugs Market

10 European Generic Medicines Market

11 Middle East & Africa Generic Drugs Market

12 APAC Generic Drugs Market

13 Competitive landscape

14 company profiles

15 Appendix

Companies cited

  • Abbott Healthcare Pvt. ltd.

  • Allergan PLC

  • Amneal Pharmaceuticals, Inc.

  • Aspen Pharmacare Holdings Ltd.

  • Aurobindo Pharma Ltd.

  • Baxter International Inc.

  • Cipla inc.

  • Eli Lilly and company

  • Endo Pharmaceuticals Inc.

  • Fresenius medical care

  • GSK-API

  • Apotex Inc.

  • Lupine Ltd.

  • Mylan AG

  • Novartis International

  • Pfizer Inc.

  • Sandoz International GmbH

  • STADA Arzneimittel AG

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/6dznz2

read more
Prescription drugs

Navigating High Prescription Drug Prices

Steven and Jenna Emerson are the two faces of type 1 diabetes. They need thousands of dollars in drugs and supplies to stay alive.

“I would say $15 to $30,000 a year, depending on the year,” said their mother, Kelly Emerson.

That’s what the Emerson family pays after the insurance.

“Some days you have to rob Peter to pay Paul so you can afford to keep your kids alive,” she said. “When you have a child who is sick or needs medicine, you do whatever you have to do, and they know it.”

Emerson answers calls from creditors, chooses one need over another, and manages to keep his house whole. She is one of more than 100 million Americans working to cover up what will save someone’s life.

Marta Wosinska has spent more than two decades studying drug pricing and policy. She says prices are dictated by a web of interests that aren’t always aligned with those in need.

“Insurance companies are responsible for designing insurance benefits. List prices for drugs are set by pharmaceutical companies. Pharmacy benefit managers negotiate discounts, but they work for insurance companies,” Wosinska said. “Employers are the ones who select which plans to offer, often focusing on those that cost them the least.”

Wosinska said everyone has an incentive to embrace a system that sometimes works against them, with no federal solution in sight. But a partial answer may come from an unlikely source: nonprofit drug companies. They are popping up all over the country and competing with big pharma.

Allan Coukell is Senior Vice President at Civica RX. It’s one of many companies making deals with hospitals and winning federal grants. They are trying to create competition and ultimately drive down the price of generic drugs.

“Our first drug will actually launch this summer. Our insulins will hit the market in early 2024. And our goal is to make them available through a variety of mail-order channels and brick-and-mortar pharmacies,” Coukell said.

In the meantime, Emerson continues to search for elusive relief. Until then, she says, she will continue to answer calls from creditors, make tough decisions and take nothing for granted.

“You never know what the future holds. Things can change in no time,” she said. “But I want to give my children the best opportunity to live their best life.”

read more
Prescription drugs

Sue Menegat: Making prescription drugs affordable |

SUE MENEGAT

A recent editorial by Drew Johnson (Missoulian July 27) demonstrates that a barking dog can’t bite when it has false teeth, and Johnson’s statistics are ill-fitting dentures. With strategically played stats, anyone can twist a topic from their own point of view, especially if they have an agenda. Mr Johnson’s agenda appeared to be for “Big Pharma” and against improving health care for Americans. Statistics are everywhere – any statistic one wants to prove any desired point, whether accurate or not, can be found. The problem is that statistics are flexible, but facts are stubborn things. The truth will come out.

The statistics I found in a quick Google search point to a different conclusion than Mr. Johnson. One set, from the Kaiser Foundation, notes that, since 2014, drug prices have increased by 35% compared to a much smaller price increase of 19% for all other products. Another set of statistics, that of the AMA, points out that between 2008 and 2021, the cost of each newly introduced drug has increased by 11% per year. And a Medicare study found that the price of half of all drugs rose faster than the rate of inflation.

People also read…

Johnson is trying to dissuade readers from supporting President Biden’s Build Back Better plan, which would increase funding for Medicaid and allow Medicare to negotiate drug prices with “Big Pharma.” The reasons for the changes proposed by the President are simple; 90% of seniors and 50% of adults take prescription drugs, and 18 million Americans cannot afford their medications. Another 118 million people cannot afford health care, let alone insurance – ahhh, statistics again. Let’s make it more personal. People who can’t afford the necessary health care and necessary medication live shorter lives, can get sick and sometimes die Yes, people are dying.

Think of older couples who split pills into 2 or 3 to reduce drug costs. How about the woman who asks her pharmacist to fill only 1/4 of her prescription because she can’t afford the cost of $270/month. (Others pay $0 to $4 through insurance.) Think Lisa Ann. After seeing insulin prices rise every year, she tried to increase the doses, but was reluctant to tell anyone about her situation. She worked two jobs all her life, but had no drug coverage. She died, alone, of insulin shock at the age of 60. Or think of Jan. She had lower back pain and thought it was a bad disc from lifting heavy things at work. Years before, a non-cancerous cyst had been removed from her neck. After that, her husband’s insurance classified her as having a “pre-existing condition” and declined additional coverage (this was before Obamacare). She postponed her visit to the doctor, waiting to be eligible for Medicare, after all, it was a disc problem. But that was not the case. Jan died of colon cancer four months before her 65th birthday.

A death is a tragedy; a million deaths is a statistic, and statistics erase names. Millions of people are in the same boat, and they all have names. Johnson calls Democrats socialists because they want all Americans to have access to health care. Yet, in reality, various federal, state, and local government programs and policies are, by definition, socialist…the public school system, state universities, national parks and national forests, the military, the AV, police and firefighters, Social Security, Medicaid and Medicare, agricultural subsidies, oil subsidies, all paid for in a “socialist” way by our taxes. All were proposed and instituted by Republicans and Democrats. Slinging tags and calling names is useless and doesn’t solve any problems.

Yes, the poor are and will always be with us. But our society has the means to lighten people’s burdens. Why do prescriptions for Americans cost so much more than the same drug in Canada, Mexico, European countries and for the VA? Why is the life expectancy of Americans ranked 46th among the nations of the world?

If billionaires can spend their money building spaceships just to personally experience weightlessness, Americans can solve our health care debacle. Mr. Johnson, can’t America, the land of the free and the brave, afford to build back better? There, but for the grace of God, I go, or any of us.

Sue Menegat is a retired historian and special education teacher. She volunteers at the Missoula Senior Center.

You must be logged in to react.
Click on any reaction to connect.
read more
Generic drugs

Indian Generic Drugs Market Report 2022: A $24.53 Billion Market in 2022

DUBLIN, August 3, 2022 /PRNewswire/ — India’s “generic drugs market, by type (small molecule generics vs. biosimilars), by mode of drug delivery (oral, parenteral, topical, others), by form, by source, by distribution channel, by “Application, By Region, Competition, Forecast & Opportunities, 2018-2028F” report has been added to from ResearchAndMarkets.com offer.

India’s generic drug market stood at $24.53 billion in 2022 and is expected to grow at a steady CAGR of 6.97% over the forecast period.

Rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, etc., and sedentary lifestyle propel the growth of the market. The expanding geriatric population is contributing to the growth of the market as comorbidities are more prevalent in the elderly population, thus requiring appropriate drugs with the easiest route of administration.

In developing countries like India, government agencies and other regulatory bodies have encouraged manufacturers to launch effective generic drugs to sustain the market growth. The introduction of 3D printing technology is helping to manufacture generic drugs with varying release dates and tastes and is expected to propel the market growth.

The short expiration and the gap between new filings of the new drug encourage various companies to produce generic drugs due to increased competition, which further reduces the prices of generic drugs. Improved accessibility to healthcare services and growing healthcare awareness among the public is driving the growth of the market.

Several initiatives are undertaken by government agencies to publicize the availability of generics such as Pradhan Mantri Bhartiya and Jan Aushadi Yojana have become the highlight, providing quality medicines at affordable prices to the people. This program is currently underway in each state of India with its high popularity among low to middle income people providing public access to medicines.

The Indian generic drugs market is segmented on the basis of type, mode of drug delivery, form, source, distribution channel, application and region. Based on type, the market can be divided into generics and small molecule biosimilars. Generic small molecule drugs held the largest market share of 70.01% in 2022. This is due to the low cost of generic drugs compared to branded drugs and affordability for the large segment of patients from families to middle to low income.

Goal of the study:

  • To analyze the historical market size growth of India Generic Drugs Market from 2018 to 2021.
  • Estimate and forecast the market size of India Generic Drugs Market from 2023 to 2028 and the growth rate till 2028.
  • To classify and forecast the India Generic Drugs Market based on type, mode of drug delivery, form, source, distribution channel, application, regional distribution, and competitive landscape.
  • To identify the dominant region or segment in the Indian generic drugs market.
  • Identify drivers and challenges of the Indian generic drugs market.
  • Examine competitive developments such as expansions, new product launches, mergers and acquisitions, etc., in the Indian generic drugs market.
  • Identify and analyze the profile of major players operating in the Indian generic drugs market.
  • Identify the key sustainable strategies adopted by market players in the Indian generic drugs market.

Competitive landscape

Major market players operating in India generic drugs market include

  • Sun Pharmaceutical Industries Limited
  • Torrent Pharmaceuticals Limited
  • Cipla Limited
  • Lupine Limited
  • Piramal Group
  • Glenmark Pharmaceuticals Limited
  • Biocon Limited
  • Dr. Reddy’s Laboratories Limited
  • Aurobindo Pharma Limited
  • Teva Pharmaceuticals Limited

Report Scope:

Years considered for this report:

  • Historical years: 2018-2021
  • Reference year: 2022
  • Estimated year: 2023
  • Forecast period: 2024-2028

India Generic Drugs Market, By Type:

  • Small Molecule Generics
  • Biosimilars

Indian Generic Drugs Market, By Mode Of Drug Delivery:

  • Oral
  • Topical
  • Parenteral
  • Others

India Generic Drugs Market, By Form:

  • Tablets
  • Capsule
  • Injection
  • Others

India Generic Drugs Market, By Source:

  • Contract manufacturing organizations
  • internally

India Generic Drugs Market, By Distribution Channel:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Others

India Generic Drugs Market, By Application:

  • Neurology
  • Oncology
  • Cardiovascular illnesses
  • Diabetes
  • Anti-inflammatory
  • Others

Generic Drugs Market in India, by Region:

For more information about this report visit https://www.researchandmarkets.com/r/uzkyhy

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

read more
Medical supplies

Gambia: WHO hands over medical supplies and equipment to Moh

The World Health Organization (WHO) handed over medical supplies and equipment to the Ministry of Health last Friday during a handover ceremony held at the Central Medical Store in Kotu.

Items vary in size and value and include surgical masks and disposable gloves, triple-wrapped insulated cryobox and freezer boxes. The items, hailing from various countries, namely China, India and the United Arab Emirates, cost more than two hundred and seventeen thousand dollars (US$217,000).

Welcoming the gathering, Babanding Sabally, director of pharmaceutical services at the ministry, reiterated that quality health services mean availability of essential drugs and medical products.

He praised the WHO for its consistent support since the start of the pandemic, acknowledging that the UN agency has also played a crucial role in advocating for support from other partners to complement the government in the fight against the disease. pandemic.

“Our partners are aware of this fact and therefore they always come to our aid to complement whatever the government is doing.”

The UN agency, he added, has been supporting the country’s health care sector not only technically, but by providing much-needed financial support to the country.

Introducing the papers, Dr Desta Tiruneh, WHO Representative to The Gambia, recalled that with the onset of the Covid-19 pandemic, the past few years have been a difficult journey for people in The Gambia and around the world. .

He observed that since the start of the pandemic, WHO has worked in tandem with the government, the United Nations system, the private sector and multilateral and bilateral partners to support the development and implementation of a strong strategy and guidelines for the response to the pandemic.

“The close collaborative partnerships we have fostered have fostered a rapid scale-up of the pandemic response in the country and helped us cushion the drastic blow of Covid-19.”

Dr Tiruneh described that the event was not only a celebration of such fruitful partnerships across sectors, but also a move to further cement the relationship in a demonstration of shared commitment to improving public health in The Gambia. .

“I would like to take this opportunity to sincerely thank our esteemed partners for their continued support of WHO’s emergency work in The Gambia. In particular, we would like to thank our most generous partners, including the governments of the United Kingdom, from Canada, the United States, Germany, France, the Netherlands and Azerbaijan.”

On receiving the articles, Dr Ahmad Lamin Samateh, Minister of Health, hailed the long-standing partnership between the Gambian government and WHO.

This mutual partnership, he noted, is growing stronger, recognizing that the WHO, as a global leader in the health sector, has truly done its job as expected by the peoples of the world.

“All over the world, there must certainly be coordination of every activity of life, otherwise countries and people will have their own notions, norms and ways of doing things. But we are lucky to have an institution like the WHO which harmonizes all of this and sets out benchmarks that countries could use as standards and guidelines to measure performance, productivity and all the parameters that need to be measured.”

The WHO office in The Gambia, Minister Samateh acknowledged, has really fulfilled this role, adding that since the start of the Covid-19 pandemic, the WHO country office and the entire United Nations system in The Gambia have worked harmoniously exchanging ideas to ensure that the country responds adequately to Covid-19.

read more
Medical supplies

Research Segments by Global Emergency Medical Supplies Market Size, Industry Trends, Share and Forecast 2022-2028 | Bound Tree Medical, Henry Schein, Inc.

Emergency Medical Supplies Market

The recent research report on Global Emergency Medical Supplies Market 2022-2028 explains current market trends, possible growth rate, differentiable industry strategies, future prospects, significant players and their profiles, regional analysis and industry shares along with forecast details. The detailed study offers a wide range of considerable information which also emphasizes the significance of key parameters of the global Emergency Medical Supplies Market.

The emergency medical supplies market is expected to grow at a CAGR of 16% during the forecast period.

Click Here For Free Sample PDF Copy Of Emergency Medical Supplies Market 2022 Latest Research Before Purchase: @ https://www.theresearchinsights.com/request_sample.php?id=531281&mode=07RJ

Top Key Players are covered in this report:

Bound Tree Medical, Henry Schein, Inc., McKesson Medical-Surgical, Inc., Medline Industries, Inc., Stryker Corporation, Emergency Medical Products, Inc., Cardinal Health, Smiths Medical, Inc., Life-Assist, Medtronic plc. among others.

On the basis of product, the emergency medical supplies market is primarily split into:

By Product (Life Support and Emergency Resuscitation, Patient Monitoring Systems, Wound Care Consumables, Patient Treatment Equipment, Infection Control Supplies, Other EMS Products)

KBased on end users/application, this report covers

N / A

Market segment by region/country comprising:

Asia Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East and Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]

Key Highlights of the Emergency Medical Supplies Market report study:
• A detailed overview of the global emergency medical supplies industry
• The report analyzes the global emergency medical supplies market and provides its stakeholders with important actionable insights
• The report has considered all the major developments in the recent past, helping the users of the report with the latest industry updates
• The study of the report should help the key decision makers in the industry to help them in the decision-making process
• The study includes data on Emergency Medical Supplies market intelligence, changing market dynamics, current and forecasted market trends, etc.
• The report includes an in-depth analysis of macroeconomic and microeconomic factors affecting the global emergency medical supplies market
• Market ecosystem and adoption in all market regions
• Key trends shaping the global emergency medical supplies market
• Historical and forecast size of the emergency medical supplies market in terms of revenue (USD Million)

SPECIAL OFFER: GET UP TO 30% OFF THIS REPORT: https://www.theresearchinsights.com/ask_for_discount.php?id=531281&mode=07RJ

The Emergency Medical Supplies Market report provides a primary review of the industry along with definitions, classifications, and the form of the business chain. Market analysis is provided for global markets which includes improving trends, assessment of hostile views and development of key regions. Development policies and plans are discussed in addition to manufacturing strategies and royalty systems are also analyzed. This file also indicates import/export consumption, supply and demand, expenses, sales and gross margins.

Browse the full report at:https://www.theresearchinsights.com/reports/global-emergency-medical-supplies-market-growth-2022-2028-531281?mode=07RJ

Research covers the following objectives:
– To study and analyze the global Emergency Medical Supplies consumption by key regions/countries, product type and application, history data from 2016 to 2022, and forecast to 2026.
– To understand the structure of Emergency Medical Supplies by identifying its various subsegments.
– Focuses on the key global Emergency Medical Supplies manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, Five Forces Analysis of Porter, SWOT analysis and development plans over the next few years.
– To analyze the Emergency Medical Supplies with respect to individual growth trends, future prospects, and their contribution to the total market.
– Share detailed information about key factors influencing market growth (growth potential, opportunities, drivers, industry-specific challenges, and risks).
– To project the consumption of Emergency Medical Supplies submarkets, with respect to key regions (along with their respective key countries).
Report customization:
Emergency Medical Supplies, the report can be customized to suit your business needs as we recognize what our customers want, we have extended customization by 25% at no additional cost to all of our customers for any of our syndicated reports .
In addition to customizing our reports, we also offer fully customized research solutions to our clients across all industries we track.
Our research and insights help our clients identify compatible business partners.
To note: All of the reports we list tracked the impact of COVID-19 on the market. In doing so, the upstream and downstream flows of the entire supply chain have been taken into account. Additionally, where possible, we will provide an additional COVID-19 update report/supplement to the Q3 report, please check with the Commercial team.

About Us:
The Research Insights – A world leader in analysis, research and advice that can help you renew your business and change your approach. With us, you will learn to make decisions without fear. We make sense of disadvantages, opportunities, circumstances, estimates and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and results. We have effectively led businesses around the world through our market research reports and are in an excellent position to lead digital transformations. Therefore, we create greater value for customers by presenting advanced opportunities in the global market.

Contact us:
robin
Commercial director
Contact number: +91-996-067-0000
[email protected]
https://www.theresearchinsights.com

read more
Medical products

Kenya and Novo Nordisk sign MoU to provide medical products to children with diabetes

The Government of Kenya and Novo Nordisk, a Danish multinational pharmaceutical company, have signed a memorandum of understanding for the supply of medical products to improve the treatment and self-management of type 1 diabetes in children.

Speaking at the ceremony, Cabinet Secretary for Health Mutahi Kagwe said the long-term aspiration of the program was not only to improve the lives of children enrolled in the project, but also to find ways to integrate the components of the program into the delivery of health care in the country.

He said the parties have entered into a partnership to use their respective skills and strengths to improve the well-being of people living with diabetes in Kenya through sustainable partnerships and collaborations, as well as to improve the diabetes care for children with type 1 diabetes in Kenya. the country.

“We welcome you and thank you for your support. Your partnership is important and we value it. We invite you to think about investing in the country in terms of manufacturing,” said the Health CS.

To reach more children with diabetes, Kenya needs to establish additional type 1 diabetes clinics and build the capacity of health workers, with Novo Nordisk committing two billion shillings to support the program for the next 3 years.

The two parties have agreed on how to improve and establish the infrastructure of diabetes clinics and the provision of medical and laboratory equipment, training and education of health professionals working on diabetes in type 1 in children and adolescents, the provision of human insulin and blood glucose monitoring equipment and supplies at no cost to children and adolescents. They also agreed to educate children and teens with type 1 diabetes and their families, create a registry for children and teens with type 1 diabetes, and share ideas and results for improvement. Continuation of the Changing Diabetes in Children Project between parties. .

In the agreement, the Government of Kenya will be obliged, among other things, to gradually integrate the Changing Diabetes in Children program into the national health system and to ensure that diabetes and specifically type 1 diabetes is included in the national non-communicable disease agenda. consistent with the Sustainable Development Goals.

Novo Nordisk, in turn, will have to provide the diagnostic, screening and monitoring equipment necessary for the organization and operation of diabetes clinics and the patient registry, provide free human insulin to cover diabetes treatment needs type 1 in children and adolescents up to 25 years old in the health structures supported by the CDiC project.

The company will also have to support the training of health professionals in the management of type 1 diabetes in children and adolescents, support awareness campaigns in collaboration with various stakeholders, support education on diabetes self-management for children, adolescents and their families, including development The CDiC project provides educational materials to patients and supports the improvement of infrastructure in some of the diabetes clinics, as determined by the ministry of Health.

The MoU was signed by Vinay Ransiwal, Managing Director and Vice President on behalf of Novo Nordisk and CS Mutahi Kagwe on behalf of the Government of Kenya and in the presence of Danish Ambassador to Kenya Ole Thonke.

The Changing Children’s Diabetes program was launched in Kenya in 2012 to ensure that children with type 1 diabetes have access to appropriate treatment and support. The partnership was between Novo Nordisk, the Government of Kenya, Roche Diabetes and the Kenya Diabetes Management and Information Center (DMI). It was created to identify solutions that can lead to an integrated approach to the diagnosis, treatment and control of diabetes in children with type 1 diabetes.

(With contributions from APO)

read more
Medical supplies

Darlington man Ken Longstaff struggles to get NHS medical supplies

The wife of a man who needs round-the-clock care after being struck down with a rare disease has raised concerns after struggling to get the medical supplies he needs to stay alive.

Ken Longstaff, of Darlington, depends on care for his daily needs after being diagnosed with Guillain Barre syndrome in 2012.

The condition left him locked up for seven weeks and the 64-year-old, who has discovered a talent for art since his diagnosis, is now confined to a wheelchair and requires round-the-clock care.

Read more: How good is it? Brilliant mural appears in Darlington to celebrate women’s football

His wife Beverley, 62, has raised concerns about obtaining essential medical supplies for the past six months via the Darlington District Nursing Team, through whom she is believed to be able order them.

County Durham and the Darlington NHS Foundation Trust, which is leading the team, said global logistics issues were having a “significant impact” on the supply of some items in the North East – but decided to reassure patients that the trust was working to ensure patients were never deprived of essential equipment.

Ken Longstaff of Darlington

Mrs Longstaff wants to raise awareness of the issue after struggling to get replacement tubes for her husband’s tracheostomy, which he needs to help him breathe, as well as a special type of essential water for his ventilator , which he needs at night .

He usually keeps a spare game in his bag, which accompanies him everywhere, as well as two at home.

However, the couple struggled to replace the kit as it is used and recently recorded backup compliance due to difficulty obtaining the tracheostomy tube.

She said: “I had an incident where they said they couldn’t have a tracheotomy. I kept trying and trying, then they sent me one that was completely different.

“We got to the stage about a week ago where we only had one left, which is the one he wears all the time.”

Recalling an incident last week, she said she was called at 5 a.m. by her carer to help as he was struggling to breathe.

After being unable to clear her airway by suction, she feared having to use the unknown tracheotomy, and would then find herself in a position where she would have no reserve in case of another emergency. Fortunately, after several attempts, they managed to clear the airways.

She added: “My problem is that if we were to use the other one and it hadn’t worked, I would have a dead man on my hands.”

Darlington and Stockton Times: Ken Longstaff has discovered a talent for art since his diagnosis Ken Longstaff has discovered a talent for art since his diagnosis

Mrs. Longstaff, who works as a receptionist at Woodland Hospital, at Darlington, spent several days last week trying to get supplies, which she managed to get to intensive care from James Cook University Hospital, Middlesbrough and Darlington Memorial Hospital.

To get more Darlington stories straight to your email basket, click here

She said, “The only reason we have them is because I begged and borrowed and stole from other people. I got them from the intensive care units, but that means they no longer have those supplies.

“There will be people like us who will struggle to get supplies and they won’t have the contacts we have.”

She added: “We’re lucky because where I work I have contacts. What about an OAP who doesn’t know who to ask for help? danger.

“It shouldn’t be something I deal with at all. People need to know that’s a problem.

A spokesperson for County Durham and Darlington NHS Foundation Trust, said: “The current global manufacturing and logistics issues are having a significant impact on the supply of certain clinical and other items across the NHS. We are working closely with the NHS supply chain to find alternative products if needed.

“Our patients always come first and we fully understand Mr Longstaff’s family’s concern that certain equipment is not currently as readily available as it once was and we apologize for the concern this has caused them. We are in close contact with Mr. Longstaff’s family to ensure they have the equipment he needs.

Read next:

If you want to read more great stories, why not subscribe to your Northern Echo for as little as £1.25 a week. Click here

read more
Medical products

Physical testing for 3D printed medical products

Image Credit: Stable Micro Systems Ltd

3D printing has become a niche manufacturing method, allowing consumers to design and manufacture their own products. As such, it now occupies an important place in the manufacturing industry. Objects can be constructed in almost any format the consumer desires, and this has overcome the early limitations of certain groups of polymers as a building material. It’s now a potential tool in many industries, including bone and organ replacements, meat manufacturing, and even customizable baking.

Stable Micro Systems manufactures instruments that measure the tensile and compressive properties of 3D printed parts. As with any manufacturing innovation, the final product must go through a quality control process to assess its physical properties. A Texture Analyzer is a crucial part of this procedure, providing a reliable way to test the mechanical properties of 3D printed objects by applying a choice of compression, tension, extrusion, adhesion, bending or cutting tests to measure the resistance of a product physical properties for example tensile strength, flexural modulus, fracturability, compressibility, to name but a few.

3D Printing Materials Test Example – Extrusion

The printability of materials used in extrusion 3D printing is one of the most important properties, especially when manufacturing objects with architectural complexities. This parameter is influenced by several factors (temperature, components and additives), which makes a thorough evaluation and classification difficult. Interest in 3D printing for biomedical applications is growing and the pharmaceutical industry is beginning to explore how 3D printing can help us deliver better medicines. Achieving reproducibility in 3D printing of biomaterials requires a robust polymer synthesis method to reduce batch-to-batch variation as well as methods to ensure thorough characterization throughout the manufacturing process. In particular, biomaterial inks containing large solid fractions such as ceramic particles, often required for bone tissue engineering applications, are prone to inhomogeneity from improper mixing or particle aggregation which can lead to inconsistent print results. The production of such ink can be optimized to ensure consistent and repeatable print results by using a TA.XTPlusC Texture Analyzer to perform extrusion force measurements to predict the printability of inks. To read a sample post of this texture analyzer app at ETH Zurich, Click here.

Direct extrusion test on a texture analyzer. Image Credit: Stable Micro Systems Ltd

3D Printing Materials Test Example – Compression

Due to the low price of 3D printing equipment and its versatility, materials such as antioxidant PLA composites containing lignin can be used in hospitals to print dressings for patients on demand. 3D printing can also benefit plastic and reconstructive surgeries by fabricating patient-specific tissue substitutes with tissue-like functions and mechanical properties. A texture analyzer can be used to perform compression test on samples to characterize their mechanical properties which are important for their structural integrity. To read a sample post of this Texture Analyzer app at the University of Nottingham, Click here.

Unconfined compression on a texture analyzer. Image Credit: Stable Micro Systems Ltd

3D Printing Materials Test Example – Bending and Bending

3D printing offers a new approach to the fabrication of drug-eluting implantable medical devices, as it allows complex and custom shapes of tissue scaffolds to be flexibly extruded. Given the simplicity, it can be easily transferred to a clinical setting, where implants could be designed on demand to meet patient needs after surgery. These implants may be suitable for administering drugs for localized treatment. For example, chemotherapy agents, antibiotics or local anesthetics. Alternatively, they could be adapted by coating them for prolonged administration of drugs for the treatment of chronic diseases.

Compared to other printable biomaterials, polyurethane elastomers have several advantages, including excellent mechanical properties and good biocompatibility. However, some intrinsic behaviors, especially high melting point and slow degradation rate, hinder their application in 3D printed tissue engineering. The development of a 3D printable amino acid modified biodegradable water-based polyurethane means that the flexibility of this material provides better tissue compliance during implantation and prevents high modulus grafts from scratching tissue surrounding. The use of a texture analyzer to perform flexibility measurements (three-point curvature) on 3D printed samples allows to evaluate if this can be used as an alternative biomaterial for tissue engineering with low temperature printing, biodegradability and compatibility. To read a sample post of this texture analyzer app at Beijing Science and Technology University, Click here Where Click here to see similar work at Queen’s University Belfast.

3-point flexibility and bending test on a texture analyzer. Image Credit: Stable Micro Systems Ltd

Example of testing 3D printing materials – Perforation, Elongation and Tension:

Orodispersible films (ODF) are promising dosage forms for children or the elderly who may have swallowing problems with solid oral dosage forms. By printing active pharmaceutical ingredients on orodispersible films, the flexibility of drug dosing is increased and offers potential for personalized drugs. Warfarin is an example of a drug with a narrow therapeutic index which requires a personalized dosage which is not currently achieved by marketed products. 3D printing by extrusion can be used to produce transparent, smooth and thin, yet flexible and resistant orodispersible films containing therapeutic doses. Using a texture analyzer, films can measure their properties of burst strength and flexibility as part of their critical physical characteristics that could impact their usability.

To read a sample post of this texture analyzer app at Heinrich Heine University Dusseldorf Click hereWhere Click here for similar work done at Åbo Akademi University.

Bursting strength, tensile strength and film flexibility on a texture analyzer. Image Credit: Stable Micro Systems Ltd

How a Texture Analyzer Can Assess the Flow of Base Powder

Texture analysis can also be used at other stages of the 3D printing process, not just to measure the properties of the final product. For example, the properties of the base powder used in selective laser sintering affect the sintering process as well as the properties of the final product. The flow of the powder is one of these properties. As each new layer of powder is swept over the sinter bed, the layer should be even and of the correct thickness and distribution. A Powder flow analyzer (PFA) is a very useful addition to a Texture Analyzer Plus to help measure these flow properties.

PFA proves to be an accurate and reliable method for measuring the flow characteristics of dry and wet powders, with the ability to measure cohesion, clumping and velocity flow dependence as well as bulk density and other properties. It can be quickly retrofitted to a TA.XTPlusC Texture Analyzer, allowing manufacturers to assess and avoid typical issues such as batch and source variation of ingredients, clumping during storage/transportation and problems unloading hoppers or bins, as well as 3D printing. specific properties of the powder. The powder is conditioned at the start of each test to eliminate any load variation and the patented precision blade is then rotated through the sample causing a controlled flow.

Image Credit: Stable Micro Systems Ltd

The need to measure dimensional profiles

If you designed a product and then print it, one of the concerns will be whether what was printed matches what you designed. In many cases you will need your printed object to be dimensionally accurate and printing iterations of your design are almost inevitable to adjust the print settings to achieve a dimensionally accurate product. A precise numerical evaluation of the physical dimensions thus becomes a necessity. A Volscan Profiler provides such a solution – a benchtop laser scanner that measures the volume, density and dimensional profiles of solid products. Rapid three-dimensional scanning of products allows for the automatic calculation of several detailed dimension-related parameters, the results of which can be mathematically manipulated for immediate use or future retrieval in a variety of data formats for your printed objects.

Volscan Profiler models for measuring volume, density and dimensional profiles. Image Credit: Stable Micro Systems Ltd

Bone sample ready for scanning and an archived scan of the sample. Image Credit: Stable Micro Systems Ltd

The medical industry is increasingly dependent on the TA.XTmoreC Texture Analyzer as a tool for measuring all types of physical/mechanical properties.

See a wider range of test and measurement possibilities in this area.

read more
Prescription drugs

Prescription Hyperlipidemia Drugs Market Size by Share, Growth and Forecast 2029 – Instant Interview

Global Prescription Drugs for Hyperlipidemia Market is expected to grow at a CAGR of 14.50% to reach USD xx million through 2029

Overview of the Prescription Drugs for Hyperlipidemia Market

Prescription Drugs for Hyperlipidemia research report includes all the necessary details. By providing accurate data to its clients, it helps them make important decisions and gives market forecasts. This study, which combines primary and secondary research, provides market size, share, trends and forecasts for important segments and sub-segments. This market research monitors all the latest developments and changes in the industry. It provides information on the obstacles encountered when starting a business and offers advice on how to deal with impending difficulties.

Download a sample exclusive report:

https://pharmaresearchconsulting.com/reports/hyperlipidemia-prescription-drugs-market-global-growth-trends-and-forecast-2022-2029-by-type-hmg-coa-reductase-inhibitors-fibric-acid-derivatives- nicotinic-acid-by-hospital-clinical-application-and-by-regions/demand

Report scope

The research analysis of the Global Prescription Drugs for Hyperlipidemia Market takes a close look at the market size, trends, and potential opportunities. By offering in-depth details of technology expenditure for the projection year, this research provides a unique perspective on the global Prescription Hyperlipidemia Drugs market across various categories. Clients can learn more about the potential and limitations of the industry by reading the study on the Global Prescription Drugs for Hyperlipidemia Market. The study discusses in detail a number of factors that have been identified as influencing the growth trajectory of the market. The issues facing the market are also identified in the study.

Key companies influencing this market include:

Amgen, are Eli Lilly, GlaxoSmithKline Pharmaceuticals, Isis Pharmaceuticals, Merck, Dr. Reddy’s Laboratories, Immuron Limited, Esperion Therapeutics and Pfizer, Formac Pharmaceuticals and others.

Global Prescription Hyperlipidemia Drugs Market Segmentation:

By Type, it is segmented into

  • HMG COA reductase inhibitors
  • Fibric acid derivatives
  • nicotinic acid
  • Bile acid sequestering agents
  • Cholesterol absorption inhibitors
  • Combination drug therapy

By Application, it is segmented into

Regional coverage:

The research mentions the regional scope of the market, mainly focusing on the following areas:

  1. North America (United States, Canada and Mexico)
  2. Europe (Germany, France, UK, Russia and Italy)
  3. Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
  4. South America (Brazil, Argentina, Colombia, etc.)
  5. Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa)

Buy a full copy of Prescription Drugs for Hyperlipidemia Market report:

https://pharmaresearchconsulting.com/reports/hyperlipidemia-prescription-drugs-market-global-growth-trends-and-forecast-2022-2029-by-type-hmg-coa-reductase-inhibitors-fibric-acid-derivatives- nicotinic-acid-by-hospital-clinical-application-and-by-regions.

Key information covered Hyperlipidemia Prescription drugs Market research:

  • Manufacturers Production Capacity Analysis of Prescription Hyperlipidemia Drugs
  • Key factors shaping the growth of the Prescription Hyperlipidemia Drugs Market
  • Hyperlipidemia Prescription Drugs Industry Segmentation Analysis
  • Competitive Mapping for Key Players in the Prescription Hyperlipidemia Drugs Market
  • Prescription Drugs for Hyperlipidemia Market Growth to 2029
  • Analysis of Direct and Indirect Sales of Prescription Drugs for Hyperlipidemia
  • Hyperlipidemia Prescription Drugs Industry Share 2022
  • Distribution Channel Analysis of Prescription Drugs for Hyperlipidemia

Contents:

Chapter 1: Introduction, Market Driver Product Research and Research Objectives Scope of Prescription Drugs for Hyperlipidemia Market

Chapter 2: Exclusive Summary – Basic Information on the Prescription Drugs for Hyperlipidemia Market.

Chapter 3: Revealing Market Dynamics – Drivers, Trends and Challenges

Chapter 4: Presenting the Porters Five Forces Prescription Hyperlipidemia Drugs Market factor analysis, supply/value chain, Pestel analysis, market entropy, patent/trademark analysis.

Chapter 5: View by Type, End User and Region 2022-2029

Chapter 6: Evaluation of the Prescription Drugs for Hyperlipidemia Market leading manufacturers including competitive landscape and company profiles

Chapter 7: To assess the market by segments, countries and manufacturers, with revenue sharing and sales by key countries for these various regions.

Chapters 8 and 9: Appendix, methodology and data source display

Contact us: –
Phone number+1 (704) 266-3234

Send mail to: [email protected]

read more
Prescription drugs

Board can make prescription drugs more affordable in New Mexico | My opinion

read more